{"PMC7177073": [["FundingThis work was partly supported by the Italian Ministry of Health \u201cRicerca Corrente\u201d Linea 1.", [["Linea", "ANATOMY", 91, 96]]]], "PMC7334701": [["IntroductionAs with many areas of vocational education, the medical field has challenges in teaching skills to students in safe environments where the risk from mistakes is minimal and in a way that is scalable.", [["vocational education", "TREATMENT", 34, 54], ["minimal", "OBSERVATION_MODIFIER", 173, 180]]], ["One proposed solution that has been effective across a range of skills has been to use virtual agents [4, 14, 20, 25].", [["One proposed solution", "TREATMENT", 0, 21], ["virtual agents", "TREATMENT", 87, 101], ["effective", "OBSERVATION_MODIFIER", 36, 45]]], ["Outside of the medical domain, virtual agents can take on many different roles to support the learning process including those of instructor [1], students for teacher training [9, 10], or role-player [24].", [["virtual agents", "TREATMENT", 31, 45]]], ["Across studies, environments that include virtual agents have been found to enhance learning compared to those that do not [15, 29].", [["Across studies", "TEST", 0, 14], ["virtual agents", "TREATMENT", 42, 56]]], ["Within medical trains, researchers have used virtual patients, a subset of virtual agents, to support both the acquisition of theoretical knowledge [5, 27] as well as communication skills [22, 31].", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["virtual agents", "TREATMENT", 75, 89]]], ["Virtual patients provide many advantages to medical training including standardization, accessibility and efficiency, and practice in a safe environment with feedback [5, 27].IntroductionMore recently, research within virtual agents has expanded from focusing primarily on guidance and coaching to using agents\u2019 social and affective capabilities to support learning [18], specifically interpersonal behaviors [2].", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["medical training", "TREATMENT", 44, 60], ["agents", "TREATMENT", 304, 310]]], ["For the training of interpersonal skills, students can respond realistically to virtual humans [13] and can improve their target interpersonal skills [17, 24].", [["humans", "ORGANISM", 88, 94], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94]]], ["Furthermore, these skills practiced with the virtual agent may transfer to use with real humans [14].IntroductionMoreover, virtual patients can provide increased exposure to cases that take extra care such as those with special needs [28] or dementia.", [["dementia", "DISEASE", 242, 250], ["humans", "ORGANISM", 89, 95], ["patients", "ORGANISM", 131, 139], ["humans", "SPECIES", 89, 95], ["patients", "SPECIES", 131, 139], ["humans", "SPECIES", 89, 95], ["the virtual agent", "TREATMENT", 41, 58], ["dementia", "PROBLEM", 242, 250]]], ["With virtual patients, students are able to practice in a safe environment [31] that prepares them for emotionally-charged real-life encounters and to transfer their skills to a more realistic situation [20].", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["When training students to deal with sensitive situations specifically, such as those when working with a dementia patient, there is far less work.", [["dementia", "DISEASE", 105, 113], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121]]], ["One specific challenge is to support the training of empathy, which is critical to patient outcomes [16, 30].", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["empathy", "PROBLEM", 53, 60]]], ["We define empathy as \u201ca two-phase process: (a) understand and appreciate another person\u2019s feelings and emotions and (b) communicate understanding back to the patient in a supportive way\u201d [21] with a focus on the communication through voice.", [["patient", "ORGANISM", 158, 165], ["person", "SPECIES", 81, 87], ["patient", "SPECIES", 158, 165]]], ["In these situations, the empathy exhibited by the student through both verbal and non-vernal actions is key to fruitful interactions with the patient.", [["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149]]], ["Virtual agents have shown mixed results in their ability to support empathy training with higher empathy with real people in some studies [8] and lower in others [19].", [["people", "SPECIES", 115, 121], ["empathy training", "TREATMENT", 68, 84], ["some studies", "TEST", 125, 137]]], ["One strength of using virtual agents to support empathy training is their ability to provide feedback to students [11, 12] and support reflection on their responses [19].", [["virtual agents", "TREATMENT", 22, 36], ["empathy training", "TREATMENT", 48, 64]]], ["However, virtual patients are still limited in their ability to support complex communication skills [5, 7, 27].IntroductionIn this work, we investigate how a virtual agent can be designed and support the training of empathy skills.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["a virtual agent", "TREATMENT", 157, 172]]], ["Specifically, we evaluate the use of a virtual patient for empathy training compared to that of standard practice \u2013 collaborative role playing.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["empathy training", "TREATMENT", 59, 75]]], ["Our research question is: how does the students\u2019 empathy compare over time between the virtual patient condition and the role playing condition?", [["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102]]], ["We hypothesize that students will increase their empathy over time but that they will have higher empathy when interacting with real humans [8].", [["humans", "ORGANISM", 133, 139], ["humans", "SPECIES", 133, 139], ["humans", "SPECIES", 133, 139]]], ["This research contributes to our understanding of using virtual patients to support empathy training.Virtual Patient and Collaborative Role Playing Conditions ::: MethodsWe developed the patient simulation using Unity with a narrative design, in which decisions the user makes results in different outcomes over time.", [["patients", "ORGANISM", 64, 72], ["patient", "ORGANISM", 187, 194], ["patients", "SPECIES", 64, 72], ["Patient", "SPECIES", 109, 116], ["patient", "SPECIES", 187, 194], ["empathy training", "TREATMENT", 84, 100], ["Methods", "TREATMENT", 163, 170]]], ["We represented facial expressions and body posture through a 2-D sketch and speech as both text and audio.", [["facial", "ANATOMY", 15, 21], ["body", "ANATOMY", 38, 42], ["body", "ORGANISM_SUBDIVISION", 38, 42], ["facial expressions", "PROBLEM", 15, 33], ["body posture", "PROBLEM", 38, 50], ["facial", "ANATOMY", 15, 21], ["expressions", "OBSERVATION", 22, 33]]], ["The students worked individually with the patient through simple text selections.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49]]], ["After making their choice, the students were asked to read out loud the choice that they selected in the way that they would say it to a patient.", [["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144]]], ["The students could then replay their recording to reflect on the level of empathy.", [["empathy", "OBSERVATION", 74, 81]]], ["Based on their choice, the next interaction scenario (i.e., dialogue of the patient) would appear on the screen and the facial features of the patient would change subtly to indicate the emotions of the patient (Fig. 1).", [["facial", "ANATOMY", 120, 126], ["patient", "ORGANISM", 76, 83], ["patient", "ORGANISM", 143, 150], ["patient", "ORGANISM", 203, 210], ["patient", "SPECIES", 76, 83], ["patient", "SPECIES", 143, 150], ["patient", "SPECIES", 203, 210], ["the screen", "TEST", 101, 111], ["facial", "ANATOMY", 120, 126]]]], "286db1744e15a42fa837fab01bd5311b80bc089e": [["IntroductionCovid-19 has severely tested our public health systems.", [["IntroductionCovid", "TREATMENT", 0, 17]]], ["Recovering from Covid-19 will soon test our economic systems.", [["Covid", "TEST", 16, 21]]], ["Innovation will have an important role to play in recovering from the aftermath of the coronavirus.", [["coronavirus", "DISEASE", 87, 98], ["coronavirus", "ORGANISM", 87, 98], ["the coronavirus", "PROBLEM", 83, 98]]], ["This article discusses both how to manage innovation as part of that recovery, and also derives some lessons from how we have responded to the virus so far, and what those lessons imply for managing innovation during the recovery.IntroductionCovid-19's assault has prompted a number of encouraging developments.", [["IntroductionCovid", "TREATMENT", 230, 247]]], ["One development has been the rapid mobilization of scientists, pharmaceutical companies and government officials to launch a variety of scientific initiatives to find an effective response to the virus.", [["scientific initiatives", "TREATMENT", 136, 158], ["the virus", "PROBLEM", 192, 201], ["rapid", "OBSERVATION_MODIFIER", 29, 34], ["mobilization", "OBSERVATION_MODIFIER", 35, 47]]], ["As of the time of this writing, there are tests underway of more than 50 different compounds as possible vaccines against the virus.", [["tests", "TEST", 42, 47], ["vaccines", "TREATMENT", 105, 113], ["the virus", "PROBLEM", 122, 131]]], ["1 Most of these will ultimately fail, but the severity of the crisis demands that we investigate every plausible candidate.", [["the crisis demands", "PROBLEM", 58, 76]]], ["We need rapid, parallel experimentation, and it must be the test data that select our vaccine, not internal political or bureaucratic processes.IntroductionA second development has been the release of copious amounts of information about the virus, its spread, and human responses to various public health measures.", [["human", "ORGANISM", 265, 270], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 265, 270], ["the test data", "TEST", 56, 69], ["our vaccine", "TREATMENT", 82, 93], ["internal political or bureaucratic processes", "PROBLEM", 99, 143], ["the virus", "PROBLEM", 238, 247], ["rapid", "OBSERVATION_MODIFIER", 8, 13], ["bureaucratic processes", "OBSERVATION", 121, 143]]], ["The Gates Foundation, working with the Chan-Zuckerberg Foundation and the White House Office of Science and Technology Policy have joined forces to publish all of the known medical literature on the coronavirus, in machine-readable form 2 .", [["coronavirus", "DISEASE", 199, 210], ["coronavirus", "ORGANISM", 199, 210], ["the coronavirus", "PROBLEM", 195, 210]]], ["This was done with the intent to accelerate the analysis of the existing research to identify possible new avenues of attack against Covid-19.", [["Covid", "TEST", 133, 138]]], ["The coronavirus itself was synthesized early on in the outbreak by scientists in China, providing the genetic sequence of the virus, and showing where it differed from earlier viruses such as SARS and MERS.", [["SARS", "DISEASE", 192, 196], ["coronavirus", "ORGANISM", 4, 15], ["the virus", "PROBLEM", 122, 131], ["earlier viruses", "PROBLEM", 168, 183], ["SARS", "PROBLEM", 192, 196], ["coronavirus", "OBSERVATION", 4, 15], ["early", "OBSERVATION_MODIFIER", 39, 44]]], ["At the same time, GITHUB and the Humanitarian Data Exchange each have an accumulating series of datasets on the geography of the spread of the disease (including positive test cases, hospitalizations, and deaths).", [["deaths", "DISEASE", 205, 211], ["the disease", "PROBLEM", 139, 150], ["disease", "OBSERVATION", 143, 150]]], ["Opening up mobilizes knowledge from many different places, causing our learning to advance and our progress against the disease to accelerate.", [["the disease", "PROBLEM", 116, 127]]], ["Openness leverages the human capital available in the world to tackle the disease, and also accesses the physical capital (such as plant and equipment) already in place to launch rapid testing of possible solutions.", [["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["the disease", "PROBLEM", 70, 81], ["rapid testing", "TEST", 179, 192], ["disease", "OBSERVATION", 74, 81]]], ["The Covid-19 disease appears to be doubling every 3-5 days, so a delay of just a few weeks in the search for a new vaccine (they normally take 1-2 years to develop, or more) might witness multiple doublings of size of the population infected with the disease.", [["The Covid-19 disease", "PROBLEM", 0, 20], ["a new vaccine", "TREATMENT", 109, 122], ["the disease", "PROBLEM", 247, 258], ["disease", "OBSERVATION", 13, 20], ["size", "OBSERVATION_MODIFIER", 210, 214], ["population", "OBSERVATION_MODIFIER", 222, 232], ["infected", "OBSERVATION", 233, 241], ["disease", "OBSERVATION", 251, 258]]], ["It is for this reason that Bill Gates is providing funds to construct facilities in advance for producing https://doi.org/10.1016/j.indmarman.2020.04.010 the leading vaccine candidates 4 .", [["the leading vaccine candidates", "TREATMENT", 154, 184]]], ["Though the facilities for the losing candidates will not be used, it will save precious time to make the winning vaccine in high volume, once it is found.Open innovation in medical scienceOpen innovation can help speed things up.", [["the winning vaccine", "TREATMENT", 101, 120], ["Open innovation in medical scienceOpen innovation", "TREATMENT", 154, 203]]], ["The availability of the gene sequencing of the coronavirus establishes a clear target to all of us.", [["coronavirus", "ORGANISM", 47, 58], ["the coronavirus", "PROBLEM", 43, 58]]], ["The 50+ vaccine candidates being considered are all already-approved drugs for other medical uses.", [["The 50+ vaccine candidates", "TREATMENT", 0, 26]]], ["This means that each candidate's basic safety dosage levels in humans have already been established.", [["humans", "ORGANISM", 63, 69], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69]]], ["This allows the testing to start in the middle of the usual drug development process, with the Phase 1 safety protocols already completed.", [["the testing", "TEST", 12, 23]]], ["And not just professional researchers and scientists, but also amateur researchers who have a passion and a hunch to test.Open innovation in medical scienceThis openness in the scientific domain will likely help us find a vaccine sooner.", [["a vaccine", "TREATMENT", 220, 229]]], ["Many powerful new technologies lack a clear and obvious way to create business value (think of artificial intelligence, or IoT, or blockchain).", [["artificial intelligence", "PROBLEM", 95, 118]]], ["Instead, set up the tests, and let the resulting data guide your decision.", [["the tests", "TEST", 16, 25]]], ["And notice that many of these experiments can be done by others, with their own money, people, and equipment.", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93]]], ["So practicing more openness in the science and technology that undergirds your business is well worth your consideration.Open innovation in medical scienceBut finding a vaccine is not enough.", [["a vaccine", "TREATMENT", 167, 176]]], ["There are now more than a million confirmed cases of Covid-19, with tens of thousands people in serious or critical condition in hospitals to be treated (a number that is doubling every 3-5 days).", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["Covid", "TEST", 53, 58], ["serious", "OBSERVATION_MODIFIER", 96, 103]]], ["There has been a shortage of personal protective equipment (PPE) for medical staff to protect themselves against the virus, including masks, gowns, and gloves.", [["personal protective equipment", "TREATMENT", 29, 58], ["medical staff", "TREATMENT", 69, 82], ["the virus", "PROBLEM", 113, 122], ["gloves", "TREATMENT", 152, 158]]], ["What if mask manufacturers like 3 M opened up their mask designs and IP temporarily, so that anyone in the world with a 3D printer could print a mask?Open innovation in medical scienceThere also is a severe shortage of ventilators in this crisis.", [["a mask", "TREATMENT", 143, 149], ["a severe shortage of ventilators", "PROBLEM", 198, 230], ["this crisis", "PROBLEM", 234, 245], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["shortage", "OBSERVATION_MODIFIER", 207, 215]]], ["For example, given the shortage of ventilators that are needed for the intensive care for some COVID-19 patients, ventilator manufacturers are forming partnerships with carmakers, aerospace firms and others to boost output as fast as possible.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["ventilators", "TREATMENT", 35, 46], ["the intensive care", "TREATMENT", 67, 85], ["some COVID", "TREATMENT", 90, 100], ["ventilator manufacturers", "TREATMENT", 114, 138], ["carmakers", "TREATMENT", 169, 178]]], ["6 Companies that make ventilators could also do more.", [["ventilators", "TREATMENT", 22, 33]]], ["7 Moreover, the company will post the mechanical designs of its ventilators, so that others can not only see the patents, but can use the actual designs to shorten the time needed to build more ventilators.How open innovation works: outside in and inside outTo understand better how open innovation works, it helps to compare and contrast some of its principal mechanisms in normal times to our present crisis.", [["the mechanical designs of its ventilators", "TREATMENT", 34, 75], ["patents", "OBSERVATION", 113, 120]]], ["Open innovation is defined as \"a distributed innovation process involving purposive knowledge flows across organizational boundaries for monetary or non-monetary reasons\" (Chesbrough & Bogers, 2014) .", [["Open innovation", "TREATMENT", 0, 15], ["a distributed innovation process", "PROBLEM", 31, 63]]], ["It has two principal directions on knowledge flow: outside in, and inside out.", [["two", "OBSERVATION_MODIFIER", 7, 10], ["principal", "OBSERVATION_MODIFIER", 11, 20], ["directions", "OBSERVATION_MODIFIER", 21, 31]]], ["In the Covid-19 crisis, the White House Office of Science and Technology policy published all of the relevant research on Covid-19 and the underlying SARS-Cov2 virus, to encourage collaborators to work on solutions.", [["SARS", "DISEASE", 150, 154], ["SARS-Cov2 virus", "ORGANISM", 150, 165], ["SARS-Cov2 virus", "SPECIES", 150, 165], ["Covid", "TEST", 122, 127], ["the underlying SARS", "PROBLEM", 135, 154], ["Cov2 virus", "PROBLEM", 155, 165]]], ["In Covid-19, we are seeing similar crowdsourcing for therapies for managing the disease, plus ways to design and make masks, hand sanitizers, and even modifying a ventilator to support 2 patients at a time.How open innovation works: outside in and inside outFor inside-out knowledge flows in the b2b context, Amazon famously offered its internal IT infrastructure to host external customers' websites and IT needs (Huckman, Pisano, & Kind, 2008) .", [["hand", "ANATOMY", 125, 129], ["hand", "ORGANISM_SUBDIVISION", 125, 129], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["therapies", "TREATMENT", 53, 62], ["the disease", "PROBLEM", 76, 87], ["masks, hand sanitizers", "TREATMENT", 118, 140], ["a ventilator", "TREATMENT", 161, 173]]], ["In the Covid-19 pandemic, Medtronic has opened up its ventilator design for anyone to make, posted its internal design drawings for the ventilator, and waived its IP rights to the design.", [["Covid-19 pandemic", "SPECIES", 7, 24], ["Medtronic", "TREATMENT", 26, 35], ["the ventilator", "TREATMENT", 132, 146]]], ["In the b2c context for inside-out knowledge flows, Lego allowed users and teachers to modify its Lego Mindstorms product to create a whole program of robotics instruction in middle schools (Afari & Khine, 2017) .", [["robotics instruction", "TREATMENT", 150, 170]]], ["In the Covid-19 pandemic, many companies are converting part of their manufacturing processes to produce scarce supplies like hand sanitizer.Open innovation in crisis managementThis openness could go still further.", [["hand", "ANATOMY", 126, 130], ["hand", "ORGANISM_SUBDIVISION", 126, 130], ["Covid-19 pandemic", "SPECIES", 7, 24], ["Open innovation", "TREATMENT", 141, 156], ["crisis management", "TREATMENT", 160, 177], ["hand", "ANATOMY", 126, 130], ["sanitizer", "OBSERVATION", 131, 140]]], ["We have a severe shortage of hospital beds.", [["severe", "OBSERVATION_MODIFIER", 10, 16]]], ["We also have a lockdown on non-essential business travel, causing most business hotel rooms to go empty.", [["empty", "OBSERVATION", 98, 103]]], ["Could we devise ways to allow non-contagious patients in hospitals to migrate to these unused hotel rooms?", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["It is likely to be much cheaper than the fully allocated costs of inpatient hospital rooms.", [["likely to be", "UNCERTAINTY", 6, 18]]], ["And this infrastructure is already built, ready to be used.Open innovation in crisis managementUser innovation may have a role to play here as well (Von Hippel, 2005; Von Hippel, 2016) -because we know that solutions to complex problems may come for non-conventional sources, particularly when the users themselves stand to benefit from the solution.", [["Open innovation", "TREATMENT", 59, 74], ["crisis management", "TREATMENT", 78, 95]]], ["Users can make their own masks, which will both reduce transmission of the disease to them and more importantly for society, reduce their transmission of the disease to others.", [["the disease", "PROBLEM", 71, 82], ["the disease", "PROBLEM", 154, 165], ["disease", "OBSERVATION", 75, 82]]], ["And these home-made masks will not deplete the scarce inventory of masks needed for front line medical staff.", [["masks", "TREATMENT", 20, 25]]], ["We are already seeing a version of this with hand sanitizers, as recipes for home-made hand sanitizers (usually featuring grain alcohol, and softeners like Aloe vera) abound on the internet.", [["hand", "ANATOMY", 45, 49], ["hand", "ANATOMY", 87, 91], ["alcohol", "CHEMICAL", 128, 135], ["Aloe vera", "DISEASE", 156, 165], ["alcohol", "CHEMICAL", 128, 135], ["hand", "ORGANISM_SUBDIVISION", 87, 91], ["Aloe vera", "SPECIES", 156, 165], ["hand sanitizers", "TREATMENT", 45, 60], ["hand sanitizers", "TREATMENT", 87, 102]]], ["With ventilators, there are reports of individual physicians modifying ventilators to serve multiple patients simultaneously.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["ventilators", "TREATMENT", 5, 16], ["ventilators", "TREATMENT", 71, 82]]], ["This is another lesson for innovation in the recovery: users can be a powerful source of innovative ideas and opportunities in your business as well.Open innovation in crisis managementThe pandemic is also stimulating innovation in the management of intellectual property (IP).", [["Open innovation", "TREATMENT", 149, 164], ["crisis management", "TREATMENT", 168, 185], ["pandemic", "OBSERVATION", 189, 197], ["stimulating", "OBSERVATION_MODIFIER", 206, 217], ["innovation", "OBSERVATION_MODIFIER", 218, 228]]], ["Some initiatives are now in place to encourage companies and universities to release portions their intellectual property (IP) in the fight against COVID-19.", [["COVID", "TEST", 148, 153]]], ["The World Health Organization (WHO) has offered a proposal to create a patent pool for all who are working on Covid-19 initiatives, providing access to all critical scientific information in return for agreeing to compulsory licensing for essential information.", [["patent", "OBSERVATION", 71, 77]]], ["Most patents in most large companies are neither used nor licensed.", [["most large", "OBSERVATION_MODIFIER", 16, 26], ["companies", "OBSERVATION", 27, 36]]], ["This is wasteful in the best of times, and is even harder to justify in times like now.Open innovation in the public sectorIn normal times, most companies take their regulatory environment as given.", [["Open innovation", "TREATMENT", 87, 102], ["wasteful", "OBSERVATION_MODIFIER", 8, 16], ["innovation", "OBSERVATION", 92, 102], ["normal times", "OBSERVATION_MODIFIER", 126, 138]]], ["In a pandemic, though, the regulators need to adapt as well.", [["pandemic", "OBSERVATION", 5, 13]]], ["While we search for an effective vaccine, regulators should allow compassionate use of promising (but not yet approved) medicines, particularly those whose safety profiles have already been vetted as noted above.", [["an effective vaccine", "TREATMENT", 20, 40], ["medicines", "TREATMENT", 120, 129]]], ["And vaccine candidate drugs that are already approved should not have to again undergo the initial safety tests that the FDA usually requires.", [["vaccine candidate drugs", "TREATMENT", 4, 27], ["the initial safety tests", "TEST", 87, 111]]], ["If regulators in Japan approve a ventilator during the crisis, that should imply provisional acceptance for that device in Spain or the US, so long as certain procedures were followed and, importantly, the Japanese regulator shared the underlying data that justified the approval.", [["a ventilator", "TREATMENT", 31, 43], ["the US", "TEST", 132, 138]]], ["Transparency offers society protection against poor or shoddy offerings, so regulatory studies themselves need to be widely shared in these times of crisis.Open innovation in the public sectorIn order to do achieve an effective response from these various open initiatives, we need to agree upon mechanisms of coordination for the open platforms that collect the initiatives and their underlying data.", [["society protection", "TREATMENT", 20, 38], ["poor or shoddy offerings", "PROBLEM", 47, 71], ["regulatory studies", "TEST", 76, 94], ["crisis", "PROBLEM", 149, 155], ["Open innovation", "TREATMENT", 156, 171], ["the open platforms", "TEST", 327, 345], ["innovation", "OBSERVATION", 161, 171]]], ["Openness can help build trust, which is an essential ingredient in fighting a pandemic, and a critical part of sustaining your brand image in more ordinary times.Open innovation in the public sectorOther public constraints also require attention in these times.", [["your brand image", "TEST", 122, 138], ["Open innovation", "TREATMENT", 162, 177], ["innovation", "OBSERVATION", 167, 177]]], ["Product liability laws may need to be suspended temporarily, and/or public indemnification for companies from litigation may be needed to speed up the rapid development and manufacture of critical equipment, diagnostics, vaccines, and so on.", [["vaccines", "TREATMENT", 221, 229]]], ["Society should be willing to accept somewhat higher riskstill insisting on transparency in the process of developmentduring this crisis period, if it results in faster availability of these items in market.Open innovation in the public sectorIf and when the crisis begins to abate in the developed countries, it sadly seems quite likely that there will be an extension of the pandemic in less developed countries.", [["Open innovation", "TREATMENT", 206, 221], ["the crisis", "PROBLEM", 254, 264], ["innovation", "OBSERVATION", 211, 221], ["pandemic", "OBSERVATION_MODIFIER", 376, 384]]], ["The openness provisions sketched here must enable those impacted countries to quickly access all of the data, techniques, vaccines, and other technologies they will need to combat the virus (along with the human, physical and financial resources they will need).", [["human", "ORGANISM", 206, 211], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211], ["vaccines", "TREATMENT", 122, 130], ["the virus", "PROBLEM", 180, 189]]], ["This is not only just and humane, it is also enlightened selfinterest.", [["not only", "UNCERTAINTY", 8, 16]]], ["Absent such assistance, people from those countries might otherwise ignite a global revival of the virus, or give rise to a viral mutation that evades our treatments, forcing us to start the pandemic cycle all over again.Managerial implications for recovery from the crisisThere are lessons here for us for managing innovation even after the crisis has finally passed.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["the virus", "PROBLEM", 95, 104], ["a viral mutation", "PROBLEM", 122, 138], ["the pandemic cycle", "TREATMENT", 187, 205], ["the crisis", "PROBLEM", 263, 273], ["managing innovation", "TREATMENT", 307, 326], ["the crisis", "PROBLEM", 338, 348], ["crisis", "OBSERVATION", 267, 273]]], ["Openness is essential to respond to the pandemic.", [["the pandemic", "PROBLEM", 36, 48]]], ["This will sharpen their own knowledge and provide additional validation for prospective innovations being considered in your company.", [["prospective innovations", "TREATMENT", 76, 99]]], ["2) Many of your most challenging problems might benefit from solutions from others in different places around the world.", [["your most challenging problems", "PROBLEM", 11, 41]]], ["Share some of these problems, along with their relevant scientific and technical data, on open platforms, so that anyone with the interest and knowledge can offer their ideas on how best to address the problem.", [["problems", "OBSERVATION", 20, 28]]], ["3) Work with your legal team to manage your internal IP more creatively and openly.", [["your internal IP", "TREATMENT", 39, 55]]], ["Instead, separate your IP into three buckets: a) the Crown Jewels, that will be protected as before; b) the Middle group that can be shared selectively with key customers, suppliers, and/or partners for mutual business benefit; and c) the Long Tail of IP that should be opened up to everyone (thus enabling others to innovate more, and saving on patent renewal fees).", [["the Long Tail of IP", "TREATMENT", 235, 254]]], ["Only now there is an entire new market waiting for the improved product, built up from the earlier generation of licensing.ConclusionGood ideas can come from anywhere, making openness is an imperative in these times of crisis.", [["crisis", "PROBLEM", 219, 225], ["entire", "OBSERVATION_MODIFIER", 21, 27], ["new", "OBSERVATION_MODIFIER", 28, 31], ["market", "OBSERVATION", 32, 38]]], ["This is one of the many lessons we are learning as we struggle to meet the challenge of our times.ConclusionThis openness contrasts sharply with some of the rising nationalist trends we are seeing.", [["the rising nationalist trends", "PROBLEM", 153, 182], ["many", "OBSERVATION_MODIFIER", 19, 23], ["lessons", "OBSERVATION", 24, 31]]], ["Excluding entire countries from access to vaccines, or ventilators, or masks, or tests, or other critical equipment will undermine the ability to enlist the creative minds and imaginations of us all to address the crisis.", [["vaccines", "TREATMENT", 42, 50], ["ventilators", "TREATMENT", 55, 66], ["masks", "TREATMENT", 71, 76], ["tests", "TEST", 81, 86], ["the crisis", "PROBLEM", 210, 220]]], ["Moreover, it is short-sighted in the extreme, as shifting the pandemic out of one country in the short term will only cause it to return later, possibly in a mutated form.", [["short", "OBSERVATION_MODIFIER", 16, 21]]]], "4475e81e95798c35efa6b7e7cc0d19b70ad9010b": [["The considerations expended in this regard are merely to study benefits of financial intermediation (size, maturity and risk transformation of intermediated funds, delegated monitoring and others), and the existing models based on macroeconomic theory are put to use to demonstrate that the ultimate effect is moderation of transaction costs for both surplus and deficit units.", [["financial intermediation (size", "PROBLEM", 75, 105], ["transaction costs", "TREATMENT", 324, 341], ["both surplus and deficit units", "TREATMENT", 346, 376], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["In spite of the declared benefits of financial intermediation and models proving its uniqueness for economic growth, what is overlooked and insufficiently recognized is that financial intermediation must be accomplished and this accomplishment may be far from being optimal.", [["financial intermediation", "TREATMENT", 37, 61], ["economic growth", "PROBLEM", 100, 115]]], ["From a macroeconomic point of view, financial intermediation is successful when effective demand for funds is satisfied with available funds collected from surplus units.", [["financial intermediation", "TREATMENT", 36, 60]]], ["Of course, there are different types of financial intermediaries.", [["course", "OBSERVATION_MODIFIER", 3, 9]]], ["Some collect funds from surplus units in the form of deposits and distribute them to deficit units in the form of loans, others are engaged with their operations more with the capital market and lend via the purchase of securities.", [["surplus units", "TREATMENT", 24, 37], ["deposits", "PROBLEM", 53, 61], ["deposits", "OBSERVATION", 53, 61]]], ["It merely describes size or depth of financial intermediation as was rendered with no reference to best practices.IntroductionWith a focus laid upon the banking provision of financial intermediation, the present paper strives to rectify this perceptible deficiency of the traditional assessment based on a single ratio.", [["financial intermediation", "PROBLEM", 37, 61], ["financial intermediation", "TREATMENT", 174, 198], ["this perceptible deficiency", "PROBLEM", 237, 264], ["the traditional assessment", "TEST", 268, 294], ["a single ratio", "TEST", 304, 318], ["size", "OBSERVATION_MODIFIER", 20, 24], ["depth", "OBSERVATION_MODIFIER", 28, 33]]], ["For the needs of macroeconomic policy and also in part of banking regulation, the paper proposes a model of financial intermediation that builds from the principles of data envelopment analysis (DEA) and that is designated to identify and measure lost opportunities in financial intermediation.", [["macroeconomic policy", "TREATMENT", 17, 37], ["banking regulation", "TREATMENT", 58, 76]]], ["These lost opportunities present themselves whenever there is a missed chance of transforming a smaller volume of available funds (deposits) into a greater volume of intermediated funds (loans).", [["smaller", "OBSERVATION_MODIFIER", 96, 103], ["greater", "OBSERVATION_MODIFIER", 148, 155], ["volume", "OBSERVATION_MODIFIER", 156, 162]]], ["In spite of confining banking production notionally to taking on one common category of deposits (on the input side) in providing different categories of loans (on the output side), the utilization of the model is much broader as the list of different categories of loans may equally well encompass noncreditory outcomes of financial intermediation such as mutual fund shares and other securities.", [["deposits", "OBSERVATION", 88, 96]]], ["The difference between the best attainable projection and the actually observed position is translated into an index of financial intermediation with the aid of deflation and inflation factors (for deposits and loans, respectively).IntroductionA thick line must be drawn at this instance between the present framework and the theoretical construct known in banking performance studies and elsewhere as the \"intermediation approach\".", [["inflation factors", "PROTEIN", 175, 192], ["financial intermediation", "TREATMENT", 120, 144], ["deflation and inflation factors", "TREATMENT", 161, 192], ["IntroductionA thick line", "TREATMENT", 232, 256], ["banking performance studies", "TEST", 357, 384], ["index", "OBSERVATION_MODIFIER", 111, 116], ["deflation", "OBSERVATION", 161, 170]]], ["In contrast, the present framework is not concerned with efficiency of all (i.e. also non-intermediary) banking activities, but isolates and measures in the form of an index merely aspects of intermediation activities.", [["index", "OBSERVATION", 168, 173]]], ["Since the intermediation approach as such is immensely proliferated and popular, its theoretical account is furnished in this text only marginally, but is available with notes on its use in a DEA context in Ahn and Le (2014) .", [["the intermediation approach", "TREATMENT", 6, 33], ["immensely", "OBSERVATION_MODIFIER", 45, 54], ["proliferated", "OBSERVATION_MODIFIER", 55, 67], ["popular", "OBSERVATION_MODIFIER", 72, 79]]], ["Still, a comparison of the traditional efficiency measurement founded on the intermediation approach and the measurement of attained financial intermediation according to the proposed modelling framework is provided.", [["the traditional efficiency measurement", "TEST", 23, 61]]], ["This comparison is part of the empirical demonstration, in which the proposed model is applied to a data set of Slovak commercial banks for a 9-year period between 2008 and 2016.IntroductionThere are no less than three outstanding features of the model.", [["the empirical demonstration", "TEST", 27, 54], ["no", "UNCERTAINTY", 200, 202], ["less", "OBSERVATION_MODIFIER", 203, 207]]], ["Since it turns out that the index devised to measure the attainment in financial intermediation reduces to the inverse of a weighted slacks-based measure (WSBM) using only the variables involved directly in financial intermediation, traditional devices can be easily adapted to handle the proposed modelling framework.", [["the index", "TEST", 24, 33], ["a weighted slacks", "TREATMENT", 122, 139], ["financial intermediation", "TREATMENT", 207, 231], ["traditional devices", "TREATMENT", 233, 252]]], ["Third, the model recognizes that diverse categories of loans as outcomes of financial intermediation display basically differentiated significance to the economy and contribute to economic prosperity differently.", [["diverse", "OBSERVATION_MODIFIER", 33, 40]]], ["This is captured through (most likely differentiated) weights assigned to different categories of loans; hence, the reason why the \"weighted\" SBM arises in the process.IntroductionThe remainder of the paper is structured into four more sections.", [["sections", "ANATOMY", 236, 244]]], ["Some minor results are postponed to \"Appendix\".Financial intermediation and its modelling in the literatureFinancial intermediation aids an economy in resource allocation and transformation of financial contracts and securities understood in a loose meaning of the term (Freixas and Rochet 2008, p.", [["Financial intermediation", "TREATMENT", 47, 71], ["financial contracts", "TREATMENT", 193, 212]]], ["A number of microeconomic models have been developed in order to provide rationale for financial intermediation and to prove its benefits to an economy (see, for example, Freixas and Rochet 2008) .", [["microeconomic models", "PROBLEM", 12, 32], ["financial intermediation", "TREATMENT", 87, 111]]], ["These models study how financial intermediation influences the economy under a variety of market conditions and how government policies affect financial intermediation.", [["These models study", "TEST", 0, 18]]], ["Another research front, which suffers from the same limitations depicted above, is empirical, and this seeks to justify dependence of economic growth and prosperity upon financial development, which has come to be known as the finance-growth nexus.", [["economic growth", "PROBLEM", 134, 149]]], ["A large body of literature has represented financial intermediation by sundry partial indicators related to the financial sector (or institutions) without measuring whether financial intermediation in itself is successful at all (e.g. Hondroyiannis et al. 2005; Sharma and Bardhan 2017; Ho and Iyke 2018; Olaniyi and Oladeji 2020) .Financial intermediation and its modelling in the literatureTo some extent the matter of measuring attainment (or excellence) in financial intermediation is handled through the loan-to-deposit ratio, an indicator that is used in studies of a macroeconomic focus.", [["Financial intermediation", "TREATMENT", 332, 356], ["large", "OBSERVATION_MODIFIER", 2, 7], ["body", "OBSERVATION_MODIFIER", 8, 12], ["extent", "OBSERVATION_MODIFIER", 400, 406], ["matter", "OBSERVATION_MODIFIER", 411, 417]]], ["This indicator is not appreciated sufficiently by the academic community, but is standard in regulatory use by central banks (Office of the Comptroller of the Currency 2016; DiSalvo and Johnston 2017; European Banking Authority 2017, p.", [["not appreciated", "UNCERTAINTY", 18, 33]]], ["One of possible interpretations of the loan-to-deposit ratio is that it is a comprehensive measure of attainment in financial intermediation by commercial banks that collect funds in the form of deposits and grant them in the form of loans.", [["deposits", "PROBLEM", 195, 203], ["deposits", "OBSERVATION", 195, 203]]], ["Apparently, its descriptive role is more pronounced in financial systems where institutionalized capital markets play a minor role.", [["more pronounced", "OBSERVATION_MODIFIER", 36, 51]]], ["Although the loan-to-deposit ratio is easily computable and interpretable, it suffers from all deficiencies that befall traditional ratio analysis (see Paradi and Zhu 2013, pp. 62-63 , and the references therein).", [["all deficiencies", "PROBLEM", 91, 107], ["traditional ratio analysis", "TEST", 120, 146]]], ["Furthermore, it is a static measure that captures the relationship between the balance sheet amounts of total deposits and total loans and does not inform whether this proportion might not be more advantageous or to what extent the intermediation potential of banks was utilized in order to create a maximum of loans possibly with a minimum of deposits.Financial intermediation and its modelling in the literatureIn spite of a misleading similarity, excellence in financial intermediation per se differs conceptually from efficiency in banking operations as is outlined under the \"intermediation approach\" irrespective of whether it efficiency is examined using DEA or a stochastic frontier approach.", [["DEA", "CHEMICAL", 662, 665], ["total deposits", "PROBLEM", 104, 118], ["Financial intermediation", "TREATMENT", 353, 377], ["banking operations", "TREATMENT", 536, 554], ["a stochastic frontier approach", "TREATMENT", 669, 699], ["deposits", "OBSERVATION", 344, 352]]], ["The model proposed in this paper zooms in upon how a bank fares in collecting deposits and dispersing them in the form of loans, whilst the intermediation approach as viewed in efficiency studies centres upon efficiency of (all) banking operations when the bank is predestined as a financial intermediary (rather than a facility producing banking services).", [["collecting deposits", "PROBLEM", 67, 86], ["the intermediation approach", "TREATMENT", 136, 163], ["banking operations", "TREATMENT", 229, 247], ["deposits", "OBSERVATION", 78, 86]]], ["The intermediation approach is in detail described, for example, in Ahn and Le (2014, pp. 9-12) and Duygun-Fethi and Pasiouras (2010, p.", [["Duygun", "TEST", 100, 106], ["Le", "ANATOMY", 76, 78]]], ["Adoption of the intermediation approach first and foremost translates into a specification of the model of banking production in which deposits are identified as (one of the) inputs and loans as outputs.", [["the intermediation approach", "TREATMENT", 12, 39]]], ["Furthermore, the sole focus the proposed modelling framework to loans and deposits ameliorates the issue with the intermediation approach observed by Fortin and Leclerc (2007) who find that an incomplete coverage of intermediated assets and liabilities in the specified input-output set produces bias in technical efficiency measurement.", [["deposits ameliorates", "PROBLEM", 74, 94], ["the intermediation approach", "TREATMENT", 110, 137], ["technical efficiency", "OBSERVATION", 304, 324]]], ["In fact, deliberate specialization to loans and deposits in measuring attainment in financial intermediation neglects other assets and liabilities that may be instrumental in intermediation activities (and leads to an incomplete coverage of the balance sheet), but also highlights what both academic and practitioners' community finds the core of financial intermediation carried out by commercial banks-transformation of deposits into loans.Financial intermediation and its modelling in the literatureTo the best knowledge of the authors, no other methodological framework is proliferated that serves the purpose of measuring attainment in financial intermediation than the one grounded in using the loan-to-deposit ratio.", [["Financial intermediation", "TREATMENT", 442, 466], ["deposits", "OBSERVATION", 422, 430]]], ["This deviation is defined in an additive fashion as a difference.Proposed modelling frameworkA somewhat simplified approach to modelling the essence and structure of financial intermediation is posited that reduces the balance sheet of a commercial bank on the assets side into different kinds of loans and on the liabilities side into total deposits.", [["This deviation", "PROBLEM", 0, 14], ["total deposits", "PROBLEM", 336, 350]]], ["Although commercial banks do employ also other funding in complement to total deposits, these purchased funds fulfil merely an accessory role and make up for slacks in deposits funding whenever traditional funds collected from depositors are not sufficient.", [["total deposits", "PROBLEM", 72, 86], ["slacks in deposits funding", "PROBLEM", 158, 184]]], ["Furthermore, in contrast to loans, it is scarcely useful to recognize different kinds of deposits as the decisively major portion of deposits comes from individual non-institutionalized depositors and not from business entities or banks.", [["different kinds of deposits", "PROBLEM", 70, 97], ["deposits", "OBSERVATION", 89, 97], ["deposits", "OBSERVATION", 133, 141]]], ["Other criteria of grouping such as profit margin or riskiness may be of import to a bank, but are immaterial whenever the measurement of financial intermediation is undertaken on a macroeconomic or regulatory level.", [["riskiness", "PROBLEM", 52, 61], ["financial intermediation", "PROBLEM", 137, 161]]], ["The reason being, various kinds of loans contribute to economic growth with varying degrees of relevance (see, for example, Choudhry 2012, pp. 59-74; \u010cernohorsk\u00fd 2017; Malikov et al. 2015) .", [["economic growth", "PROBLEM", 55, 70]]], ["Naturally, loans are not the only outcome of financial intermediation as banks also transform deposits into securities or other investments, but the avenue to generalization in this direction is obvious.Proposed modelling frameworkThe following set-up thus assumes that there is a panel of observations available for N banks over T time periods {t 1 , \u2026 , t T } .", [["financial intermediation", "TREATMENT", 45, 69]]], ["This panel may possibly be unbalanced, but for an arbitrary bankProposed modelling frameworkTo preserve the validity of mathematical presentation, in what follows, summations over bank-years are further carried out with respect to the full index setProposed modelling framework.", [["This panel", "TEST", 0, 10], ["may possibly be", "UNCERTAINTY", 11, 26]]], ["Whenever P = 0 or R = 0 , these other inputs or outputs can simply be dropped and do not enter the formulations to come.Proposed modelling frameworkThe conceptual interpretation of this situation is visualized in Fig. 1 that shows the circumstances of production and financial intermediation for a bank i in a period t .", [["P", "TEST", 9, 10]]], ["Whilst all inputs are most likely interconnected in production of all outputs as is indicated by the arrows, the visualization recognizes that the process of banking production consists of two different sub-processes: the transmutation of deposits into loans is the core of financial intermediation, and this transmutation is technically complemented by another sub-process in which typically other inputs are utilized (such as physical capital and labour force) in producing other outputs (such as various services rendered).", [["banking production", "PROBLEM", 158, 176], ["physical capital and labour force", "TREATMENT", 428, 461], ["most likely", "UNCERTAINTY", 22, 33], ["deposits", "OBSERVATION", 239, 247]]], ["Of course, the technical sub-process is effected alongside the intermediation sub-process and participates in it.Proposed modelling frameworkThere are two key economic ingredients that the proposed framework necessitates: (1) technological invariance and (2) shared non-exhaustible demand for loans.Proposed modelling frameworkFirst, in what follows, production data available for different years of the full T-year period and for various banks are pooled together, and the entire panel is utilized in constructing an estimate of the underlying production technology after the fashion of DEA.", [["DEA", "CHEMICAL", 588, 591], ["DEA", "CHEMICAL", 588, 591], ["DEA", "SIMPLE_CHEMICAL", 588, 591], ["the entire panel", "TEST", 470, 486]]], ["This is only possible by assuming hereinafter that the production technology remains invariant and without alterations throughout the entire span of T time periods.", [["only possible", "UNCERTAINTY", 8, 21]]], ["Naturally, this is barely an innocent assumption, but it is appropriate whenever there are no structural breaks, economic shifts or political upheavals.", [["structural breaks", "PROBLEM", 94, 111], ["political upheavals", "TREATMENT", 132, 151], ["no", "UNCERTAINTY", 91, 93], ["structural breaks", "OBSERVATION", 94, 111]]], ["The decision which years can be deemed as free of structural breaks is obviously judgemental, albeit it may partly be assisted by analytical tools.", [["breaks", "OBSERVATION", 61, 67]]], ["The stringent assumption of technology invariance can be relaxed, which would necessitate some further adjustment and specialization of the ensuing formulations.", [["the ensuing formulations", "TREATMENT", 136, 160]]], ["Second, with a certain flavour of abstraction, it is also assumed that all banks face a non-exhaustible demand for loans of each type and so there are no limits on the volume of loans they may provide.", [["abstraction", "OBSERVATION", 34, 45]]], ["The assumption is fairly strong since it entails that there are no serious competitive hindrances between banks and that no bank operates in markedly disadvantaged conditions.", [["fairly strong", "OBSERVATION_MODIFIER", 18, 31], ["no", "UNCERTAINTY", 64, 66]]], ["Such a conception cannot be responsibly taken for flawless since certainly some level of deposits is healthy and inevitable.", [["deposits", "OBSERVATION", 89, 97]]], ["However, this can be handled by adding a suitable constraint upon total deposits as will be discussed later.", [["total deposits", "TREATMENT", 66, 80]]], ["Downward adjustments of deposits and upward adjustments of loans of different categories may be handled multiplicatively by individual radial adjustments or additively by slacks, and both these approaches are mathematically equivalent.", [["Downward adjustments of deposits", "PROBLEM", 0, 32], ["deposits", "OBSERVATION", 24, 32], ["upward", "OBSERVATION_MODIFIER", 37, 43]]], ["In the initial portrayal of financial intermediation deposits are to be deflated whereas different categories of loans are to be inflated, which can be represented by simultaneous projec-Proposed modelling frameworkThe factors it and l it are traditional contraction and expansion adjustments of deposits and loans, respectively, which can be further restated through additive slacks in deposits s D,it (excesses such that s D,it \u2265 0 ) and in loans s l L,it (shortfalls such that s l L,it \u2265 0 ).", [["financial intermediation deposits", "TREATMENT", 28, 61], ["traditional contraction", "PROBLEM", 243, 266], ["expansion adjustments of deposits", "PROBLEM", 271, 304], ["deposits", "OBSERVATION", 53, 61], ["deflated", "OBSERVATION", 72, 80], ["contraction", "OBSERVATION", 255, 266], ["expansion", "OBSERVATION_MODIFIER", 271, 280], ["adjustments", "OBSERVATION_MODIFIER", 281, 292], ["deposits", "OBSERVATION_MODIFIER", 296, 304]]], ["Hence, the connection between the factors and slacks is governed by relationships it = 1 \u2212 s D,it \u2215D it and l it = 1 + s l L,it \u2215L l it .", [["L l", "ANATOMY_MODIFIER", 129, 132]]], ["Whenever it is felt that deposits should not be suppressed beneath a pre-specified threshold, an extra constraint may be introduced such as \u2212 \u2264 it , where \u2212 Fig. 1 Conceptual schema of banking production wherein financial intermediation is a sub-process is the maximum allowable contraction of deposits.", [["deposits", "PROBLEM", 25, 33], ["an extra constraint", "TREATMENT", 94, 113], ["deposits", "OBSERVATION", 25, 33], ["deposits", "OBSERVATION", 294, 302]]], ["The differentiated importance of different types of loans is assumed to be embodied in normalized weights v l , l \u2208 {1, \u2026 , \u03a9} , such that v l > 0 for all l \u2208 {1, \u2026 , \u03a9} and \u2211 l v l = 1.", [["different types", "OBSERVATION_MODIFIER", 33, 48]]], ["Unrealized potential in financial intermediation can be naturally identified individually with different categories of loans and depicted by normalized inflation factors l it \u2215 it that can further be assembled into a weighted average representationProposed modelling frameworkThe fundamental idea is that financial intermediation is successful and effective whenever all deposits are transmuted into loans, or possibly, with a minimum utilization of deposits maximum loans are provided.", [["all deposits", "PROBLEM", 367, 379]]], ["This suggests that deposits should be deflated to the greatest extent possible whereas loans should be inflated in like manner.", [["deposits", "PROBLEM", 19, 27], ["deposits", "OBSERVATION", 19, 27], ["deflated", "OBSERVATION", 38, 46], ["greatest extent", "OBSERVATION_MODIFIER", 54, 69]]], ["In this context, a single ratio l it \u2215 it measures in an isolated way to what extent loans of type l can be maximized relative to deposits that are wished to be jointly minimized.", [["a single ratio l", "TREATMENT", 17, 33], ["deposits", "OBSERVATION", 130, 138]]], ["Hence, the ratio l it \u2215 it represents a factor by which the actually observed loan-to-deposit ratio may be increased.", [["may be", "UNCERTAINTY", 100, 106], ["increased", "OBSERVATION_MODIFIER", 107, 116]]], ["The weighted normalized inflation factor \u2211 l (v l l it \u2215 it ) reflects stratified significance of different categories of loans and constitutes merely an importance-weighted multiplier applied to the current observed loan-to-deposit ratio.", [["loan", "PROTEIN", 217, 221], ["The weighted normalized inflation factor", "TEST", 0, 40]]], ["The suggested interpretation ofProposed modelling frameworkis that a value of 1 will imply that financial intermediation is accomplished at its maximum potential, but a value greater than 1 will indicate that there is some ex post identifiable room for improvement and squandered capacity to financially connect deficit and surplus economic agents.", [["a value", "TEST", 167, 174], ["squandered capacity", "PROBLEM", 269, 288], ["financially connect deficit", "PROBLEM", 292, 319], ["surplus economic agents", "TREATMENT", 324, 347]]], ["In order to identify the highest unrealized potential in financial intermediation, the average factor \u2211 l (v l l it \u2215 it ) need be maximized.", [["v l l it \u2215 it", "TREATMENT", 107, 120]]], ["Nevertheless, by subsequent manipulation, it is obtained that which is but the reciprocal of a weighted slacks-based measure (WSBM) defined by dint of one input D it and \u03a9 outputs L l it , l \u2208 {1, \u2026 , \u03a9} , with differentiated weights.", [["\u03a9", "PROTEIN", 170, 171], ["\u03a9}", "PROTEIN", 201, 203], ["differentiated weights", "PROBLEM", 211, 233]]], ["In consequence, the identification of the most pronounced unrealized potential in financial intermediation can be performed in a traditional WSBM framework sinceProposed modelling frameworkThe WSBM presented in (3) after the min operator does not encompass other inputs it and outputs it that are to be treated in a DEA framework as traditional non-discretionary inputs and outputs or exogenously fixed production variables in the terminology of Banker and Morey (1986) who were amongst the first to realize that some variables owing to their non-discretionary nature should not enter an efficiency measure directly.", [["traditional non-discretionary inputs", "PROBLEM", 333, 369]]], ["These variables will assist in setting-up (or rather estimation) of the underlying production set that is formed by all 1 + P inputs (deposits plus other inputs) and \u03a9 + R outputs (loans of different categories plus other outputs).Proposed modelling frameworkThe representation of the weighted normalized inflation factor as the reciprocal of the corresponding WSBM is the key ingredient to the proposed model of financial intermediation.", [["\u03a9 + R", "GENE_OR_GENE_PRODUCT", 166, 171], ["\u03a9", "PROTEIN", 166, 167], ["weighted normalized inflation factor", "PROTEIN", 285, 321], ["WSBM", "PROTEIN", 361, 365], ["\u03a9 + R outputs", "PROBLEM", 166, 179], ["the weighted normalized inflation factor", "PROBLEM", 281, 321]]], ["Whilst one variant (addressed as Model I) captures the attainment in financial intermediation of a single bank in one period, the other variant (referred to as Model II) renders this on an aggregate basis-aggregated either for several time periods (perhaps the entire period analysed) or for several banks (perhaps the entire sector).", [["Model II", "PROTEIN", 160, 168]]], ["As a consequence, the benchmark values for the average normalized inflation factor are then one and a value greater than one.", [["inflation factor", "PROTEIN", 66, 82], ["the benchmark values", "TEST", 18, 38], ["a value", "TEST", 100, 107]]], ["Apparently, the logic of this construction lends a possibility of referring the average normalized inflation factor to as the index of financial intermediation.Proposed modelling frameworkAlbeit the models are presented as fractional programming problems, they can easily be transformed to equivalent linear programming problems using the algebra of the Charnes-Cooper transformation.Proposed modelling frameworkand strives to identify the unrealized potential in financial intermediation on the basis of the following fractional programProposed modelling framework1 The transformation itself is skipped here since the model happens to be a variation of the WSBM model and a reiteration of the technique would add no novelty to Tone (2001, p.", [["inflation factor", "PROTEIN", 99, 115], ["financial intermediation", "TREATMENT", 135, 159], ["fractional programming problems", "PROBLEM", 223, 254], ["the technique", "TREATMENT", 690, 703]]], ["It depends on whether the convexity restriction requiring that intensity variables sum to unity is enforced by the optional condition in (4f).", [["the convexity restriction", "PROBLEM", 22, 47]]], ["The imposition of the optional unit sum condition should be guided by conventional wisdom and hinges upon the presumed degree of homogeneity of observed production activities and their operating setting.", [["the optional unit sum condition", "TREATMENT", 18, 49], ["observed production activities", "PROBLEM", 144, 174]]], ["In addition, condition (4d) is a mere restatement of the requirement \u2212 \u2264 it that the deflation of deposits should not be unbounded, but regulated by the carefully chosen lower bound \u2212 .", [["the deflation of deposits", "PROBLEM", 81, 106], ["deposits", "OBSERVATION", 98, 106]]], ["Obviously, this condition becomes null and redundant if \u2212 is set to zero.", [["null", "PROBLEM", 34, 38]]], ["Throughout the production possibility set, a projection upon the part of the frontier (envelope) is sought with the aid of (4) that minimizes the WSBM o and equivalently maximizes the weighted average normalized inflation factor \u22121 o .", [["inflation factor", "PROTEIN", 212, 228]]], ["A crucial aspect of (4) is that the objective function is to be minimized so the deviation from the most technically favourable weighted average loan-to-deposit ratio is to be identified.subject toFor each bank and time instance, there are as many as \u03a9 + 2 crucial variables in the optimal solution of Model I yielded by (the linearized version of) program (4) relevant from an economic standpoint: the optimal solution for the weighted average normalized inflation factor * \u22121 o , the optimized values of slacks s * D,o for deposits and s l * L,o , l \u2208 {1, \u2026 , \u03a9} , for loans of different categories.", [["Model I", "PROTEIN", 302, 309], ["inflation factor", "PROTEIN", 456, 472], ["the deviation", "PROBLEM", 77, 90], ["the optimal solution", "TREATMENT", 399, 419], ["deposits", "TEST", 525, 533], ["crucial", "OBSERVATION_MODIFIER", 2, 9]]], ["Whereas * \u22121 o is a comprehensive indicator of the missed potential in financial intermediation, the slack variables then quantify by what amount deposits might have been smaller and loans greater in order to improve in financial intermediation.subject toUnlike Model I, Model II operates on an aggregate basis and is designed to explain the average performance of a bank over the entire period or the entire sector in 1 year in terms of financial intermediation.", [["what amount deposits", "PROBLEM", 134, 154], ["financial intermediation", "TREATMENT", 438, 462], ["deposits", "OBSERVATION", 146, 154], ["smaller", "OBSERVATION_MODIFIER", 171, 178]]], ["If Model II is applied to measure financial intermediation for a bank o in the entire period, thensubject toBefore switching to Model II, consider average production quantities that arise from the aggregation and that correspond to the production set-up displayed in Fig. 1 .", [["average production quantities", "PROBLEM", 147, 176], ["the aggregation", "PROBLEM", 193, 208]]], ["These average production quantities in question are given by expressionssubject toTo this end, in the preceding enumeration and in what follows, the notation || S || is used to indicate the cardinality of a set S .", [["average", "OBSERVATION_MODIFIER", 6, 13], ["production", "OBSERVATION_MODIFIER", 14, 24], ["quantities", "OBSERVATION_MODIFIER", 25, 35]]], ["An appropriate normalized inflation factor for loans of type l then arises in aggregated form as wherein \u0304l is the inflation factor applied to total (or average) loans of type l and \u0304 is the deflation factor applied to total (or average) deposits.", [["inflation factor", "PROTEIN", 26, 42], ["\u0304l", "PROTEIN", 105, 107], ["inflation factor", "PROTEIN", 115, 131], ["deflation factor", "PROTEIN", 191, 207], ["the inflation factor", "TREATMENT", 111, 131], ["type l", "PROBLEM", 171, 177], ["the deflation factor", "TREATMENT", 187, 207], ["normalized", "OBSERVATION_MODIFIER", 15, 25], ["inflation", "OBSERVATION", 26, 35], ["deflation", "OBSERVATION", 191, 200]]], ["The totalling or averaging is here carried out for all loans and deposits reported in those bank-years that are contained in \u2111.subject toNow the weighted normalized inflation factor that measures the unrealized potential in financial intermediation in an aggregate setting is defined in a vein similar to the case of Model I, but now with the aid of average inflation and deflation factors as \u2211 l (v l\u0304l \u2215\u0304) .", [["vein", "ANATOMY", 289, 293], ["vein", "MULTI-TISSUE_STRUCTURE", 289, 293], ["inflation factor", "PROTEIN", 165, 181], ["average inflation", "TREATMENT", 350, 367], ["deflation factors", "TREATMENT", 372, 389], ["vein", "ANATOMY", 289, 293], ["inflation", "OBSERVATION", 358, 367], ["deflation", "OBSERVATION_MODIFIER", 372, 381]]], ["As before, it is immediately obtained that in which s l L and s D are non-negative quantities that satisfy \u0304l = 1 +s l L \u2215L l and \u0304= 1 \u2212s D \u2215D , and that represent the shortfall in average loans of type l and the excess in average deposits, respectively.", [["\u0304l", "TEST", 107, 109], ["L", "ANATOMY_MODIFIER", 122, 123], ["l", "ANATOMY_MODIFIER", 124, 125], ["shortfall", "OBSERVATION_MODIFIER", 168, 177], ["type l", "OBSERVATION_MODIFIER", 198, 204], ["excess", "OBSERVATION_MODIFIER", 213, 219]]], ["So, again, the weighted normalized inflationsubject tofactor is the reciprocal of the associated WSBM defined for average loans of different types and average deposits where the aggregation is done for all bank and time indices in \u2111.subject toIn step with these developments and in analogy to Model I, Model II is built upon the following fractional program helpful in identifying the missed potential in financial intermediation with the aggregation happening for all bank and time indices encompassed in \u2111 subject tosubject toThe construction of (7) is identical to (4), but now the optimization is carried out with the quantities averaged for \u2111 and the optimization conditions appearing in (7a)-(7f) are required to hold for production averages computed from all banks and times comprised in \u2111.subject toThe relevant output of Model II in the optimal solution to (the linearized version of) program (7) for a policy-maker is again the optimal weighted average normalized inflation factor * \u22121 \u2111 as well as the optimal values of slacks in deposits || \u2111|| \u22c5s * D and loans of different categories || \u2111|| \u22c5s l * L with the interpretation transcended from that of Model I. Since the optimal slacks || \u2111|| \u22c5s * D and || \u2111|| \u22c5s l * L are multiplied by || \u2111|| , they answer to totals calculated for all bank-years encompassed in \u2111.subject toNote that the groundwork for Model II that shapes its formulation in program (7) is the definition of normalized inflation factors.", [["WSBM", "PROTEIN", 97, 101], ["Model II", "PROTEIN", 830, 838], ["inflation factor", "PROTEIN", 974, 990], ["\u22c5s", "PROTEIN", 1204, 1206], ["inflation factors", "PROTEIN", 1450, 1467], ["average deposits", "PROBLEM", 151, 167], ["the aggregation", "PROBLEM", 174, 189], ["the aggregation", "PROBLEM", 435, 450], ["categories", "TEST", 1087, 1097], ["the interpretation", "TEST", 1119, 1137], ["D", "TEST", 1209, 1210], ["\u2111", "TEST", 1218, 1219], ["totals", "TEST", 1273, 1279], ["all bank", "TEST", 1295, 1303], ["normalized inflation factors", "PROBLEM", 1439, 1467], ["different types", "OBSERVATION_MODIFIER", 131, 146], ["inflation", "OBSERVATION", 1450, 1459]]], ["Suppose now that that the definitional outset of the normalized inflation factor for loans of type l in (5) is perhaps more appropriate.", [["inflation factor", "PROTEIN", 64, 80]]], ["If the normalized inflation factor is put related to the missed potential over individual bank-years in \u2111 instead of all bank-years in \u2111 en bloc, then (5) becomessubject tois the average inflation factor applied to loans of type l and \u0304= \u2211 \u2211subject tois the average deflation factor applied to deposits.", [["inflation factor", "PROTEIN", 187, 203], ["deflation factor", "PROTEIN", 266, 282], ["the normalized inflation factor", "PROBLEM", 3, 34], ["\u2111 en bloc", "TREATMENT", 135, 144], ["the average inflation factor", "TREATMENT", 175, 203]]], ["The weights are derived from shares of loans L l it and deposits D it on their total aggregates \u2211 \u2211 [i,t] \u2208\u2111 L l it and deposits \u2211 \u2211 [i,t] \u2208\u2111 D it , respectively.", [["[i,t] \u2208\u2111 D", "CHEMICAL", 133, 143], ["their total aggregates", "TEST", 73, 95], ["t", "TEST", 103, 104], ["deposits", "TEST", 120, 128], ["t", "TEST", 136, 137], ["deposits", "OBSERVATION", 56, 64]]], ["When such a formulation is applied to the entire sector for one particular time, then these weights are shares of individual banks on the loans of type l and deposits of the entire sector.", [["a formulation", "TREATMENT", 10, 23]]], ["Likewise, when it is applied to a bank in the entire period, then these weights capture how the production of loans and collection of deposits by the bank was distributed over the entire period.", [["collection of deposits", "PROBLEM", 120, 142], ["deposits", "OBSERVATION", 134, 142]]], ["As a consequence-the normalized inflation factor in (6) transforms by consecutive simplifications into in which \u2211 \u2211 [i,t] \u2208\u2111 s l L,it is the total slack amount of shortfall in loans of type l and \u2211 \u2211 [i,t] \u2208\u2111 s D,it is the total slack amount of excesses in deposits.", [["inflation factor", "PROTEIN", 32, 48], ["the normalized inflation factor", "PROBLEM", 17, 48], ["s D", "TEST", 209, 212], ["excesses in deposits", "PROBLEM", 245, 265], ["excesses", "OBSERVATION", 245, 253], ["deposits", "OBSERVATION", 257, 265]]], ["The described developments suggest the following fractional program that is drawn up for all bank-years in \u2111 and that builds directly on individual bank-year data rather than on average production quantities subject to (10) is an analogy of programs (4) and (7) presented earlier, but now the optimization is undertaken with respect to all bank-years in \u2111 and also the conditions in (10a)-(10f) are stipulated for all production quantities comprised in \u2111 on an individual basis.", [["(10a)-(10f)", "SIMPLE_CHEMICAL", 383, 394]]], ["Of import to a policy-maker are again the optimal solution * \u2111,ind and the aggregate optimal solutions for slacks in deposits \u2211 \u2211 (10) per se necessitates optimizing for || \u2111|| slacks in deposits, \u03a9 \u22c5 || \u2111|| slacks in loans and || \u2111 F || intensity variables it .", [["slacks", "DISEASE", 107, 113], ["\u2211", "CHEMICAL", 128, 129], ["\u03a9", "PROTEIN", 197, 198], ["\u2111", "PROTEIN", 204, 205], ["slacks", "PROTEIN", 208, 214], ["slacks in deposits", "PROBLEM", 107, 125], ["slacks", "TEST", 177, 183], ["deposits", "TEST", 187, 195], ["slacks", "TEST", 208, 214], ["loans", "TEST", 218, 223], ["intensity variables", "TEST", 238, 257]]], ["In such cases, it is not possible to find a common set of intensity variables it that would satisfy the conditions declared in (10a)-(10c).", [["(10a)-(10c", "SIMPLE_CHEMICAL", 127, 137]]], ["Unfortunately, it transpires that the more comprehensive formulation laid down in (10) is visited by the infeasibility issue too frequently, which is a serious hindrance to its usefulness.Much of programThe said issue may be partially rectified and alleviated by turning to different representations that provide lower and upper bounds for a feasible solution to (10).", [["a feasible solution", "TREATMENT", 340, 359]]], ["An upper bound is obtained by applying Model I individually for all bank and time indicesMuch of programHaving all these components assembled, a series of inequalities provides the desired bounds that are valid under the proviso that an optimal solution to (10) exists:Much of programfor WSBMs * \u2111 \u2264 * \u2111,ind \u2264 * \u2111,Model I (and equivalently for indices of financial intermediation * \u22121 \u2111,Model I \u2265 * \u22121 \u2111,ind \u2265 * \u22121 \u2111 ), then for slacks in deposits \u2211 \u2211 (10) and (7) is their conditions.", [["slacks", "DISEASE", 429, 435], ["\u2111", "TEST", 302, 303], ["\u2111", "TEST", 312, 313], ["Model I", "TEST", 314, 321], ["equivalently", "TEST", 327, 339], ["indices", "TEST", 344, 351], ["financial", "TEST", 355, 364], ["intermediation", "TEST", 365, 379], ["\u2212", "TEST", 382, 383], ["\u2111", "TEST", 385, 386], ["Model", "TEST", 387, 392], ["\u2111", "TEST", 402, 403], ["\u2111", "TEST", 415, 416], ["slacks", "TEST", 429, 435], ["deposits", "TEST", 439, 447], ["upper bound", "OBSERVATION_MODIFIER", 3, 14]]], ["The solution of program (7) may fail to satisfy one or more constraints (10a)-(10e) expressed as averages.", [["The solution of program", "TREATMENT", 0, 23]]], ["In consequence, * \u2111 \u2264 * \u2111,ind , \u2211 \u2211 The tightness of these bounds cannot be determined a priori, but the demonstration of the proposed framework to the Slovak banking sector suggests that these bounds are practical.", [["The tightness of these bounds", "PROBLEM", 36, 65]]], ["In this regard, the index of financial intermediation supplied by Model II described in program (7) provides not only an independent legitimate metric for measuring the attainment in financial intermediation, but also a lower bound for the index coming from program (10)Demonstration for Slovak commercial banksThe model devised for measuring the attainment in financial intermediation is applied here and demonstrated for Slovak commercial banks for the period from 2008 to 2016.", [["a lower bound", "PROBLEM", 218, 231]]], ["The 9-year time frame spans compactly years of favourable development for the Slovak economy and stability for the Slovak banking sector.", [["9-", "OBSERVATION_MODIFIER", 4, 6], ["favourable", "OBSERVATION_MODIFIER", 47, 57]]], ["Interpreting financial intermediation through depository and creditory operations is thus perfectly apposite in this context and the specification reducing financial intermediation to taking deposits and providing loans of different categories is reasonable.", [["depository and creditory operations", "TREATMENT", 46, 81]]], ["The data sample covered the period of 9 years from 2008 to 2016; yet, the nominal number of commercial banks across these years varied between 7 (in 2015 and 2016) and 13 (in 2008 and 2011).", [["The data sample", "TEST", 0, 15]]], ["In total, the sample contained nominally 91 bank-year observations.", [["the sample", "TEST", 10, 20]]], ["2 The effective number of observations was affected by missingness of some data points usually due to exits or late entries of some banks in the sample.", [["effective", "OBSERVATION_MODIFIER", 6, 15], ["number", "OBSERVATION_MODIFIER", 16, 22]]], ["The data set was investigated for a presence of outlying values by dint of the identification method developed by Wilson (1993) without finding out anomalous data points.", [["anomalous data points", "PROBLEM", 148, 169]]], ["It is true that the largest banks (SLSP, TATRA and VUB) are somewhat separated from the rest of the data, which may present grounds for preferring the VRS technology.Demonstration for Slovak commercial banksThe model of banking production assumed here for Slovak commercial banks is standard and complies with the familiar intermediation approach as it is called in efficiency studies.", [["largest", "OBSERVATION_MODIFIER", 20, 27], ["banks", "OBSERVATION_MODIFIER", 28, 33]]], ["The inputs are labour force measured by the number of employees (NoE), physical capital measured by total fixed assets (TFA) and total deposits (TD), whereas the outputs are loans to the corporate sector (TL_corp) and other loans (TL_other).", [["labour force", "PROBLEM", 15, 27], ["total deposits", "PROBLEM", 129, 143], ["labour", "OBSERVATION", 15, 21]]], ["Both loan variables considered, TL_corp and TL_other, amount to total loans provided (TL).", [["TL_corp", "PROTEIN", 32, 39], ["TL_other", "PROTEIN", 44, 52], ["TL_corp", "TREATMENT", 32, 39]]], ["The insertion of employees and fixed assets into considerations on the side of inputs follows from a classical economic view upon the transformation process, during which factors of production (such as natural resources, the capital stock and labour) are transmuted into outputs.", [["The insertion of employees and fixed assets", "TREATMENT", 0, 43], ["the transformation process", "PROBLEM", 130, 156], ["insertion", "OBSERVATION_MODIFIER", 4, 13]]], ["Beyond any doubt, labour force is one of the key factors of productivity growth in the banking sector, and its inclusion through employee numbers takes on relevance as confronting a decreasing trend of the number of employees with an increase of total assets in the Slovak banking industry.", [["productivity growth", "PROBLEM", 60, 79], ["labour", "OBSERVATION", 18, 24], ["productivity", "OBSERVATION_MODIFIER", 60, 72], ["growth", "OBSERVATION_MODIFIER", 73, 79]]], ["The specification of deposits as an input and corporate and other loans as outputs then accords with the premise underlying financial intermediation, i.e. that banks transform deposits into loans.", [["deposits", "PROBLEM", 21, 29], ["deposits", "OBSERVATION", 21, 29]]], ["The model of banking production is not discordant from the convention in this area as follows, for example, from Heffernan (2005, pp. 474-476) or Ahn and Le (2014, pp. 7-9) , and implies that P = 2 and R = 0 if sticking to the notation introduced at the outset of the previous section.", [["banking production", "OBSERVATION", 13, 31], ["not", "UNCERTAINTY", 35, 38], ["discordant", "OBSERVATION_MODIFIER", 39, 49], ["Le", "ANATOMY", 154, 156]]], ["3 The basic descriptive statistics for the data sample are reported in Table 1 and exhibit a large amount of heterogeneity between commercial banks in the sample, which is a feature displayed by most production data.", [["the data sample", "TEST", 39, 54], ["large", "OBSERVATION_MODIFIER", 93, 98], ["amount", "OBSERVATION_MODIFIER", 99, 105], ["heterogeneity", "OBSERVATION", 109, 122]]], ["The sample consists of large and small \"normal\" commercial banks as well as branch offices of foreign banks.", [["The sample", "TEST", 0, 10], ["large and small \"normal\" commercial banks", "PROBLEM", 23, 64], ["large", "OBSERVATION_MODIFIER", 23, 28], ["small", "OBSERVATION_MODIFIER", 33, 38], ["\"", "OBSERVATION_MODIFIER", 39, 40], ["normal", "OBSERVATION", 40, 46], ["commercial banks", "OBSERVATION", 48, 64], ["branch", "OBSERVATION_MODIFIER", 76, 82], ["foreign banks", "OBSERVATION", 94, 107]]], ["In this vein, labour is, for example, measured or proxied by labour expense and total fixed assets by operational (non-interest) expense.", [["vein", "ANATOMY", 8, 12], ["vein", "MULTI-TISSUE_STRUCTURE", 8, 12], ["vein", "ANATOMY", 8, 12], ["labour", "OBSERVATION", 14, 20]]], ["Although rather common, this practice intermixes technical aspects of banking production with allocative aspects, and the resulting efficiency score is related neither to technical efficiency nor economic efficiency (especially in the case when voluminous measures such as deposits and loans are employed beside cost measures such as noninterest expense and revenue.", [["the resulting efficiency score", "PROBLEM", 118, 148], ["economic efficiency", "PROBLEM", 196, 215], ["voluminous measures", "TREATMENT", 245, 264], ["cost measures", "TREATMENT", 312, 325], ["economic efficiency", "OBSERVATION", 196, 215]]], ["The specification of voluminous measures of production variables entertained here is referred to by Ahn and Le (2014, p.", [["voluminous", "OBSERVATION_MODIFIER", 21, 31]]], ["21) as the asset-oriented approach.Demonstration for Slovak commercial banksis not suggestive of any violation of the isotonicity property, the suitability of the input-output specification may also be substantiated more thoroughly.", [["the asset-oriented approach", "TREATMENT", 7, 34], ["the isotonicity property", "PROBLEM", 114, 138]]], ["There is a lately established convention of formal checking the relationship between inputs and outputs that bases upon inspection of the correlation matrix (e.g. Chiu et al. 2014; Hong and Jeong2019; Mitropoulos and Mitropoulos 2020) .", [["matrix", "CELLULAR_COMPONENT", 150, 156], ["bases", "ANATOMY_MODIFIER", 109, 114]]], ["The correlation coefficients between the variables, three inputs (NoE, TFA and TD) and two outputs (TL_corp and TL_other), are all positive and greater than 0.75.", [["TFA", "CHEMICAL", 71, 74], ["NoE", "PROTEIN", 66, 69], ["two outputs", "TEST", 87, 98], ["TL_corp", "TEST", 100, 107], ["greater", "OBSERVATION_MODIFIER", 144, 151]]], ["In addition, a canonical correlation analysis attests to a high level of significant association of inputs and outputs since the first canonical correlation is 0.9598 with Roy's largest root 0.9212 and a virtually zero p value produced by a standard F-approximation (see, for example, Muirhead 1982, pp. 548-571; Venables 1974) .", [["a canonical correlation analysis", "TEST", 13, 45]]], ["The composition of the first canonical variates indicates that there are some substitution effects between NoE and TFA (to some extent labour force can be substituted for fixed assets, and vice versa), but the canonical loadings (correlation coefficients between production variables and canonical covariates) confirm that the inputs contribute to the outputs.", [["NoE", "CHEMICAL", 107, 110], ["TFA", "CHEMICAL", 115, 118], ["NoE", "CHEMICAL", 107, 110], ["TFA", "CHEMICAL", 115, 118], ["NoE", "SIMPLE_CHEMICAL", 107, 110], ["TFA", "SIMPLE_CHEMICAL", 115, 118], ["some substitution effects between NoE", "PROBLEM", 73, 110], ["TFA", "TREATMENT", 115, 118], ["some extent labour force", "TREATMENT", 123, 147], ["production variables", "PROBLEM", 263, 283], ["some", "OBSERVATION_MODIFIER", 73, 77], ["substitution effects", "OBSERVATION", 78, 98]]], ["The correlation coefficients between NoE, TFA and TD and the output first canonical variate are 0.9198, 0.8481 and 0.9554, whereas between TL_corp and TL_other and the input canonical variate are 0.9250 and 0.9473.", [["TFA", "CHEMICAL", 42, 45], ["NoE", "GENE_OR_GENE_PRODUCT", 37, 40], ["TFA", "SIMPLE_CHEMICAL", 42, 45], ["NoE", "PROTEIN", 37, 40], ["TL_other", "PROTEIN", 151, 159], ["NoE", "TEST", 37, 40], ["TFA", "TEST", 42, 45], ["the output", "TEST", 57, 67], ["TL_corp", "TEST", 139, 146]]], ["Since canonical correlation analysis hinges gravely upon multivariate normality, the reported figures come from logarithmized values of the production variables, although with almost no quantitative Table 2 Identified indices of financial intermediation for banks in the data sampleDemonstration for Slovak commercial banksThe codes of bank names are explained in Footnote 2.", [["canonical correlation analysis", "TEST", 6, 36]]], ["The abbreviation \"FI\" denotes the three aggregate versions of the financial intermediation index: \"FI MII(7) \" announces the lower bound yielded by program (7), \"FI up(11) \" signals the upper bound yielded by Eq.", [["the upper bound", "PROBLEM", 182, 197], ["upper", "ANATOMY_MODIFIER", 186, 191]]], ["\"NA\" signals that the data point was not available or that the value was not computable difference from those when the logarithmic transformation to improve normality is not conducted.", [["the logarithmic transformation", "PROBLEM", 115, 145]]], ["The relative importance of corporate loans for economic stability and growth was gauged to be threefold as high as of other loans, which entailed weights v 1 = 0.75 and v 2 = 0.25 for corporate and other loans, respectively.", [["economic stability", "PROBLEM", 47, 65], ["weights v", "TEST", 146, 155]]], ["Setting a restriction for deposits to be deflated to a maximum of 90% of their observed amounts (specifying thus \u2212 = 0.90 ) and opting for VRS produced main results reported in Table 2 and minor results shown in the three tables of \"Appendix\".", [["deposits", "PROBLEM", 26, 34], ["VRS", "TEST", 139, 142], ["Appendix", "ANATOMY", 233, 241]]], ["The inside of Table 2 shows indices of financial intermediation for each of the 91 bank-years as indicated by Model I, whereas the marginal three columns and rows answer to indices of financial intermediation arising in connection with Model II.", [["Model II", "PROTEIN", 236, 244]]], ["In the eventuality of excellent attainment relative to the observed best practices, deflation and inflation factors are optimized in unison at a value of one and the index of financial intermediation is found one.", [["deflation and inflation factors", "TREATMENT", 84, 115]]], ["Hence, values of the index greater than one in Table 2 merely entail that some potential in financial intermediation was squandered.", [["the index", "TEST", 17, 26], ["financial intermediation", "TREATMENT", 92, 116]]], ["Whilst the columns present indices of financial intermediation aggregated for banks over the entire period, the rows are aggregated for years considering all the banks.", [["columns", "OBSERVATION_MODIFIER", 11, 18]]], ["The columns and rows labelled \"FI MII(7) \" then show indices associated with Model II computed by program (7) in which improvements in financial intermediation are perceived in respect of average quantities.", [["financial intermediation", "TREATMENT", 135, 159], ["columns", "OBSERVATION_MODIFIER", 4, 11]]], ["The values presented under the labels \"FI MII(7) \" and \"FI up(11) \" provide lower and upper bounds for the optimal solutions of program (10) whose results are stated as \"FI ind(10) \".", [["The values", "TEST", 0, 10]]], ["Nonetheless, the widths of the intervals implied by these bounds are quite narrow.", [["widths", "OBSERVATION_MODIFIER", 17, 23], ["narrow", "OBSERVATION_MODIFIER", 75, 81]]], ["The tables in \"Appendix\" then show the corresponding deflation Table 3 Programs for calculation of the index of financial intermediation and WSBM technical efficiency score under the intermediation approach factors (Table 5) , and inflation factors for corporate and other loans (Tables 6, 7) .", [["intermediation approach factors", "PROTEIN", 183, 214], ["inflation factors", "PROTEIN", 231, 248], ["financial intermediation", "TREATMENT", 112, 136], ["Appendix", "ANATOMY", 15, 23]]], ["The deflation factors in Table 3 testify that the specified threshold \u2212 = 0.90 was hit and reached a good many times.Demonstration for Slovak commercial banksIt must be said that the estimated indices of financial intermediation agree with the general characteristic and temporal development of the Slovak banking sector.", [["deflation factors", "PROTEIN", 4, 21], ["The deflation factors", "TREATMENT", 0, 21], ["deflation", "OBSERVATION", 4, 13], ["temporal", "OBSERVATION_MODIFIER", 271, 279]]], ["For instance, the extraordinarily poor performance of KOBA in financial intermediation in 2008 and its rapid improvement past 2010 is just a mere consequence of a change in the business model that it managed to execute.", [["KOBA", "CHEMICAL", 54, 58]]], ["During the few years between 2008 and 2011, the bank boosted the size of depository and creditory operations substantially whilst growing in employee numbers and fixed assets only slightly, and it also strengthened the share of corporate loans on total creditory operations.", [["depository and creditory operations", "TREATMENT", 73, 108], ["total creditory operations", "TREATMENT", 247, 273], ["size", "OBSERVATION_MODIFIER", 65, 69]]], ["TATRA is engaged especially in financing business activities and over the past few years has waged a persistent campaign to preserve its unique status.", [["TATRA", "CHEMICAL", 0, 5]]], ["The entrepreneurial segment is also targeted by CSOB and UNICB.", [["entrepreneurial", "OBSERVATION_MODIFIER", 4, 19], ["segment", "ANATOMY_MODIFIER", 20, 27]]], ["The former bank in 2009 merged with ISTRO and the merger eventually led to restructuring the deposit and loan portfolios of both banks, which is discernible in more favourable indices of financial intermediation of CSOB after the merger.", [["CSOB", "DISEASE", 215, 219], ["CSOB", "CANCER", 215, 219], ["ISTRO", "TREATMENT", 36, 41], ["CSOB", "PROBLEM", 215, 219], ["more favourable", "OBSERVATION_MODIFIER", 160, 175]]], ["An uprise of interest in loans taken under mild conditions meant that various commercial banks reported higher volumes of loans and attained the most favourable performance relative to best practices.Demonstration for Slovak commercial banksThe severity of the infeasibility issue associated with program (10) comes out well when the program is solved for even a few bank-years to be aggregated.", [["mild conditions", "PROBLEM", 43, 58], ["the infeasibility issue", "PROBLEM", 257, 280]]], ["The point is illustrated for the case when aggregation is performed for banks over the entire period and only the first two and 3 years are taken into account (providing that at least two or three such bank-years are available, which excludes ISTRO).", [["aggregation", "PROBLEM", 43, 54]]], ["When the first two observed years are attempted, program (10) is feasible for 6 banks (OTP with FI = 2.063, SBER with FI = 1.943, SLSP with FI = 1.864, TATRA with FI = 1.346, UNICB with FI = 1.584 and VUB with FI = 1.740).", [["FI", "TEST", 96, 98], ["FI", "TEST", 118, 120], ["FI", "TEST", 140, 142], ["TATRA", "TEST", 152, 157], ["FI", "TEST", 163, 165], ["FI", "TEST", 186, 188], ["VUB", "TEST", 201, 204], ["FI", "TEST", 210, 212]]], ["Adding one more effective year lowers feasibility to 5 banks (OTP with FI = 2.085, SBER with FI = 1.840, SLSP with FI = 1.762, TATRA with FI = 1.276 and VUB with FI = 1.555).Demonstration for Slovak commercial banksAs already underlined in the introduction, the present notion of attainment in financial intermediation should not be confused with the notion of efficiency in banking undertaking when the bank is construed as a financial intermediary.", [["FI", "TEST", 71, 73], ["FI", "TEST", 93, 95], ["FI", "TEST", 115, 117], ["TATRA", "TEST", 127, 132], ["FI", "TEST", 138, 140], ["VUB", "TEST", 153, 156], ["FI", "TEST", 162, 164], ["confused", "PROBLEM", 333, 341]]], ["In addition, the index of financial intermediation is a function of deposits and loans as contrasts from the technical efficiency score that embodies the information about all proportions in which deposits plus other inputs are transmuted into loans and other outputs.", [["a function of deposits", "PROBLEM", 54, 76], ["index", "OBSERVATION_MODIFIER", 17, 22], ["financial intermediation", "OBSERVATION", 26, 50], ["deposits", "OBSERVATION", 68, 76], ["deposits", "OBSERVATION", 197, 205]]], ["Program (12) on the left-hand side of Table 3 is the model for measuring attainment in financial intermediation, and program (13) on the right-hand side is an analogous model for measuring efficiency under the intermediation approach.", [["left-hand", "ANATOMY", 20, 29], ["right-hand", "ANATOMY", 137, 147], ["an analogous model", "TREATMENT", 156, 174], ["the intermediation approach", "TREATMENT", 206, 233], ["left", "ANATOMY_MODIFIER", 20, 24], ["right", "ANATOMY_MODIFIER", 137, 142]]], ["The choice of a WSBM model in program (13) is dictated by the fact that the index of financial intermediation has a formulation closely linked with the WSBM as was demonstrated in Sect.", [["WSBM", "DNA", 152, 156], ["a WSBM model in program", "TREATMENT", 14, 37]]], ["Both programs are stated under VRS and are specialized to the particular case entertained in the demonstration, in which banking activities are understood as a production of corporate and other loans ( L 1 it and L 2 it ) as the only outputs by using labour force ( x 1 it ) and physical capital ( x 2 it ) and deposits ( D it ) as the only inputs.", [["labour force", "TREATMENT", 251, 263]]], ["So, there are no other outputs and no y \u22c5 it variables to appear in the programs.", [["no", "UNCERTAINTY", 14, 16]]], ["Program (13) also necessitates introduction of slacks on other inputs s 1Demonstration for Slovak commercial banksx,it and s 2 x,it (associated with x 1 it and x 2 it , respectively).", [["Slovak commercial banksx", "TREATMENT", 91, 115]]], ["To ensure comparability, the restriction for maximum permissible deflation of deposits governed by \u2212 is also implemented with program (13).", [["the restriction", "TREATMENT", 25, 40], ["maximum permissible deflation of deposits", "TREATMENT", 45, 86], ["deposits", "OBSERVATION", 78, 86]]], ["Figure 2 presents in turn three graphs: the scatter graph of FI \u22121 and TE with an identity line and a nonparametric estimate of the regression relationship, the graph juxtaposing Table 4 Confrontation of indices of financial intermediation and traditional efficiency scores corresponding to the intermediation approachDemonstration for Slovak commercial banksThe abbreviations \"FI\" and \"FI \u22121 \" denote the intermediation index and its reciprocal calculated for individual bank-years by dint of program (12), whereas \"TE\" is the traditional WSBM score calculated under the intermediation approach adopting the weighting scheme for corporate and other weights and respecting the maximum permissible deflation of deposits Cleveland (1981) , the estimates of probability densities of TE and FI \u22121 were rendered by the logspline method of Stone et al. (1997) .", [["financial intermediation", "PROBLEM", 215, 239], ["traditional efficiency scores", "PROBLEM", 244, 273], ["the intermediation index", "TEST", 402, 426], ["the intermediation approach", "TREATMENT", 568, 595], ["other weights", "TEST", 644, 657], ["identity line", "OBSERVATION", 82, 95], ["deflation", "OBSERVATION_MODIFIER", 697, 706], ["Stone", "OBSERVATION", 834, 839]]], ["The choice of density smoothing was guided by the fact that FI \u22121 and TE are restricted to the interval [0,1] and are hence truncated, which is also the case of their difference FI \u22121 -TE.", [["FI \u22121", "GENE_OR_GENE_PRODUCT", 60, 65], ["TE", "DNA", 70, 72], ["density", "OBSERVATION", 14, 21]]], ["Nevertheless, FI \u22121 and TE are not identical as mostly FI \u22121 > TE.", [["FI \u22121", "GENE_OR_GENE_PRODUCT", 14, 19], ["FI \u22121", "GENE_OR_GENE_PRODUCT", 55, 60]]], ["Therefore, the index of financial intermediation shows the banks in the sample in a more favourable light than the WSBM, and average benefit of the former over the latter is 0.094 (which is the mean of the difference FI \u22121 -TE).", [["financial intermediation", "TEST", 24, 48]]], ["In addition, the values FI \u22121 and TE have completely different distributions with a bimodal pattern for their difference FI \u22121 -TE.", [["the values FI", "TEST", 13, 26]]], ["The prevalence of FI \u22121 being greater than TE and the shapes of all the three estimated densities indicate that the proposed model for measuring attainment in financial intermediation tends to yield generally a less stringent assessment than the model for measuring technical efficiency under the intermediation approach.Demonstration for Slovak commercial banksOwing to the complicated structure of programs (12) and (13) in Table 3 , it is difficult, if not impossible, to determine under which circumstances there is a discrepancy between the assessment that is obtained by measuring attainment in financial intermediation and the assessment arising from measuring efficiency under the intermediation approach.", [["FI \u22121", "TREATMENT", 18, 23], ["the intermediation approach", "TREATMENT", 293, 320], ["the assessment", "TEST", 542, 556], ["the assessment", "TEST", 630, 644], ["the intermediation approach", "TREATMENT", 685, 712], ["greater", "OBSERVATION_MODIFIER", 30, 37], ["densities", "OBSERVATION", 88, 97]]], ["An exploration of patterns with which input and output production variables affect the difference FI \u22121 -TE is undertaken in Fig. 3 .", [["An exploration", "TEST", 0, 14], ["output production variables", "PROBLEM", 48, 75], ["exploration", "OBSERVATION", 3, 14]]], ["This exploration attempts to explain the sign and magnitude of FI \u22121 -TE with respect to the structural links that underlying production variables and that are expressed as ratios.", [["This exploration", "TEST", 0, 16]]], ["A plot is displayed in Fig. 3 for each of these four ratio factors: corporate to other loans (TL_corp/TL_other), total loans to deposits (TL/TD), total loans per employee (TL/NoE), total loans to total fixed assets (TL/TFA).", [["A plot", "TEST", 0, 6], ["TL/TFA", "TREATMENT", 216, 222]]], ["The horizontal axes display factors and the vertical axes identify differences FI \u22121 -TE shown as downward-or upward-oriented spikes (for negative and positive differences, respectively) or points (for no differences).", [["upward-oriented spikes", "PROBLEM", 110, 132]]], ["Figure 3 does not provide an explanation in which situations indices of financial intermediation are typically greater than or equal to efficiency scores answering to the intermediation approach (i.e. when FI \u22121 -TE \u2265 0 is typically the case).", [["financial intermediation", "PROBLEM", 72, 96]]], ["Nonetheless, the other Confrontation of indices of financial intermediation and traditional efficiency scores corresponding to the intermediation approach three structural factors seem effective.", [["financial intermediation", "PROBLEM", 51, 75], ["traditional efficiency scores", "PROBLEM", 80, 109], ["the intermediation approach", "TREATMENT", 127, 154]]], ["The largest downside differences FI \u22121 -TE are discernible in situations when the TL/TD ratio is around 1.00 (roughly from 0.75 to 1.10), when the TL/NoE ratio is small (roughly up to 2000 \u20ac per employee) as well as when also the TL/TFA ratio is small (roughly up to 50).", [["TFA", "CHEMICAL", 233, 236], ["TFA", "SIMPLE_CHEMICAL", 233, 236], ["the TL/TD ratio", "TEST", 78, 93], ["the TL/NoE ratio", "TEST", 143, 159], ["the TL/TFA ratio", "TEST", 226, 242], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["small", "OBSERVATION_MODIFIER", 163, 168], ["small", "OBSERVATION_MODIFIER", 246, 251]]], ["It is worthwhile pointing out that all these three last factors are productivity indicators, and so more stringent indices of financial intermediation are prevalent in situations when productivity of loan provision was small in comparison to (especially) labour, physical capital and (partly) deposits.", [["labour, physical capital and (partly) deposits", "PROBLEM", 255, 301], ["small", "OBSERVATION_MODIFIER", 219, 224]]], ["In this demonstration, standard measurement of technical efficiency grounded in the intermediation approach tended to show performance of banks in the sample in a more favourable light than the proposed modelling framework.", [["technical efficiency", "OBSERVATION", 47, 67]]], ["It thus appears that the proposed approach to measuring financial intermediation penalizes more significantly for low productivity in loan provision (the ultimate output of financial intermediation) as these are the cases when potential in financial intermediation is utterly realized in a low extent.Concluding remarksIt is true that financial intermediation is thoroughly studied and assessed in the form of simple ratio indicators.", [["financial intermediation", "TREATMENT", 173, 197], ["low extent", "OBSERVATION_MODIFIER", 290, 300]]], ["Some indicators measure size of banking operations (such as banking assets to gross domestic product or banking deposits to gross domestic product) and only the loan-to-deposit ratio catches the inner legacy of financial intermediation as it juxtapose depository and creditory activities of banks or banking sectors.", [["banking operations", "TREATMENT", 32, 50], ["gross domestic product", "TREATMENT", 78, 100], ["banking deposits", "PROBLEM", 104, 120], ["financial intermediation", "TREATMENT", 211, 235], ["size", "OBSERVATION_MODIFIER", 24, 28], ["banking operations", "OBSERVATION", 32, 50]]], ["The proposed approach to modelling and measuring financial intermediation emphasizes the necessity to compare in a descriptive way both sides of the intermediation process and builds on the ideas of DEA to instil a normative aspect into the assessment.", [["the assessment", "TEST", 237, 251]]], ["To the best knowledge of the authors, neither are there approaches that compare depository and creditory activities of banks or sectors aside from ratio analysis, nor are there approaches that relate depository and creditory activities to best practices.", [["ratio analysis", "TEST", 147, 161]]], ["The terms deposits and loans can be thought of as universal wild cards and should not be treated literally.", [["deposits", "OBSERVATION", 10, 18]]], ["Notwithstanding a tempting resemblance with the intermediation approach, attainment of financial intermediation must be emphatically distinguished form technical efficiency under the intermediation approach.", [["the intermediation approach", "TREATMENT", 44, 71], ["financial intermediation", "TREATMENT", 87, 111]]], ["The reason being, the former focuses merely upon success with which deposits are intermediated into loans, whereas the latter broadens its scope to include success also in non-intermediation activities and technically stipulates chiefly that deposits be Analysis of the deviations between indices of financial intermediation and traditional efficiency scores placed on the input side and loans on the output side of production.", [["the deviations", "PROBLEM", 266, 280], ["financial intermediation", "PROBLEM", 300, 324], ["traditional efficiency scores", "PROBLEM", 329, 358]]], ["The case study demonstrated that differences between assessment may arise and do arise quite frequently, particularly in cases when loans are produced with a lower productivity of labour and physical capital.Concluding remarksTo explain the above made allusion to wildcards, the proposed modelling framework is adaptable by replacing deposits and loans by other measures of financing activity.", [["The case study", "TEST", 0, 14], ["assessment", "TEST", 53, 63], ["a lower productivity of labour", "PROBLEM", 156, 186]]], ["In this present period of economic difficulties brought about by the coronavirus pandemic, the model may be put to use in measuring financial intermediation that takes place between the European Central Bank (ECB) and national banking systems of the euro area (de Guindos and Schnabel 2020; Lagarde 2020; European Central Bank 2020).", [["coronavirus pandemic", "DISEASE", 69, 89], ["coronavirus", "ORGANISM", 69, 80], ["economic difficulties", "PROBLEM", 26, 47], ["economic", "OBSERVATION_MODIFIER", 26, 34], ["difficulties", "OBSERVATION", 35, 47]]], ["The adapted index of financial intermediation would then be a metric of the success with which the ECB disperses and channels its liquidity towards national needs with a view of encouraging banks to extend loans to economic agents with less access to credit.", [["financial intermediation", "TREATMENT", 21, 45], ["economic agents", "TREATMENT", 215, 230]]], ["This interpretation of financial intermediation would substitute deposits for the presently released funds of the ECB (with a maturity up to 3 years and at negative interest rates) as well as the purchases of public and private sector bonds.", [["financial intermediation", "TREATMENT", 23, 47]]], ["A value of the index of financial intermediation around 1 would indicate that the ECB's response to the crisis came to fruition and that banking systems in the euro area allocated all the newly available funds to national economies.", [["A value", "TEST", 0, 7], ["the ECB", "TEST", 78, 85], ["the crisis", "PROBLEM", 100, 110]]], ["A value greater than 1 would then imply that also some national resources were mobilized.Concluding remarksThe present framework, as formulated, aims at the needs of macroeconomic policy decision-making and planning and is not yet tuned-up to the needs of regulatory assessment.", [["A value", "TEST", 0, 7], ["regulatory assessment", "TEST", 256, 277]]], ["The framework strives to maximize the loan-to-deposit ratio, but this maximization in regulation must respect some limits.", [["some limits", "OBSERVATION_MODIFIER", 110, 121]]], ["Too small a value of the loan-to-deposit ratio is not adequate as it is generally a testimony of excessive liquidity, whereas if the value is too high, it is a sign of heightened riskiness.", [["excessive liquidity", "PROBLEM", 97, 116], ["heightened riskiness", "PROBLEM", 168, 188], ["small", "OBSERVATION_MODIFIER", 4, 9]]], ["European banks are screened by regulatory bodies for the value of this indicator (more precisely, for loan-to-deposit ratios for households and non-financial corporations) and the risk heatmap sets that a value between 1 and 1.5 is considered as a moderate risk and a value greater than 1.5 is deemed to be an indication of considerable risk (European Banking Authority 2017).", [["the risk heatmap sets", "TEST", 176, 197], ["a moderate risk", "PROBLEM", 246, 261], ["moderate", "OBSERVATION_MODIFIER", 248, 256]]], ["The regulatory risk threshold can be implemented into the present framework by introducing an upper bound for the resulting loan-to-deposit ratios such as the one for the deflation factors in conditions (d) of all the programs.", [["loan", "PROTEIN", 124, 128], ["deflation factors", "PROTEIN", 171, 188], ["an upper bound", "PROBLEM", 91, 105], ["the deflation factors", "PROBLEM", 167, 188], ["deflation", "OBSERVATION", 171, 180]]], ["Several thresholds can be considered and the assessment may proceed in the spirit of a regulatory sensitivity analysis.", [["the assessment", "TEST", 41, 55], ["a regulatory sensitivity analysis", "TEST", 85, 118]]], ["Nonetheless, the suggested alteration of the presently proposed framework to make it more compliant with regulatory needs would predestine a different interpretation and use.Concluding remarksAnother route worthy of exploration to tackling the definition of the index of financial intermediation is, for example, is constructing the weighted normalized inflation factor in the spirit of a geometric mean.", [["weighted normalized inflation factor", "PROTEIN", 333, 369], ["exploration", "TEST", 216, 227], ["inflation", "OBSERVATION", 353, 362]]], ["The index of financial intermediation would become \u03a0 l ( l it \u2215 it ) v l , which would eventually lead to a version of the geometric distance function devised by Thanassoulis (2005, 2007) .", [["index", "OBSERVATION_MODIFIER", 4, 9]]], ["This may be mended by conducting an ex post stochastic sensitivity analysis that accommodates different specifications of such weights that still comply with the analyst's a priori views.", [["an ex post stochastic sensitivity analysis", "TEST", 33, 75]]], ["A viable approach is to adapt and extend the procedure suggested by Bo\u010fa (2017) in a context of modelling market shares.Concluding remarksFinally, indices of financial intermediation yielded by the model may be useful not only in explorations of the finance-growth nexus as neat proxies of financial development (e.g. Ho and Iyke 2018; Olaniyi and Oladeji 2020), but also as contextual variables in a two-stage DEA analysis of banking efficiency (e.g. Banya and Biekpe 2018) or in assessments of financial stability and transparency (e.g. Bashir et al. 2020; Dutta and Mukherjee 2018) .", [["the procedure", "TREATMENT", 41, 54], ["banking efficiency", "PROBLEM", 427, 445], ["banking efficiency", "OBSERVATION", 427, 445]]], ["Table 5 Identified deposit deflation factors for banks in the data sampleConcluding remarksThe codes of bank names are explained in Footnote 2.", [["deposit deflation factors", "PROBLEM", 19, 44], ["the data sample", "TEST", 58, 73], ["deposit deflation", "OBSERVATION", 19, 36]]], ["The symbol \"\u03b8\" denotes for three different aggregate situations maximum deflation of deposits: \"\u03b8 MII(7) \" appertains to Model II and the lower bound case after program (7), \"\u03b8 up(11) \" relates to the upper bound case answering to Eq.", [["Model II", "PROTEIN", 121, 129]]], ["\"NA\" signals that the data point was not available or that the value was not computable Table 6 Identified inflation factors for corporate loans for banks in the data sampleConcluding remarksThe codes of bank names are explained in Footnote 2.", [["inflation factors", "PROTEIN", 107, 124], ["inflation factors", "PROBLEM", 107, 124], ["the data sample", "TEST", 158, 173]]], ["The symbol \"\u03c8\" denotes for three different aggregate situations maximum inflation of corporate loans: \"\u03c8 MII(7) \" appertains to Model II and the lower bound case after program (7), \"\u03c8 up(11) \" relates to the upper bound case answering to Eq.", [["Model II", "PROTEIN", 128, 136]]], ["\"NA\" signals that the data point was not available or that the value was not computable", [["the value", "TEST", 59, 68]]]], "PMC7315687": [["BackgroundWith the COVID-19 pandemic, globally, we now face unprecedented challenges to access essential medicines and other health commodities.", [["the COVID", "TEST", 15, 24], ["pandemic", "PROBLEM", 28, 36], ["essential medicines", "TREATMENT", 95, 114]]], ["Drug shortages, hoarding of medicines and supplies, and the circulation of falsified health products have already exacerbated this once in a century global health challenge [1].BackgroundPre-COVID-19, it was already estimated that 2 billion people lacked regular access to essential medicines [2].", [["hoarding", "DISEASE", 16, 24], ["people", "ORGANISM", 241, 247], ["people", "SPECIES", 241, 247], ["medicines", "TREATMENT", 28, 37], ["BackgroundPre-COVID", "TEST", 177, 196], ["essential medicines", "TREATMENT", 273, 292]]], ["Despite decades of donor funding and international programs, availability of essential medicines remains wanting.", [["donor funding", "TREATMENT", 19, 32], ["international programs", "TREATMENT", 37, 59], ["essential medicines", "TREATMENT", 77, 96]]], ["High prices, lack of coverage, poor purchasing and distribution, uncertain product quality, inappropriate prescribing, and corruption are but some of the reasons why availability is undermined, whether it be in the United States or Malawi [3].BackgroundIn anticipation of vital products to treat and prevent COVID-19, policy decisions about how to secure equitable access and affordability of these products globally need to happen in earnest.", [["High prices", "PROBLEM", 0, 11], ["vital products", "TREATMENT", 272, 286], ["these products", "TREATMENT", 393, 407]]], ["Simple questions about who will get access when a COVID-19 vaccine is developed, the price, how it will be paid for, who manufactures and distributes it, and ensuring the integrity of these products is protected from fake or substandard versions need meaningful deliberation now.", [["a COVID-19 vaccine", "TREATMENT", 48, 66]]], ["Hence, the international debate about access to medicines has to be accelerated given the real-world needs of millions currently afflicted by COVID-19 and countless others who will in the future.BackgroundIn the past, the importance of securing access to medicines for global health challenges, such as HIV/AIDS and hepatitis C virus, has been made abundantly and painfully clear [4, 5].", [["HIV/AIDS and hepatitis C virus", "DISEASE", 303, 333], ["HIV/AIDS", "ORGANISM", 303, 311], ["hepatitis C virus", "ORGANISM", 316, 333], ["HIV", "SPECIES", 303, 306], ["hepatitis C virus", "SPECIES", 316, 333], ["HIV", "SPECIES", 303, 306], ["hepatitis C virus", "SPECIES", 316, 333], ["medicines", "TREATMENT", 48, 57], ["securing access to medicines", "TREATMENT", 236, 264], ["global health challenges", "TREATMENT", 269, 293], ["HIV/AIDS", "PROBLEM", 303, 311], ["hepatitis C virus", "PROBLEM", 316, 333]]], ["Overlaying these questions is the fact that travel bans, trade-related retaliation, abuse of intellectual property (IP) rights, and other forms of protectionism have and may further limit supplies of needed therapies [6].", [["abuse of intellectual property", "DISEASE", 84, 114], ["protectionism", "DISEASE", 147, 160], ["therapies", "TREATMENT", 207, 216]]], ["In fact, many countries have already banned or significantly limited export of protective equipment, medical devices, or medicines related to COVID-19 [7].BackgroundAs a consequence of legitimate supply chains being blocked, the risk of falsified and substandard medicines grows [1].", [["COVID-19", "CHEMICAL", 142, 150], ["protective equipment", "TREATMENT", 79, 99], ["medical devices", "TREATMENT", 101, 116], ["medicines", "TREATMENT", 121, 130], ["legitimate supply chains", "TREATMENT", 185, 209]]], ["Evidencing this risk, the European Medicines Agency and the World Health Organization (WHO) have issued warnings about the increase of falsified medicines and testing kits claiming to prevent, detect, treat, or cure COVID-19 [8, 9].", [["the European Medicines", "TREATMENT", 22, 44], ["falsified medicines", "TREATMENT", 135, 154], ["testing kits", "TEST", 159, 171]]], ["Yet, the risk of falsified medicines is not limited only to products that may treat COVID-19, but extends to other drugs where shortages will persist [7].Call to action?The world is waiting with tremendous hope and urgency for therapies and vaccines to treat and/or prevent COVID-19.", [["COVID-19", "CHEMICAL", 84, 92], ["COVID-19", "CHEMICAL", 84, 92], ["falsified medicines", "TREATMENT", 17, 36], ["COVID", "TEST", 84, 89], ["urgency", "PROBLEM", 215, 222], ["therapies", "TREATMENT", 227, 236], ["vaccines", "TREATMENT", 241, 249], ["COVID", "TEST", 274, 279]]], ["The strong pressure on the pharmaceutical industry may very well incentivize a company or drug regulatory agency to rush an immature product to market.", [["strong", "OBSERVATION_MODIFIER", 4, 10], ["pressure", "OBSERVATION_MODIFIER", 11, 19]]], ["We need to be circumspect that in the urgent quest for life-saving therapies, existing regulatory safeguards put in place to ensure safety and efficacy are not bypassed.", [["life-saving therapies", "TREATMENT", 55, 76], ["existing regulatory safeguards", "TREATMENT", 78, 108]]], ["These concerns are even more acute with recent retractions of studies from The New England Journal of Medicine and The Lancet involving the antimalarial drug hydroxychloroquine, and announcement by the WHO that drug trials would be halted due to safety concerns [10].Call to action?There is also a need to raise and manage legitimate concerns about the power and influence of pharmaceutical companies and the potential for systematic bias within the R&D process.", [["hydroxychloroquine", "CHEMICAL", 158, 176], ["hydroxychloroquine", "CHEMICAL", 158, 176], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 158, 176], ["recent retractions of studies", "PROBLEM", 40, 69], ["the antimalarial drug hydroxychloroquine", "TREATMENT", 136, 176], ["drug trials", "TREATMENT", 211, 222], ["systematic bias", "PROBLEM", 423, 438], ["more", "OBSERVATION_MODIFIER", 24, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["retractions", "OBSERVATION", 47, 58]]], ["This raises questions of whether during grave public health emergencies, decisions about the research and development and access to essential and potentially life-saving treatments should be left to laissez-faire economic principles.", [["saving treatments", "TREATMENT", 163, 180]]], ["There is a clear conflict of interest when relying on private companies to solve public health needs.", [["clear", "OBSERVATION_MODIFIER", 11, 16], ["conflict", "OBSERVATION", 17, 25]]], ["Companies, by their nature, are required to bring value to their shareholders, but this approach may be flawed at normal times and decidedly more dangerous during health crises when the provision of public goods is needed.Call to action?Positively, we are seeing a shift in the speed of innovation and level of collaboration to stop this pandemic.", [["this pandemic", "PROBLEM", 333, 346]]], ["This includes greater cooperation between governments, researchers, and with and within the life sciences industry.", [["greater", "OBSERVATION_MODIFIER", 14, 21]]], ["For example, Gilead Sciences recently announced deals with generic companies to manufacture and distribute experimental drug remdesivir via non-exclusive voluntary licenses.", [["remdesivir", "CHEMICAL", 125, 135], ["remdesivir", "SIMPLE_CHEMICAL", 125, 135]]], ["Less positively, nationalism, policy fragmentation, and the shutting down of borders may pose risks to the rapidity and reach of future treatments as countries turn increasingly inward [7].", [["policy fragmentation", "PROBLEM", 30, 50], ["future treatments", "TREATMENT", 129, 146]]], ["Hence, now is the time to raise the urgency of ensuring equitable access to medicines to a supranational body, one focused on ensuring that there is a system in place to coordinate rational selection, procurement, access, distribution, and use across all countries before it is too late.ConclusionFortunately, the framework for this approach has already been put in place with international organizations, such as UNITAID, creating models to better ensure access to HIV, tuberculosis, and malaria medications; the Medicines Patent Pool which helps lower costs of medicines through voluntary licensing of IP; and the UN High-level Panel on Access to Medicines making a series of recommendations on how to promote and advance health technology and access.ConclusionMore recently, the WHO announced the launch of the COVID-19 Access Pool, an international project to voluntarily share IP, scientific data, and health technology-related knowledge to fight COVID-19.", [["body", "ANATOMY", 105, 109], ["tuberculosis", "DISEASE", 471, 483], ["malaria", "DISEASE", 489, 496], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["HIV", "SPECIES", 466, 469], ["medicines", "TREATMENT", 76, 85], ["a supranational body", "TREATMENT", 89, 109], ["this approach", "TREATMENT", 328, 341], ["HIV", "PROBLEM", 466, 469], ["tuberculosis", "PROBLEM", 471, 483], ["malaria medications", "TREATMENT", 489, 508], ["the Medicines", "TREATMENT", 510, 523], ["medicines", "TREATMENT", 563, 572], ["voluntary licensing of IP", "TREATMENT", 581, 606], ["Medicines", "TREATMENT", 649, 658], ["the COVID", "TEST", 810, 819], ["COVID", "TEST", 952, 957], ["tuberculosis", "OBSERVATION", 471, 483], ["Patent", "OBSERVATION", 524, 530]]], ["The UN General Assembly also adopted a resolution calling for international cooperation to ensure global access to medicines, vaccines, and medical equipment for COVID-19, and this year\u2019s World Health Assembly included a European Union-led resolution calling for \u201cuniversal, timely and equitable access\u201d to COVID-19 treatments.ConclusionThese past and current actions should act as a catalyst for a global call to action to improve access to COVID-19 treatment, vaccine, and other countermeasures.", [["COVID-19", "CHEMICAL", 442, 450], ["medicines", "TREATMENT", 115, 124], ["vaccines", "TREATMENT", 126, 134], ["COVID-19 treatments", "TREATMENT", 307, 326], ["COVID", "TREATMENT", 442, 447], ["treatment", "TREATMENT", 451, 460], ["vaccine", "TREATMENT", 462, 469]]], ["It should also form the foundation for bolder international action to establish a global access to medicines regime charged with ensuring that no one gets left behind and that anyone who requires essential treatment for COVID-19 or other health maladies will get it.", [["bolder international action", "TREATMENT", 39, 66], ["medicines regime", "TREATMENT", 99, 115], ["essential treatment", "TREATMENT", 196, 215], ["COVID", "TREATMENT", 220, 225]]]], "PMC7263071": [["IntroductionCOVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) [1].", [["respiratory", "ANATOMY", 26, 37], ["respiratory disease", "DISEASE", 26, 45], ["SARS-CoV-2", "ORGANISM", 77, 87], ["coronavirus", "SPECIES", 64, 75], ["IntroductionCOVID", "TEST", 0, 17], ["a respiratory disease", "PROBLEM", 24, 45], ["a novel coronavirus", "PROBLEM", 56, 75], ["respiratory disease", "OBSERVATION", 26, 45]]], ["Two other coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle Eastern respiratory syndrome coronavirus (MERS- CoV) had been identified in 2002 and 2012 [4].", [["acute respiratory syndrome coronavirus", "DISEASE", 32, 70], ["SARS-CoV)", "DISEASE", 72, 81], ["Middle Eastern respiratory syndrome coronavirus", "DISEASE", 86, 133], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 25, 70], ["SARS-CoV", "ORGANISM", 72, 80], ["Middle Eastern respiratory syndrome coronavirus", "ORGANISM", 86, 133], ["MERS- CoV", "ORGANISM", 135, 144], ["syndrome coronavirus", "SPECIES", 113, 133], ["severe acute respiratory syndrome coronavirus", "SPECIES", 25, 70], ["SARS-CoV", "SPECIES", 72, 80], ["Middle Eastern respiratory syndrome coronavirus", "SPECIES", 86, 133], ["MERS- CoV", "SPECIES", 135, 144], ["Two other coronaviruses", "PROBLEM", 0, 23], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 25, 70], ["Middle Eastern respiratory syndrome coronavirus", "PROBLEM", 86, 133], ["coronaviruses", "OBSERVATION", 10, 23], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome coronavirus", "OBSERVATION", 38, 70], ["Middle", "ANATOMY_MODIFIER", 86, 92], ["respiratory syndrome", "OBSERVATION", 101, 121]]], ["While both of these caused significant outbreaks of disease, they were more lethal and less transmissible, and did not cause pandemics.IntroductionSARS-CoV-2 has already spread through most of the world.", [["IntroductionSARS-CoV-2", "CHEMICAL", 135, 157], ["disease", "PROBLEM", 52, 59], ["pandemics", "PROBLEM", 125, 134], ["IntroductionSARS", "TEST", 135, 151], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["outbreaks", "OBSERVATION_MODIFIER", 39, 48], ["disease", "OBSERVATION", 52, 59]]], ["And most countries have restricted travel, closed large parts of industry, restructured their economies, and focussed their efforts on its control.", [["large", "OBSERVATION_MODIFIER", 50, 55]]], ["By the 29th April, 3 053 457 cases of COVID-19 had been confirmed by testing and 214 862 of those individuals had died [5].", [["COVID", "TEST", 38, 43]]], ["Cases have been reported in 207 countries.IntroductionVarious measures have been adopted to control the spread of the virus.", [["IntroductionVarious measures", "TREATMENT", 42, 70], ["the virus", "PROBLEM", 114, 123]]], ["The most stringent of these have been termed \u201clockdown\u201d, and almost entirely restricted people to their own homes.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["most stringent", "OBSERVATION_MODIFIER", 4, 18]]], ["At the end of April, some European countries began to try relaxing some of restrictions, but, in late-May, there continue to be large numbers of mortalities in most parts of the world [5].", [["large numbers of mortalities", "PROBLEM", 128, 156], ["large", "OBSERVATION_MODIFIER", 128, 133], ["numbers", "OBSERVATION_MODIFIER", 134, 141], ["mortalities", "OBSERVATION", 145, 156]]], ["We therefore need to understand both the transmissibility of the virus and the effectiveness of the social distancing and lockdown measures that have been taken.", [["the virus", "PROBLEM", 61, 70], ["lockdown measures", "TREATMENT", 122, 139]]], ["The difference between the initial spread of the virus, before the restrictions were imposed, and its spread under lockdown gives an estimate of how effective lockdown measures have been.", [["the virus", "PROBLEM", 45, 54], ["effective lockdown measures", "TREATMENT", 149, 176], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["virus", "OBSERVATION", 49, 54]]], ["It can also suggest how far those measures can be relaxed without a resurgence of infection.IntroductionThis paper uses publically available data from multiple countries to model the spread of SARS-CoV-2, both before and under the lockdown, and estimate the scope for relaxing the current restrictions.Data ::: MethodsData on the numbers of new confirmed cases of COVID-19, and numbers of deaths reported for people known to have COVID-19, are available from the European Centre for Disease Prevention and Control (ECDC) website (www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-COVID-19-19-cases-worldwide).", [["infection", "DISEASE", 82, 91], ["SARS", "DISEASE", 193, 197], ["deaths", "DISEASE", 389, 395], ["people", "ORGANISM", 409, 415], ["people", "SPECIES", 409, 415], ["SARS-CoV", "SPECIES", 193, 201], ["infection", "PROBLEM", 82, 91], ["COVID", "TEST", 364, 369], ["COVID", "TEST", 430, 435], ["Disease Prevention", "TREATMENT", 483, 501], ["infection", "OBSERVATION", 82, 91]]], ["Mortality data was used for countries that had reported at least 100 deaths, and numbers of cases for those where at least 1000 confirmed cases had been reported.", [["deaths", "DISEASE", 69, 75], ["Mortality data", "TEST", 0, 14]]], ["The pattern of arrival of infectious individuals determines the course of the initial stages of outbreaks, therefore days before a total of 10 deaths or 100 cases had been reported in each country were discarded.", [["deaths", "DISEASE", 143, 149], ["infectious individuals", "PROBLEM", 26, 48], ["infectious", "OBSERVATION", 26, 36]]], ["That left 89 countries with sufficient data for further consideration.Data ::: MethodsBoth these types of data have important limitations: varying proportions of infections and deaths were not recorded, in each country and over time.", [["infections", "DISEASE", 162, 172], ["deaths", "DISEASE", 177, 183], ["infections", "PROBLEM", 162, 172], ["infections", "OBSERVATION", 162, 172]]], ["But they do provide a large, stable, and standardised source of information that covers most countries.", [["large", "OBSERVATION_MODIFIER", 22, 27], ["stable", "OBSERVATION_MODIFIER", 29, 35]]], ["Confirmed cases are individuals who have tested positive for SARS-CoV-2.", [["SARS", "DISEASE", 61, 65], ["SARS-CoV-2", "ORGANISM", 61, 71], ["SARS-CoV", "SPECIES", 61, 69], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69]]], ["Unfortunately, no country has managed complete and continuous testing, and limitations and changes in testing strategies make this data particularly problematic.", [["continuous testing", "TEST", 51, 69], ["changes in testing strategies", "TEST", 91, 120]]], ["Data are skewed towards hospitalised cases and asymptomatic or paucisymptomatic cases, in particular, will be underreported.", [["asymptomatic", "PROBLEM", 47, 59], ["paucisymptomatic cases", "PROBLEM", 63, 85]]], ["The mortality data have an intrinsic lag that reduces their sensitivity to recent changes.", [["an intrinsic lag", "PROBLEM", 24, 40]]], ["Nevertheless, most countries have systematic testing of hospitalised cases and most mortality occurs in hospitals, so disease specific mortality is potentially less biased than confirmed cases.", [["systematic testing", "TEST", 34, 52], ["disease specific mortality", "PROBLEM", 118, 144]]], ["Data for each included country were examined for inconsistencies and artefacts.", [["artefacts", "PROBLEM", 69, 78]]], ["The data for China on 18th April showed a spike that appears to be an artefact of redefinition, and was also discarded.", [["a spike", "PROBLEM", 40, 47], ["appears to be", "UNCERTAINTY", 53, 66], ["artefact", "OBSERVATION", 70, 78]]], ["Iran reported nothing on the 4th April and a spike on the 5th, so those reports were split evenly across the 2 days.Structure of the models ::: MethodsThe number of people a directly transmitted disease will infect each day is proportional to the number of infectious people multiplied by the number of susceptible people.", [["people", "ORGANISM", 165, 171], ["people", "ORGANISM", 268, 274], ["people", "ORGANISM", 315, 321], ["people", "SPECIES", 165, 171], ["people", "SPECIES", 268, 274], ["people", "SPECIES", 315, 321], ["a spike", "PROBLEM", 43, 50], ["Methods", "TREATMENT", 144, 151], ["a directly transmitted disease", "PROBLEM", 172, 202], ["infectious", "OBSERVATION", 257, 267]]], ["While the absolute numbers of COVID-19 cases and deaths are shocking, the daily numbers are very small proportions of each country's population and, therefore, the numbers of susceptible individuals are almost constant.", [["deaths", "DISEASE", 49, 55], ["COVID", "TEST", 30, 35], ["the daily numbers", "TEST", 70, 87], ["susceptible individuals", "PROBLEM", 175, 198], ["very", "OBSERVATION_MODIFIER", 92, 96], ["small", "OBSERVATION_MODIFIER", 97, 102], ["susceptible", "OBSERVATION_MODIFIER", 175, 186], ["individuals", "OBSERVATION", 187, 198], ["almost", "OBSERVATION_MODIFIER", 203, 209], ["constant", "OBSERVATION_MODIFIER", 210, 218]]], ["This means that, during periods of constant behaviour, exponential trajectories can be expected.", [["constant behaviour", "PROBLEM", 35, 53], ["exponential trajectories", "PROBLEM", 55, 79]]], ["And this should hold whether the daily numbers were increasing or decreasing.Structure of the models ::: MethodsEach country introduced restrictions in a different pattern, so rather than attempting to interpret those rules, and how people responded to them, the data were used to identify periods of steady increase and decline.", [["people", "ORGANISM", 233, 239], ["people", "SPECIES", 233, 239], ["MethodsEach country", "TREATMENT", 105, 124], ["the data", "TEST", 259, 267], ["steady increase", "PROBLEM", 301, 316], ["decreasing", "OBSERVATION_MODIFIER", 66, 76], ["steady", "OBSERVATION_MODIFIER", 301, 307], ["increase", "OBSERVATION", 308, 316]]], ["This required identifying, and discarding, the transitional period where the data were affected by both the original, pre-lockdown, and modified, lockdown behaviour.Structure of the models ::: MethodsThe data were loaded into R 3.6.1 (R Core Team 2019) [9] and mortality and cases from each country were analysed separately.", [["Methods", "TREATMENT", 193, 200], ["The data", "TEST", 200, 208]]], ["Preliminary examination of the data showed that residuals around models fitted to almost all the datasets were overdispersed relative to the Poisson distribution.", [["Preliminary examination of the data", "TEST", 0, 35], ["residuals around models", "PROBLEM", 48, 71], ["residuals", "OBSERVATION", 48, 57]]], ["All the models therefore used the negative binomial error family, with a log link function.Exponential models ::: MethodsTo find the best representation of the initial, exponential growth, phase, a pair of generalised linear models were fitted for each combination of start and finish date at least 10 days apart such that the finish date was no later than 5 days before the day that the maximum number of events was observed.", [["Methods", "TREATMENT", 114, 121], ["a pair of generalised linear models", "PROBLEM", 196, 231]]], ["The 5 day interval was chosen after exploration of the Spanish and Italian data, where tight lockdowns were associated with obvious changes in the trajectory.", [["exploration", "TEST", 36, 47], ["obvious changes in the trajectory", "PROBLEM", 124, 157]]], ["These changes were particularly visible because of the large numbers of infections in those countries at that time.", [["infections", "DISEASE", 72, 82], ["infections", "PROBLEM", 72, 82], ["large", "OBSERVATION_MODIFIER", 55, 60], ["numbers", "OBSERVATION_MODIFIER", 61, 68], ["infections", "OBSERVATION", 72, 82]]], ["Adjusting this interval changes the estimates, and estimability, of individual countries' trajectories but produces similar overall patternsExponential models ::: MethodsThe first model, of each pair, simply contained a linear term for time.", [["Methods", "TREATMENT", 163, 170], ["linear", "OBSERVATION_MODIFIER", 220, 226]]], ["The second model contained both linear and quadratic terms for time.", [["both", "OBSERVATION_MODIFIER", 27, 31], ["linear", "OBSERVATION_MODIFIER", 32, 38], ["quadratic", "OBSERVATION_MODIFIER", 43, 52]]], ["Exploratory analyses using AIC [11] showed this selected very short intervals, and the small sample correction, AICc, worsens this problem.", [["Exploratory analyses", "TEST", 0, 20], ["AIC", "TEST", 27, 30], ["the small sample correction", "TREATMENT", 83, 110], ["small", "OBSERVATION_MODIFIER", 87, 92]]], ["In BIC the penalty for additional parameters is proportional to the natural logarithm of the number of datapoints, so it is less eager to increase the complexity of models as sample size increases.Exponential models ::: MethodsLinear models were considered potential representations of the initial exponential growth phase if they:; 1) had positive point estimates of slope; and 2) had BIC lower than their parallel quadratic model.", [["MethodsLinear models", "TREATMENT", 220, 240], ["BIC lower than their parallel quadratic model", "PROBLEM", 386, 431], ["number", "OBSERVATION_MODIFIER", 93, 99], ["size", "OBSERVATION_MODIFIER", 182, 186], ["increases", "OBSERVATION_MODIFIER", 187, 196]]], ["If multiple models satisfied these criteria, the model where BIC was furthest below that of its quadratic equivalent was used.Exponential models ::: MethodsFor the exponential period under lockdown, the model was chosen in a similar way, but with its data not beginning before 5 days after the finish of the first exponential period.", [["the model where BIC", "TREATMENT", 45, 64]]], ["No requirement was placed on the slope of the second exponential period, so this could be negative or positive.", [["requirement", "OBSERVATION_MODIFIER", 3, 14], ["positive", "OBSERVATION", 102, 110]]], ["It could even be larger than that for the first period, if that produced a better fit to the data.", [["larger", "OBSERVATION_MODIFIER", 17, 23]]], ["One exponential period was identified in the case data from 19 countries, and two exponential periods for 68 others.", [["exponential", "OBSERVATION_MODIFIER", 4, 15]]], ["For the mortality data, these numbers were 1 and 53.Model checking ::: MethodsTo provide a visual check on these models, a generalised additive model (GAM) of the whole trajectory was also fitted [12].", [["the mortality data", "TEST", 4, 22], ["these numbers", "TEST", 24, 37], ["Methods", "TREATMENT", 71, 78], ["a visual check", "TEST", 89, 103], ["a generalised additive model (GAM) of the whole trajectory", "TREATMENT", 121, 179]]], ["In most cases, the ends of this curve are similar to the exponential models.", [["this curve", "TEST", 27, 37]]], ["It should be noted that GAMs favour steady change and curvature, while many of the changes in behaviour were quite sudden.", [["GAMs", "SIMPLE_CHEMICAL", 24, 28], ["steady change and curvature", "PROBLEM", 36, 63], ["curvature", "OBSERVATION_MODIFIER", 54, 63]]], ["For a few countries the mismatch between the GAM and exponential models gave, subjectively, cause for concern.", [["GAM", "DNA", 45, 48], ["mismatch", "OBSERVATION", 24, 32]]], ["These are indicated in the figures.Model checking ::: MethodsThe slopes, and confidence intervals around them, are of limited direct use.", [["Methods", "TREATMENT", 54, 61], ["slopes", "OBSERVATION_MODIFIER", 65, 71]]], ["However, dividing the natural logarithm of 2 by them gives the doubling time of epidemic growth or halving time of its decay.Reproduction (R) number ::: MethodsR0, the basic reproduction number for the disease, is the expected number of people one infected person would pass the disease to in a na\u00efve population.", [["people", "ORGANISM", 237, 243], ["MethodsR0", "PROTEIN", 153, 162], ["people", "SPECIES", 237, 243], ["person", "SPECIES", 257, 263], ["epidemic growth", "PROBLEM", 80, 95], ["MethodsR0", "TREATMENT", 153, 162], ["the disease", "PROBLEM", 198, 209], ["the disease", "PROBLEM", 275, 286], ["disease", "OBSERVATION", 202, 209], ["infected", "OBSERVATION", 248, 256]]], ["It is critical to disease spread: above 1 an epidemic will accelerate, below that the outbreak will fade away.", [["disease", "OBSERVATION", 18, 25]]], ["This approach requires an estimated distribution for the serial interval of infection.", [["infection", "DISEASE", 76, 85], ["infection", "PROBLEM", 76, 85], ["infection", "OBSERVATION", 76, 85]]], ["The lognormal with mean 4 days and standard deviation of 2.9 days calculated by Nishiura, Linton and Akhmetzhanov [15] was used for this.", [["Linton", "TREATMENT", 90, 96], ["Akhmetzhanov", "TREATMENT", 101, 113]]], ["While changing this distribution changes the individual estimated values for R0, the relationship between the estimates before and under lockdown is relatively insensitive to plausible choices.Estimates of the effect of \u201clockdown\u201d ::: MethodsMost discussion of R considers it as either indicating whether a disease outbreak will grow or fade away.", [["a disease outbreak", "PROBLEM", 305, 323], ["disease", "OBSERVATION", 307, 314]]], ["At best the size of R is used as an indication of these changes.", [["these changes", "PROBLEM", 50, 63], ["size", "OBSERVATION_MODIFIER", 12, 16]]], ["However, it is also a measure of how frequently individuals come into sufficiently close contact to pass the disease.", [["the disease", "PROBLEM", 105, 116], ["disease", "OBSERVATION", 109, 116]]], ["The difference between the value of R and 1 therefore contains information on how much behaviour needs to change to stop the spread of a disease, or how much restrictions on contact between individuals can be relaxed without causing a resurgence in infections.Estimates of the effect of \u201clockdown\u201d ::: MethodsFour estimates of the scope for relaxing lockdown were then considered (table 1).", [["infections", "DISEASE", 249, 259], ["a disease", "PROBLEM", 135, 144], ["infections", "PROBLEM", 249, 259], ["relaxing lockdown", "TREATMENT", 341, 358], ["infections", "OBSERVATION", 249, 259]]], ["It is the proportion that contact under lockdown could be increased without causing a resurgence of the epidemic.", [["the epidemic", "PROBLEM", 100, 112]]]], "82df15cd2620c224affd4ce100e7fac7fcff7b10": [["\u25a0 INTRODUCTIONmRNA-based therapies and vaccines hold tremendous potential for the treatment and prevention of a wide range of diseases, including cancer, genetic disorders, and infectious diseases.", [["cancer", "ANATOMY", 146, 152], ["cancer", "DISEASE", 146, 152], ["genetic disorders", "DISEASE", 154, 171], ["infectious diseases", "DISEASE", 177, 196], ["cancer", "CANCER", 146, 152], ["INTRODUCTIONmRNA-based therapies", "TREATMENT", 2, 34], ["vaccines", "TREATMENT", 39, 47], ["the treatment", "TREATMENT", 78, 91], ["a wide range of diseases", "PROBLEM", 110, 134], ["cancer", "PROBLEM", 146, 152], ["genetic disorders", "PROBLEM", 154, 171], ["infectious diseases", "PROBLEM", 177, 196], ["infectious", "OBSERVATION_MODIFIER", 177, 187]]], ["1\u22124 For example, the first potential mRNA vaccine against SARS-CoV-19 was administered just 63 days after the identification of the virus sequence.", [["SARS-CoV-19", "CHEMICAL", 58, 69], ["SARS-CoV-19", "ORGANISM", 58, 69], ["SARS-CoV-19", "SPECIES", 58, 69], ["mRNA vaccine", "TREATMENT", 37, 49], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["the virus sequence", "TEST", 128, 146]]], ["5 Lipid nanoparticles (LNPs) are the premier vehicles that package, protect, and deliver mRNA inside cells, currently deployed as delivery vectors for mRNA vaccines in clinical trials.\u25a0 INTRODUCTIONLNPs are multicomponent lipid systems containing an ionizable lipid, a phospholipid, cholesterol, and a PEG-lipid.", [["cells", "ANATOMY", 101, 106], ["cholesterol", "CHEMICAL", 283, 294], ["PEG", "CHEMICAL", 302, 305], ["cholesterol", "CHEMICAL", 283, 294], ["PEG", "CHEMICAL", 302, 305], ["5", "SIMPLE_CHEMICAL", 0, 1], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 2, 21], ["LNPs", "SIMPLE_CHEMICAL", 23, 27], ["cells", "CELL", 101, 106], ["lipid", "SIMPLE_CHEMICAL", 260, 265], ["phospholipid", "SIMPLE_CHEMICAL", 269, 281], ["cholesterol", "SIMPLE_CHEMICAL", 283, 294], ["PEG-lipid", "SIMPLE_CHEMICAL", 302, 311], ["Lipid nanoparticles (LNPs)", "TREATMENT", 2, 28], ["mRNA inside cells", "TREATMENT", 89, 106], ["delivery vectors", "TREATMENT", 130, 146], ["mRNA vaccines", "TREATMENT", 151, 164], ["multicomponent lipid systems", "TREATMENT", 207, 235], ["an ionizable lipid", "TREATMENT", 247, 265], ["a phospholipid, cholesterol", "TREATMENT", 267, 294], ["a PEG-lipid", "TREATMENT", 300, 311], ["ionizable lipid", "OBSERVATION", 250, 265]]], ["6 The ionizable lipid complexes the mRNA to form a core structure while helper lipids (phospholipid and cholesterol) envelop the lipid\u2212mRNA complex, and the PEG-lipid protects the nanoparticle shell.", [["cholesterol", "CHEMICAL", 104, 115], ["PEG", "CHEMICAL", 157, 160], ["cholesterol", "CHEMICAL", 104, 115], ["PEG", "CHEMICAL", 157, 160], ["lipids", "SIMPLE_CHEMICAL", 79, 85], ["phospholipid", "SIMPLE_CHEMICAL", 87, 99], ["cholesterol", "SIMPLE_CHEMICAL", 104, 115], ["lipid\u2212mRNA", "GENE_OR_GENE_PRODUCT", 129, 139], ["PEG-lipid", "SIMPLE_CHEMICAL", 157, 166], ["mRNA", "RNA", 36, 40], ["lipid\u2212mRNA complex", "PROTEIN", 129, 147], ["The ionizable lipid complexes", "TREATMENT", 2, 31], ["helper lipids (phospholipid and cholesterol)", "TREATMENT", 72, 116], ["the lipid\u2212mRNA complex", "TREATMENT", 125, 147], ["the PEG-lipid protects the nanoparticle shell", "TREATMENT", 153, 198], ["ionizable lipid", "OBSERVATION", 6, 21], ["nanoparticle shell", "OBSERVATION", 180, 198]]], ["7 However, the role of cholesterol in the LNP structure and the contribution of the said structure to cellular uptake and endosomal escape have yet to be revealed.", [["cellular", "ANATOMY", 102, 110], ["endosomal", "ANATOMY", 122, 131], ["cholesterol", "CHEMICAL", 23, 34], ["cholesterol", "CHEMICAL", 23, 34], ["cholesterol", "SIMPLE_CHEMICAL", 23, 34], ["cellular", "CELL", 102, 110], ["endosomal", "CELLULAR_COMPONENT", 122, 131], ["endosomal escape", "TEST", 122, 138], ["LNP", "ANATOMY", 42, 45], ["cellular uptake", "OBSERVATION", 102, 117], ["endosomal escape", "OBSERVATION", 122, 138]]], ["LNP morphology is an essential determinant for efficient packaging and release of its cargo and remains an intriguing area of research.\u25a0 INTRODUCTIONThe formation and structure of LNPs have been mainly studied in the context of the delivery of smaller siRNA (<30 nucleotides).", [["LNPs", "SIMPLE_CHEMICAL", 180, 184], ["LNPs", "PROTEIN", 180, 184], ["efficient packaging", "TREATMENT", 47, 66], ["smaller siRNA", "PROBLEM", 244, 257], ["structure", "OBSERVATION_MODIFIER", 167, 176], ["mainly", "OBSERVATION_MODIFIER", 195, 201], ["smaller", "OBSERVATION_MODIFIER", 244, 251], ["siRNA", "OBSERVATION", 252, 257]]], ["However, the question remains whether or not the lessons learned from the improvements of the LNP structure for siRNA delivery apply to the mRNA due to its larger size (10 3 nucleotides).", [["mRNA", "RNA", 140, 144], ["siRNA delivery", "TREATMENT", 112, 126], ["larger", "OBSERVATION_MODIFIER", 156, 162], ["size", "OBSERVATION_MODIFIER", 163, 167]]], ["1 Evidence suggests that the incorporation of mRNA can rearrange the LNP organization, causing the formation of inverted-hexagonal nanostructures, 8 unlike siRNA that is confined in lamellar nanostructures by ionizable lipids.", [["lipids", "SIMPLE_CHEMICAL", 219, 225], ["mRNA", "RNA", 46, 50], ["the incorporation of mRNA", "PROBLEM", 25, 50], ["the LNP organization", "PROBLEM", 65, 85], ["inverted-hexagonal nanostructures", "PROBLEM", 112, 145], ["8 unlike siRNA", "PROBLEM", 147, 161], ["ionizable lipids", "TREATMENT", 209, 225], ["LNP", "OBSERVATION_MODIFIER", 69, 72], ["hexagonal nanostructures", "OBSERVATION", 121, 145], ["siRNA", "OBSERVATION", 156, 161], ["lamellar nanostructures", "OBSERVATION", 182, 205], ["ionizable lipids", "OBSERVATION", 209, 225]]], ["9 This is further complicated by the multidimensional nature of both LNP lipid formulations and the RNA nucleotide composition.\u25a0 INTRODUCTIONRecently, we investigated the substitution of cholesterol in LNP formulations with naturally occurring analogs with different chemical structures and the consequent effect on LNP size, mRNA encapsulation, internalization, and transfection.", [["nucleotide", "CHEMICAL", 104, 114], ["cholesterol", "CHEMICAL", 187, 198], ["LNP", "CHEMICAL", 202, 205], ["nucleotide", "CHEMICAL", 104, 114], ["cholesterol", "CHEMICAL", 187, 198], ["LNP", "SIMPLE_CHEMICAL", 69, 72], ["cholesterol", "SIMPLE_CHEMICAL", 187, 198], ["LNP", "SIMPLE_CHEMICAL", 202, 205], ["LNP", "SIMPLE_CHEMICAL", 316, 319], ["both LNP lipid formulations", "TREATMENT", 64, 91], ["the RNA nucleotide composition", "TREATMENT", 96, 126], ["cholesterol in LNP formulations", "TREATMENT", 187, 218], ["naturally occurring analogs", "PROBLEM", 224, 251], ["different chemical structures", "PROBLEM", 257, 286], ["LNP size", "TREATMENT", 316, 324], ["mRNA encapsulation", "TREATMENT", 326, 344], ["size", "OBSERVATION_MODIFIER", 320, 324], ["encapsulation", "OBSERVATION_MODIFIER", 331, 344]]], ["10 The substitution of cholesterol (Chol) with \u03b2sitosterol (Sito) in the formulation showed a substantial improvement in cell transfection.", [["cell", "ANATOMY", 121, 125], ["cholesterol", "CHEMICAL", 23, 34], ["Chol", "CHEMICAL", 36, 40], ["\u03b2sitosterol", "CHEMICAL", 47, 58], ["Sito", "CHEMICAL", 60, 64], ["cholesterol", "CHEMICAL", 23, 34], ["Chol", "CHEMICAL", 36, 40], ["\u03b2sitosterol", "CHEMICAL", 47, 58], ["Sito", "CHEMICAL", 60, 64], ["cholesterol", "SIMPLE_CHEMICAL", 23, 34], ["Chol", "SIMPLE_CHEMICAL", 36, 40], ["\u03b2sitosterol", "SIMPLE_CHEMICAL", 47, 58], ["Sito", "SIMPLE_CHEMICAL", 60, 64], ["cell", "CELL", 121, 125], ["The substitution of cholesterol (Chol)", "TREATMENT", 3, 41], ["\u03b2sitosterol (Sito)", "TREATMENT", 47, 65], ["cell transfection", "TREATMENT", 121, 138], ["substantial", "OBSERVATION_MODIFIER", 94, 105], ["improvement", "OBSERVATION_MODIFIER", 106, 117], ["cell transfection", "OBSERVATION", 121, 138]]], ["Upon further inspection of Sito LNPs with a cryo-transmission electron microscope (cryo-TEM), we found that Sito LNPs have a faceted surface, as opposed to spherical Chol LNPs with smooth curvature, likely due to phase separation of comprising lipids, 11 and potentially, the formation of two-dimensional lipid crystals in the LNP membrane.", [["surface", "ANATOMY", 133, 140], ["LNP membrane", "ANATOMY", 327, 339], ["Chol", "CHEMICAL", 166, 170], ["Chol", "CHEMICAL", 166, 170], ["Sito LNPs", "SIMPLE_CHEMICAL", 108, 117], ["spherical Chol LNPs", "SIMPLE_CHEMICAL", 156, 175], ["lipids", "SIMPLE_CHEMICAL", 244, 250], ["LNP membrane", "MULTI-TISSUE_STRUCTURE", 327, 339], ["Sito LNPs", "DNA", 27, 36], ["a cryo-transmission electron microscope", "TEST", 42, 81], ["lipids", "TEST", 244, 250], ["two-dimensional lipid crystals in the LNP membrane", "TREATMENT", 289, 339], ["faceted", "OBSERVATION_MODIFIER", 125, 132], ["surface", "OBSERVATION_MODIFIER", 133, 140], ["spherical Chol", "OBSERVATION", 156, 170], ["smooth curvature", "OBSERVATION", 181, 197], ["likely due to", "UNCERTAINTY", 199, 212], ["lipid crystals", "OBSERVATION", 305, 319], ["LNP", "ANATOMY", 327, 330], ["membrane", "ANATOMY_MODIFIER", 331, 339]]], ["8 In this study, we investigated the structure of LNPs containing naturally occurring phytosterols (namely, \u03b2sitosterol (Sito), fucosterol (Fuco), campesterol (Camp), and stigmastanol (Stig)) using cryo-TEM, thermal analysis, and a fluorescent assay (TMA-DPH probe).", [["LNPs", "CHEMICAL", 50, 54], ["phytosterols", "CHEMICAL", 86, 98], ["\u03b2sitosterol", "CHEMICAL", 108, 119], ["Sito", "CHEMICAL", 121, 125], ["fucosterol", "CHEMICAL", 128, 138], ["Fuco", "CHEMICAL", 140, 144], ["campesterol", "CHEMICAL", 147, 158], ["stigmastanol", "CHEMICAL", 171, 183], ["phytosterols", "CHEMICAL", 86, 98], ["\u03b2sitosterol", "CHEMICAL", 108, 119], ["Sito", "CHEMICAL", 121, 125], ["fucosterol", "CHEMICAL", 128, 138], ["Fuco", "CHEMICAL", 140, 144], ["campesterol", "CHEMICAL", 147, 158], ["stigmastanol", "CHEMICAL", 171, 183], ["Stig", "CHEMICAL", 185, 189], ["DPH", "CHEMICAL", 255, 258], ["LNPs", "SIMPLE_CHEMICAL", 50, 54], ["phytosterols", "SIMPLE_CHEMICAL", 86, 98], ["\u03b2sitosterol", "SIMPLE_CHEMICAL", 108, 119], ["Sito", "SIMPLE_CHEMICAL", 121, 125], ["fucosterol", "SIMPLE_CHEMICAL", 128, 138], ["Fuco", "SIMPLE_CHEMICAL", 140, 144], ["campesterol", "SIMPLE_CHEMICAL", 147, 158], ["Camp", "SIMPLE_CHEMICAL", 160, 164], ["stigmastanol", "SIMPLE_CHEMICAL", 171, 183], ["Stig", "SIMPLE_CHEMICAL", 185, 189], ["this study", "TEST", 5, 15], ["phytosterols", "TREATMENT", 86, 98], ["\u03b2sitosterol (Sito)", "TREATMENT", 108, 126], ["fucosterol (Fuco)", "TREATMENT", 128, 145], ["campesterol (Camp)", "TREATMENT", 147, 165], ["stigmastanol (Stig)", "TREATMENT", 171, 190], ["thermal analysis", "TEST", 208, 224], ["a fluorescent assay", "TEST", 230, 249], ["TMA-DPH probe", "TREATMENT", 251, 264]]], ["We found that the incorporation of Chol analogs significantly affects the morphology of the LNPs and enhances nucleic acid delivery.", [["Chol", "CHEMICAL", 35, 39], ["nucleic acid", "CHEMICAL", 110, 122], ["Chol", "CHEMICAL", 35, 39], ["Chol analogs", "SIMPLE_CHEMICAL", 35, 47], ["LNPs", "SIMPLE_CHEMICAL", 92, 96], ["nucleic acid", "SIMPLE_CHEMICAL", 110, 122], ["Chol analogs", "PROBLEM", 35, 47], ["nucleic acid delivery", "TREATMENT", 110, 131], ["Chol analogs", "OBSERVATION", 35, 47], ["nucleic acid", "OBSERVATION", 110, 122]]], ["The findings of this study provide unique insights into the LNP structure that perhaps causes improvement in mRNA transfection.", [["LNP", "CANCER", 60, 63], ["this study", "TEST", 16, 26], ["mRNA transfection", "TREATMENT", 109, 126], ["LNP", "ANATOMY", 60, 63], ["perhaps causes", "UNCERTAINTY", 79, 93], ["improvement", "OBSERVATION_MODIFIER", 94, 105], ["mRNA transfection", "OBSERVATION", 109, 126]]], ["The deconvolution of the LNP structure can lead to new designs that enable efficient gene transfer.\u25a0 RESULTS AND DISCUSSIONBasic Nanoparticle Properties.", [["LNP", "ANATOMY", 25, 28]]], ["LNPs containing cholesterol analogs , DLin-MC3-DMA, DSPC, DMG-PEG-2000 (38.5:50:10:1.5 lipid molar ratios, respectively), and FLuc mRNA, were prepared using a standard microfluidic mixing procedure.", [["cholesterol", "CHEMICAL", 16, 27], ["DLin-MC3-DMA", "CHEMICAL", 38, 50], ["DSPC", "CHEMICAL", 52, 56], ["DMG-PEG-2000", "CHEMICAL", 58, 70], ["cholesterol", "CHEMICAL", 16, 27], ["DLin-MC3-DMA", "CHEMICAL", 38, 50], ["DSPC", "CHEMICAL", 52, 56], ["DMG-PEG-2000", "CHEMICAL", 58, 70], ["LNPs", "SIMPLE_CHEMICAL", 0, 4], ["cholesterol", "SIMPLE_CHEMICAL", 16, 27], ["DLin-MC3-DMA", "SIMPLE_CHEMICAL", 38, 50], ["DSPC", "SIMPLE_CHEMICAL", 52, 56], ["DMG-PEG-2000", "SIMPLE_CHEMICAL", 58, 70], ["FLuc", "SIMPLE_CHEMICAL", 126, 130], ["FLuc mRNA", "RNA", 126, 135], ["LNPs", "TEST", 0, 4], ["cholesterol analogs", "TEST", 16, 35], ["DLin", "TEST", 38, 42], ["DMA", "PROBLEM", 47, 50], ["DSPC", "PROBLEM", 52, 56], ["DMG-PEG", "TREATMENT", 58, 65], ["lipid molar ratios", "TEST", 87, 105], ["FLuc mRNA", "TREATMENT", 126, 135], ["a standard microfluidic mixing procedure", "TREATMENT", 157, 197], ["FLuc", "ANATOMY", 126, 130]]], ["10, 12 The structures of cholesterol analogs are shown in Figure 1A .", [["cholesterol", "CHEMICAL", 25, 36], ["cholesterol", "CHEMICAL", 25, 36], ["cholesterol", "SIMPLE_CHEMICAL", 25, 36], ["cholesterol analogs", "OBSERVATION", 25, 44]]], ["Overall, all LNPs showed a narrow size distribution (see Figure 1B ) as measured by dynamic light scattering (DLS) and >90% encapsulation efficiency ( Figure S1 ).", [["LNPs", "PATHOLOGICAL_FORMATION", 13, 17], ["all LNPs", "TEST", 9, 17], ["a narrow size distribution", "PROBLEM", 25, 51], ["DLS", "TEST", 110, 113], ["narrow", "OBSERVATION_MODIFIER", 27, 33], ["size", "OBSERVATION_MODIFIER", 34, 38], ["encapsulation efficiency", "OBSERVATION", 124, 148]]], ["Chol LNPs had the highest mRNA encapsulation efficiency and smallest size and polydispersity index (PDI), while Stig LNPs had the largest size with the largest PDI and slightly less efficient encapsulation.", [["Chol", "CHEMICAL", 0, 4], ["Chol", "CHEMICAL", 0, 4], ["Chol LNPs", "SIMPLE_CHEMICAL", 0, 9], ["Stig LNPs", "SIMPLE_CHEMICAL", 112, 121], ["PDI", "PROTEIN", 160, 163], ["Chol LNPs", "TEST", 0, 9], ["the highest mRNA encapsulation efficiency", "PROBLEM", 14, 55], ["smallest size", "PROBLEM", 60, 73], ["polydispersity index", "PROBLEM", 78, 98], ["Stig LNPs", "TEST", 112, 121], ["the largest PDI", "PROBLEM", 148, 163], ["highest mRNA", "OBSERVATION_MODIFIER", 18, 30], ["encapsulation efficiency", "OBSERVATION", 31, 55], ["smallest", "OBSERVATION_MODIFIER", 60, 68], ["size", "OBSERVATION_MODIFIER", 69, 73], ["polydispersity", "OBSERVATION_MODIFIER", 78, 92], ["index", "OBSERVATION_MODIFIER", 93, 98], ["largest", "OBSERVATION_MODIFIER", 130, 137], ["size", "OBSERVATION_MODIFIER", 138, 142], ["largest", "OBSERVATION_MODIFIER", 152, 159], ["slightly", "OBSERVATION_MODIFIER", 168, 176], ["less", "OBSERVATION_MODIFIER", 177, 181], ["efficient", "OBSERVATION_MODIFIER", 182, 191], ["encapsulation", "OBSERVATION", 192, 205]]], ["Transfection of HeLa cells with prepared LNPs ( Figure 1C ) showed up to 10-fold improvement in gene transfection ( Figure S2 ).", [["HeLa cells", "ANATOMY", 16, 26], ["HeLa cells", "CELL", 16, 26], ["LNPs", "SIMPLE_CHEMICAL", 41, 45], ["HeLa cells", "CELL_LINE", 16, 26], ["HeLa cells", "TEST", 16, 26], ["HeLa cells", "OBSERVATION", 16, 26], ["gene transfection", "OBSERVATION", 96, 113]]], ["At the highest dose, a slight decrease in protein expression is often observed due to the saturation of cellular machinery.", [["cellular", "ANATOMY", 104, 112], ["cellular", "CELL", 104, 112], ["a slight decrease in protein expression", "PROBLEM", 21, 60], ["slight", "OBSERVATION_MODIFIER", 23, 29], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["protein expression", "OBSERVATION", 42, 60], ["cellular machinery", "OBSERVATION", 104, 122]]], ["10,13\u221215 Cryo-Electron Microscopy.", [["Electron Microscopy", "TEST", 14, 33]]], ["We employed cryo-TEM to investigate the structure of LNPs ( Figure 2 ).", [["LNPs", "SIMPLE_CHEMICAL", 53, 57], ["LNPs", "PROTEIN", 53, 57], ["cryo-TEM", "TREATMENT", 12, 20]]], ["We found that Sito and Stig LNPs have a faceted surface, as opposed to spherical Chol and Camp LNPs.", [["surface", "ANATOMY", 48, 55], ["Chol", "CHEMICAL", 81, 85], ["Chol", "CHEMICAL", 81, 85], ["Sito", "SIMPLE_CHEMICAL", 14, 18], ["Stig LNPs", "SIMPLE_CHEMICAL", 23, 32], ["Chol", "SIMPLE_CHEMICAL", 81, 85], ["Camp LNPs", "SIMPLE_CHEMICAL", 90, 99], ["Camp LNPs", "TREATMENT", 90, 99], ["faceted", "OBSERVATION_MODIFIER", 40, 47], ["surface", "OBSERVATION_MODIFIER", 48, 55], ["spherical Chol", "OBSERVATION", 71, 85], ["Camp LNPs", "OBSERVATION", 90, 99]]], ["Camp, Stig, and Sito LNPs formed multilamellar structures, while Chol and Fuco LNPs mostly formed a single bilayer.", [["multilamellar structures", "ANATOMY", 33, 57], ["Chol", "CHEMICAL", 65, 69], ["Chol", "CHEMICAL", 65, 69], ["Stig", "SIMPLE_CHEMICAL", 6, 10], ["Sito LNPs", "SIMPLE_CHEMICAL", 16, 25], ["multilamellar structures", "PATHOLOGICAL_FORMATION", 33, 57], ["Chol", "SIMPLE_CHEMICAL", 65, 69], ["Fuco LNPs", "SIMPLE_CHEMICAL", 74, 83], ["Camp", "TEST", 0, 4], ["multilamellar structures", "OBSERVATION", 33, 57]]], ["Fuco LNPs have distinctly different morphology from other LNPs, containing domains with distinctly different electron density forming at the LNP boundaries, which may be the result of lipid crystallization and mRNA separating from the lipid core.\u25a0 RESULTS AND DISCUSSIONWe quantified the number of particles containing bi-and multilamellar structures and internal defects (areas of different electron densities).", [["multilamellar structures", "ANATOMY", 326, 350], ["LNPs", "SIMPLE_CHEMICAL", 58, 62], ["electron", "SIMPLE_CHEMICAL", 109, 117], ["lipid", "SIMPLE_CHEMICAL", 184, 189], ["LNPs", "PROTEIN", 58, 62], ["mRNA", "RNA", 210, 214], ["distinctly different electron density", "PROBLEM", 88, 125], ["lipid crystallization", "TREATMENT", 184, 205], ["the lipid core", "TREATMENT", 231, 245], ["bi-and multilamellar structures", "TREATMENT", 319, 350], ["internal defects", "PROBLEM", 355, 371], ["distinctly", "OBSERVATION_MODIFIER", 15, 25], ["different", "OBSERVATION_MODIFIER", 26, 35], ["morphology", "OBSERVATION_MODIFIER", 36, 46], ["distinctly", "OBSERVATION_MODIFIER", 88, 98], ["different", "OBSERVATION_MODIFIER", 99, 108], ["electron density", "OBSERVATION", 109, 125], ["LNP", "ANATOMY", 141, 144], ["may be the result of", "UNCERTAINTY", 163, 183], ["lipid crystallization", "OBSERVATION", 184, 205], ["internal defects", "OBSERVATION", 355, 371], ["areas", "OBSERVATION_MODIFIER", 373, 378], ["different", "OBSERVATION_MODIFIER", 382, 391], ["electron densities", "OBSERVATION", 392, 410]]], ["The results are shown in Figure 3A ,B. Yanez Arteta et al. have previously proposed a lamellar structure of DLin-MC3-DMA/DSPC/DMG-PEG-2000/Chol LNPs (similar to this work) with human erythropoietin mRNA on the basis of scattering length density measurements.", [["DLin-MC3-DMA", "CHEMICAL", 108, 120], ["DSPC", "CHEMICAL", 121, 125], ["DMG-PEG-2000", "CHEMICAL", 126, 138], ["Chol", "CHEMICAL", 139, 143], ["DLin-MC3-DMA", "CHEMICAL", 108, 120], ["DSPC", "CHEMICAL", 121, 125], ["DMG", "CHEMICAL", 126, 129], ["PEG-2000", "CHEMICAL", 130, 138], ["Chol", "CHEMICAL", 139, 143], ["DLin-MC3-DMA", "SIMPLE_CHEMICAL", 108, 120], ["DSPC", "SIMPLE_CHEMICAL", 121, 125], ["DMG-PEG-2000/Chol LNPs", "SIMPLE_CHEMICAL", 126, 148], ["human", "ORGANISM", 177, 182], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 183, 197], ["human erythropoietin mRNA", "RNA", 177, 202], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["a lamellar structure of DLin", "PROBLEM", 84, 112], ["DMA", "PROBLEM", 117, 120], ["DSPC", "PROBLEM", 121, 125], ["DMG", "TREATMENT", 126, 129], ["PEG", "TREATMENT", 130, 133], ["Chol LNPs", "TREATMENT", 139, 148], ["human erythropoietin mRNA", "TREATMENT", 177, 202], ["scattering length density measurements", "TEST", 219, 257], ["lamellar structure", "OBSERVATION", 86, 104], ["MC3", "ANATOMY", 113, 116], ["erythropoietin mRNA", "OBSERVATION", 183, 202], ["scattering", "OBSERVATION_MODIFIER", 219, 229], ["length", "OBSERVATION_MODIFIER", 230, 236], ["density", "OBSERVATION", 237, 244]]], ["8 In their work, it is suggested that the core mostly contains cationic lipid, mRNA, and cholesterol and is surrounded by layers of DSPC and PEG-lipid.", [["cholesterol", "CHEMICAL", 89, 100], ["DSPC", "CHEMICAL", 132, 136], ["PEG", "CHEMICAL", 141, 144], ["cholesterol", "CHEMICAL", 89, 100], ["DSPC", "CHEMICAL", 132, 136], ["PEG", "CHEMICAL", 141, 144], ["lipid", "SIMPLE_CHEMICAL", 72, 77], ["cholesterol", "SIMPLE_CHEMICAL", 89, 100], ["DSPC", "SIMPLE_CHEMICAL", 132, 136], ["PEG-lipid", "SIMPLE_CHEMICAL", 141, 150], ["mRNA", "RNA", 79, 83], ["DSPC", "TREATMENT", 132, 136], ["PEG-lipid", "TREATMENT", 141, 150], ["cationic lipid", "OBSERVATION", 63, 77]]], ["The differences in particle morphology are likely due to the separation of the comprising lipids.", [["lipids", "SIMPLE_CHEMICAL", 90, 96], ["particle morphology", "OBSERVATION", 19, 38], ["likely due to", "UNCERTAINTY", 43, 56]]], ["11 The comparison of LNP sizes measured by DLS and cryo-TEM ( Figure 3C ) revealed a consistently smaller size in the micrographs, likely due to the contrast challenges associated with cryo-EM where the PEG chains may not be visible.", [["PEG", "CHEMICAL", 203, 206], ["PEG chains", "SIMPLE_CHEMICAL", 203, 213], ["PEG chains", "PROTEIN", 203, 213], ["The comparison of LNP sizes", "TEST", 3, 30], ["DLS", "TEST", 43, 46], ["a consistently smaller size in the micrographs", "PROBLEM", 83, 129], ["the contrast challenges", "PROBLEM", 145, 168], ["cryo-EM where the PEG chains", "TREATMENT", 185, 213], ["LNP", "OBSERVATION_MODIFIER", 21, 24], ["sizes", "OBSERVATION_MODIFIER", 25, 30], ["consistently", "OBSERVATION_MODIFIER", 85, 97], ["smaller", "OBSERVATION_MODIFIER", 98, 105], ["size", "OBSERVATION_MODIFIER", 106, 110], ["likely due to", "UNCERTAINTY", 131, 144], ["contrast challenges", "OBSERVATION", 149, 168], ["PEG chains", "OBSERVATION", 203, 213], ["may not be", "UNCERTAINTY", 214, 224]]], ["Additionally, the average thickness of the bilayers in these LNPs varies from ca.", [["LNPs", "ANATOMY", 61, 65], ["LNPs", "CANCER", 61, 65], ["average", "OBSERVATION_MODIFIER", 18, 25], ["thickness", "OBSERVATION_MODIFIER", 26, 35], ["bilayers", "OBSERVATION_MODIFIER", 43, 51], ["ca", "OBSERVATION", 78, 80]]], ["3 nm for Chol LNPs to ca.", [["Chol", "CHEMICAL", 9, 13], ["Chol", "CHEMICAL", 9, 13], ["Chol LNPs", "SIMPLE_CHEMICAL", 9, 18], ["Chol LNPs", "TREATMENT", 9, 18], ["ca", "ANATOMY", 22, 24]]], ["5 nm for Fuco LNPs, which attests to the changes in lipid organization.\u25a0 RESULTS AND DISCUSSIONThese findings paint an interesting picture of particle morphology and its potential impact on gene transfection.", [["lipid", "SIMPLE_CHEMICAL", 52, 57], ["Fuco LNPs", "TREATMENT", 9, 18], ["the changes in lipid organization", "PROBLEM", 37, 70], ["gene transfection", "TREATMENT", 190, 207], ["lipid organization", "OBSERVATION", 52, 70], ["gene transfection", "OBSERVATION", 190, 207]]], ["Sito, Camp, and Stig LNPs all have a large fraction of multilamellar particles in the population (ca.", [["multilamellar particles", "SIMPLE_CHEMICAL", 55, 78], ["large", "OBSERVATION_MODIFIER", 37, 42], ["fraction", "OBSERVATION", 43, 51], ["multilamellar particles", "OBSERVATION", 55, 78], ["population", "OBSERVATION_MODIFIER", 86, 96], ["ca", "OBSERVATION", 98, 100]]], ["45%, 50%, and 75%, respectively); however, Camp and Stig LNPs show a similar improvement in transfection (ca.", [["Stig LNPs", "SIMPLE_CHEMICAL", 52, 61], ["Camp and Stig LNPs", "TEST", 43, 61], ["similar", "OBSERVATION_MODIFIER", 69, 76], ["improvement", "OBSERVATION_MODIFIER", 77, 88], ["transfection", "OBSERVATION", 92, 104]]], ["5-fold) while improvement for Sito LNPs is ca.", [["Sito LNPs", "SIMPLE_CHEMICAL", 30, 39]]], ["We speculate that there is an optimal percentage of multilamellar structures per Nano Letters pubs.acs.org/NanoLett Letter particle population.", [["multilamellar structures", "ANATOMY", 52, 76], ["optimal", "OBSERVATION_MODIFIER", 30, 37], ["percentage", "OBSERVATION_MODIFIER", 38, 48], ["multilamellar structures", "OBSERVATION", 52, 76]]], ["Out of these three analogs, Camp LNPs have the highest percentage of internal defects (15%), while Sito and Stig LNPs have <2% of particles with irregularities in the internal structure.", [["Camp LNPs", "SIMPLE_CHEMICAL", 28, 37], ["Stig LNPs", "SIMPLE_CHEMICAL", 108, 117], ["Camp LNPs", "TEST", 28, 37], ["internal defects", "PROBLEM", 69, 85], ["Sito", "TEST", 99, 103], ["Stig LNPs", "TEST", 108, 117], ["irregularities in the internal structure", "PROBLEM", 145, 185], ["highest", "OBSERVATION_MODIFIER", 47, 54], ["percentage", "OBSERVATION_MODIFIER", 55, 65], ["internal", "ANATOMY_MODIFIER", 69, 77], ["defects", "OBSERVATION", 78, 85], ["irregularities", "OBSERVATION", 145, 159], ["internal structure", "ANATOMY", 167, 185]]], ["Interestingly, Sito and Stig LNPs formed faceted structures, suggesting the formation of two-dimensional crystals.", [["Sito", "SIMPLE_CHEMICAL", 15, 19], ["Stig LNPs", "SIMPLE_CHEMICAL", 24, 33], ["faceted", "OBSERVATION_MODIFIER", 41, 48], ["crystals", "OBSERVATION_MODIFIER", 105, 113]]], ["8 Camp LNPs, however, show a predominantly smooth curvature (much like the previously proposed \"onion\" structure).", [["onion", "TISSUE", 96, 101], ["Camp LNPs", "TEST", 2, 11], ["a predominantly smooth curvature", "PROBLEM", 27, 59], ["predominantly", "OBSERVATION_MODIFIER", 29, 42], ["smooth", "OBSERVATION_MODIFIER", 43, 49], ["curvature", "OBSERVATION_MODIFIER", 50, 59]]], ["16 Chol LNPs have a small fraction of particles with internal defects (8%) but hardly any multilamellarity.", [["Chol", "CHEMICAL", 3, 7], ["16 Chol LNPs", "SIMPLE_CHEMICAL", 0, 12], ["internal defects", "PROBLEM", 53, 69], ["small fraction", "OBSERVATION_MODIFIER", 20, 34], ["particles", "OBSERVATION_MODIFIER", 38, 47], ["internal", "ANATOMY_MODIFIER", 53, 61], ["defects", "OBSERVATION", 62, 69], ["multilamellarity", "OBSERVATION", 90, 106]]], ["Fuco LNPs have ca. a 2-fold improved transfection compared to Chol LNPs, and 95% of Fuco LNPs have internal defects and no multilamellarity.", [["Chol", "CHEMICAL", 62, 66], ["Chol", "CHEMICAL", 62, 66], ["Chol LNPs", "SIMPLE_CHEMICAL", 62, 71], ["Fuco LNPs", "SIMPLE_CHEMICAL", 84, 93], ["a 2-fold improved transfection", "PROBLEM", 19, 49], ["Chol LNPs", "TEST", 62, 71], ["Fuco LNPs", "TEST", 84, 93], ["internal defects", "PROBLEM", 99, 115], ["multilamellarity", "PROBLEM", 123, 139], ["ca", "OBSERVATION", 15, 17], ["improved", "OBSERVATION_MODIFIER", 28, 36], ["transfection", "OBSERVATION", 37, 49], ["internal defects", "OBSERVATION", 99, 115], ["no", "UNCERTAINTY", 120, 122], ["multilamellarity", "OBSERVATION_MODIFIER", 123, 139]]], ["Except for Fuco LNPs, all LNPs demonstrated a homogeneous core.", [["Fuco LNPs", "SIMPLE_CHEMICAL", 11, 20], ["LNPs", "SIMPLE_CHEMICAL", 26, 30], ["LNPs", "CELL_TYPE", 26, 30], ["Fuco LNPs", "TEST", 11, 20], ["all LNPs", "TEST", 22, 30], ["homogeneous", "OBSERVATION_MODIFIER", 46, 57], ["core", "OBSERVATION_MODIFIER", 58, 62]]], ["On the basis of the cryo-EM results, we can divide the phytosterol LNPs into three classes: (1) high lamellarity and few internal defects (Sito, Camp, and Stig); (2) low lamellarity and a high number of defects (Fuco); (3) low lamellarity and few defects (Chol).", [["Chol", "CHEMICAL", 256, 260], ["phytosterol", "CHEMICAL", 55, 66], ["Chol", "CHEMICAL", 256, 260], ["phytosterol", "SIMPLE_CHEMICAL", 55, 66], ["Chol", "SIMPLE_CHEMICAL", 256, 260], ["phytosterol LNPs", "PROTEIN", 55, 71], ["high lamellarity", "PROBLEM", 96, 112], ["few internal defects", "PROBLEM", 117, 137], ["Camp", "TEST", 145, 149], ["low lamellarity", "PROBLEM", 166, 181], ["a high number of defects (Fuco)", "PROBLEM", 186, 217], ["low lamellarity", "PROBLEM", 223, 238], ["few defects (Chol)", "PROBLEM", 243, 261], ["few", "OBSERVATION_MODIFIER", 117, 120], ["internal defects", "OBSERVATION", 121, 137], ["high number", "OBSERVATION_MODIFIER", 188, 199], ["defects", "OBSERVATION", 203, 210], ["few", "OBSERVATION_MODIFIER", 243, 246], ["defects", "OBSERVATION", 247, 254]]], ["We have previously shown that a polymorphic shape can influence intracellular delivery.", [["intracellular", "ANATOMY", 64, 77], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["a polymorphic shape", "PROBLEM", 30, 49], ["intracellular delivery", "TREATMENT", 64, 86]]], ["10 Increased lamellarity may allow multiple fusion events with the endosomal membrane.", [["endosomal membrane", "ANATOMY", 67, 85], ["endosomal membrane", "CELLULAR_COMPONENT", 67, 85], ["Increased lamellarity", "PROBLEM", 3, 24], ["multiple fusion events", "PROBLEM", 35, 57], ["the endosomal membrane", "TREATMENT", 63, 85], ["Increased", "OBSERVATION_MODIFIER", 3, 12], ["lamellarity", "OBSERVATION", 13, 24], ["multiple", "OBSERVATION_MODIFIER", 35, 43], ["fusion", "OBSERVATION", 44, 50], ["endosomal membrane", "OBSERVATION", 67, 85]]], ["Taken together, the impact of the structure on the mechanism of gene delivery for individual analogs requires further investigation.\u25a0 RESULTS AND DISCUSSIONIn the context of chemical structures of these phytosterols, all of the analogs have at least one additional carbon atom in the C24 aliphatic chain compared to cholesterol, which likely disrupts lipid packing.", [["phytosterols", "CHEMICAL", 203, 215], ["C24 aliphatic", "CHEMICAL", 284, 297], ["cholesterol", "CHEMICAL", 316, 327], ["phytosterols", "CHEMICAL", 203, 215], ["carbon", "CHEMICAL", 265, 271], ["cholesterol", "CHEMICAL", 316, 327], ["phytosterols", "SIMPLE_CHEMICAL", 203, 215], ["carbon atom", "SIMPLE_CHEMICAL", 265, 276], ["C24 aliphatic chain", "SIMPLE_CHEMICAL", 284, 303], ["cholesterol", "SIMPLE_CHEMICAL", 316, 327], ["lipid", "SIMPLE_CHEMICAL", 351, 356], ["gene delivery", "TREATMENT", 64, 77], ["individual analogs", "TREATMENT", 82, 100], ["further investigation", "TEST", 110, 131], ["cholesterol", "TEST", 316, 327], ["lipid packing", "TREATMENT", 351, 364], ["carbon atom", "OBSERVATION", 265, 276], ["C24", "ANATOMY_MODIFIER", 284, 287], ["aliphatic chain", "OBSERVATION", 288, 303], ["lipid packing", "OBSERVATION", 351, 364]]], ["The structural differences align with the proposed cryo-EM classification: Sito, Camp, and Stig have saturated aliphatic tails with 1\u22122 additional carbon atoms compared to Chol.", [["carbon atoms", "CHEMICAL", 147, 159], ["Chol", "CHEMICAL", 172, 176], ["carbon", "CHEMICAL", 147, 153], ["Chol", "CHEMICAL", 172, 176], ["Stig", "SIMPLE_CHEMICAL", 91, 95], ["carbon atoms", "SIMPLE_CHEMICAL", 147, 159], ["Chol", "SIMPLE_CHEMICAL", 172, 176], ["additional carbon atoms", "TREATMENT", 136, 159], ["aliphatic tails", "OBSERVATION", 111, 126]]], ["In comparison, Fuco has two additional carbon atoms and a double bond.", [["Fuco", "CHEMICAL", 15, 19], ["carbon", "CHEMICAL", 39, 45], ["Fuco", "SIMPLE_CHEMICAL", 15, 19], ["carbon atoms", "SIMPLE_CHEMICAL", 39, 51], ["additional carbon atoms", "TREATMENT", 28, 51], ["a double bond", "TREATMENT", 56, 69], ["carbon atoms", "OBSERVATION", 39, 51], ["double bond", "OBSERVATION", 58, 69]]], ["It must be noted that Stig, unlike other analogs, also has a fully saturated stanol core.", [["Stig", "CHEMICAL", 22, 26], ["stanol", "CHEMICAL", 77, 83], ["Stig", "SIMPLE_CHEMICAL", 22, 26], ["stanol", "SIMPLE_CHEMICAL", 77, 83]]], ["Iwahashi et al. previously reported that cholestanol has a lower enthalpy of fusion compared to cholesterol, confirming that the double bond in the sterol core reduces the bond strain compared to the stanol core and improves the lipid packing.", [["cholestanol", "CHEMICAL", 41, 52], ["cholesterol", "CHEMICAL", 96, 107], ["sterol", "CHEMICAL", 148, 154], ["stanol", "CHEMICAL", 200, 206], ["cholestanol", "CHEMICAL", 41, 52], ["cholesterol", "CHEMICAL", 96, 107], ["sterol", "CHEMICAL", 148, 154], ["stanol", "CHEMICAL", 200, 206], ["cholestanol", "SIMPLE_CHEMICAL", 41, 52], ["cholesterol", "SIMPLE_CHEMICAL", 96, 107], ["sterol", "SIMPLE_CHEMICAL", 148, 154], ["stanol", "SIMPLE_CHEMICAL", 200, 206], ["lipid", "SIMPLE_CHEMICAL", 229, 234], ["a lower enthalpy of fusion", "TREATMENT", 57, 83], ["cholesterol", "TEST", 96, 107], ["the double bond in the sterol core", "TREATMENT", 125, 159], ["the bond strain", "PROBLEM", 168, 183], ["the stanol core", "TREATMENT", 196, 211], ["the lipid packing", "TREATMENT", 225, 242], ["lower enthalpy", "OBSERVATION_MODIFIER", 59, 73], ["fusion", "OBSERVATION", 77, 83], ["double bond", "OBSERVATION", 129, 140], ["sterol", "ANATOMY_MODIFIER", 148, 154], ["bond strain", "OBSERVATION", 172, 183], ["lipid packing", "OBSERVATION", 229, 242]]], ["17 In conclusion, we can posit that both the sterol core and the additional substituents in the C24 alkyl tail improve transfection.\u25a0 RESULTS AND DISCUSSIONLipid Membrane Rigidity.", [["C24 alkyl", "CHEMICAL", 96, 105], ["sterol", "CHEMICAL", 45, 51], ["sterol", "SIMPLE_CHEMICAL", 45, 51], ["C24 alkyl tail", "SIMPLE_CHEMICAL", 96, 110], ["the sterol core", "TREATMENT", 41, 56], ["the additional substituents in the C24 alkyl tail", "TREATMENT", 61, 110], ["DISCUSSIONLipid Membrane Rigidity", "PROBLEM", 146, 179], ["substituents", "OBSERVATION_MODIFIER", 76, 88], ["C24", "ANATOMY_MODIFIER", 96, 99], ["alkyl tail", "ANATOMY", 100, 110], ["transfection", "OBSERVATION", 119, 131], ["Membrane Rigidity", "OBSERVATION", 162, 179]]], ["TMA-DPH is a fluorescent probe used to investigate lipid membrane rigidity.", [["lipid membrane", "ANATOMY", 51, 65], ["TMA", "CHEMICAL", 0, 3], ["DPH", "CHEMICAL", 4, 7], ["rigidity", "DISEASE", 66, 74], ["TMA", "CHEMICAL", 0, 3], ["DPH", "CHEMICAL", 4, 7], ["TMA-DPH", "SIMPLE_CHEMICAL", 0, 7], ["lipid membrane", "CELLULAR_COMPONENT", 51, 65], ["a fluorescent probe", "TREATMENT", 11, 30], ["lipid membrane rigidity", "PROBLEM", 51, 74], ["lipid membrane rigidity", "OBSERVATION", 51, 74]]], ["18\u221220 As the probe lodges in the outer leaflet of the bilayer, it may take a preferential orientation and, therefore, change its spatial anisotropy (lower anisotropy = less organized bilayer structure).", [["outer leaflet", "ANATOMY", 33, 46], ["18\u221220", "CHEMICAL", 0, 5], ["outer leaflet", "CELLULAR_COMPONENT", 33, 46], ["bilayer", "CELLULAR_COMPONENT", 54, 61], ["its spatial anisotropy (lower anisotropy", "TREATMENT", 125, 165], ["outer", "ANATOMY_MODIFIER", 33, 38], ["leaflet", "ANATOMY_MODIFIER", 39, 46], ["bilayer", "ANATOMY_MODIFIER", 54, 61]]], ["Bernsdorff and Winter previously used TMA-DPH in structurally similar DPPC vesicles to investigate their phase transitions and were able to identify changes in the probe orientation as a function of vesicle composition and temperature.", [["DPPC vesicles", "ANATOMY", 70, 83], ["vesicle", "ANATOMY", 199, 206], ["TMA", "CHEMICAL", 38, 41], ["DPH", "CHEMICAL", 42, 45], ["DPPC", "CHEMICAL", 70, 74], ["TMA", "CHEMICAL", 38, 41], ["DPH", "CHEMICAL", 42, 45], ["DPPC", "CHEMICAL", 70, 74], ["TMA-DPH", "SIMPLE_CHEMICAL", 38, 45], ["vesicle", "CELLULAR_COMPONENT", 199, 206]]], ["18 We utilized this probe to investigate if lipid membranes of phytosterol LNPs exhibit differences in rigidity, as this observation could provide more insights into their cellular uptake and endosomal escape; Sun et al. have LNPs possess a dense inner core, bilamellar structure, and smooth particle curvature.", [["lipid membranes", "ANATOMY", 44, 59], ["cellular", "ANATOMY", 172, 180], ["endosomal", "ANATOMY", 192, 201], ["inner core", "ANATOMY", 247, 257], ["bilamellar structure", "ANATOMY", 259, 279], ["smooth particle", "ANATOMY", 285, 300], ["phytosterol", "CHEMICAL", 63, 74], ["rigidity", "DISEASE", 103, 111], ["phytosterol", "CHEMICAL", 63, 74], ["lipid membranes", "CELLULAR_COMPONENT", 44, 59], ["phytosterol LNPs", "SIMPLE_CHEMICAL", 63, 79], ["cellular", "CELL", 172, 180], ["endosomal", "CELLULAR_COMPONENT", 192, 201], ["LNPs", "SIMPLE_CHEMICAL", 226, 230], ["LNPs", "PROTEIN", 226, 230], ["this probe", "TREATMENT", 15, 25], ["lipid membranes of phytosterol LNPs", "PROBLEM", 44, 79], ["rigidity", "PROBLEM", 103, 111], ["this observation", "TEST", 116, 132], ["LNPs", "TREATMENT", 226, 230], ["a dense inner core, bilamellar structure", "PROBLEM", 239, 279], ["endosomal escape", "OBSERVATION", 192, 208], ["dense", "OBSERVATION_MODIFIER", 241, 246], ["inner", "OBSERVATION_MODIFIER", 247, 252], ["core", "OBSERVATION_MODIFIER", 253, 257], ["bilamellar structure", "OBSERVATION", 259, 279], ["smooth", "OBSERVATION_MODIFIER", 285, 291], ["particle curvature", "OBSERVATION", 292, 310]]], ["Camp, Stig, and Sito LNPs all form multilamellar structures, although only Stig and Sito LNPs demonstrate a polymorphic shape, with multilamellar structures forming along the flatter edges.", [["multilamellar structures", "ANATOMY", 35, 59], ["multilamellar structures", "ANATOMY", 132, 156], ["Sito LNPs", "SIMPLE_CHEMICAL", 16, 25], ["Stig", "SIMPLE_CHEMICAL", 75, 79], ["Stig and Sito LNPs", "CELL_LINE", 75, 93], ["Camp", "TEST", 0, 4], ["a polymorphic shape", "PROBLEM", 106, 125], ["multilamellar structures", "PROBLEM", 132, 156], ["multilamellar structures", "OBSERVATION", 35, 59], ["polymorphic", "OBSERVATION_MODIFIER", 108, 119], ["shape", "OBSERVATION_MODIFIER", 120, 125], ["multilamellar structures", "OBSERVATION", 132, 156], ["flatter", "OBSERVATION_MODIFIER", 175, 182], ["edges", "OBSERVATION_MODIFIER", 183, 188]]], ["Fuco LNPs show inner areas with distinctly different electron density, also referred to as internal defects.", [["electron", "SIMPLE_CHEMICAL", 53, 61], ["Fuco LNPs", "TEST", 0, 9], ["inner areas", "PROBLEM", 15, 26], ["distinctly different electron density", "PROBLEM", 32, 69], ["internal defects", "PROBLEM", 91, 107], ["inner", "OBSERVATION_MODIFIER", 15, 20], ["distinctly different", "OBSERVATION_MODIFIER", 32, 52], ["electron density", "OBSERVATION", 53, 69], ["internal", "ANATOMY_MODIFIER", 91, 99], ["defects", "OBSERVATION", 100, 107]]], ["Examples of LNP classification are highlighted in the boxes: green, bilamellar, internal defects; black, bilamellar, no internal defects; blue, multilamellar, no internal defects; white, multilamellar, internal defects; red, multilamellar, no internal defects, faceted.", [["bilamellar", "ANATOMY", 68, 78], ["bilamellar", "ANATOMY", 105, 115], ["multilamellar", "ANATOMY", 187, 200], ["internal defects", "PROBLEM", 80, 96], ["black, bilamellar", "PROBLEM", 98, 115], ["internal defects", "PROBLEM", 120, 136], ["internal defects", "PROBLEM", 162, 178], ["white, multilamellar, internal defects", "PROBLEM", 180, 218], ["internal defects", "PROBLEM", 243, 259], ["LNP", "ANATOMY", 12, 15], ["green", "OBSERVATION_MODIFIER", 61, 66], ["internal", "ANATOMY_MODIFIER", 80, 88], ["defects", "OBSERVATION", 89, 96], ["black", "OBSERVATION_MODIFIER", 98, 103], ["no", "UNCERTAINTY", 117, 119], ["internal defects", "OBSERVATION", 120, 136], ["blue", "OBSERVATION", 138, 142], ["multilamellar", "OBSERVATION_MODIFIER", 144, 157], ["no", "UNCERTAINTY", 159, 161], ["internal defects", "OBSERVATION", 162, 178], ["white", "OBSERVATION_MODIFIER", 180, 185], ["multilamellar", "OBSERVATION_MODIFIER", 187, 200], ["internal defects", "OBSERVATION", 202, 218], ["multilamellar", "OBSERVATION_MODIFIER", 225, 238], ["no", "UNCERTAINTY", 240, 242], ["internal defects", "OBSERVATION", 243, 259], ["faceted", "OBSERVATION_MODIFIER", 261, 268]]], ["The scale bar in all images denotes 100 nm.", [["100 nm", "OBSERVATION_MODIFIER", 36, 42]]], ["Nano Letters pubs.acs.org/NanoLett Letter previously reported that \"rigid\" polymeric nanoparticles were more successful at passing the cellular barrier compared to the \"soft\" ones, suggesting that the higher rigidity should correlate with the higher transfection.", [["cellular", "ANATOMY", 135, 143], ["rigidity", "DISEASE", 208, 216], ["polymeric nanoparticles", "SIMPLE_CHEMICAL", 75, 98], ["cellular", "CELL", 135, 143], ["rigid\" polymeric nanoparticles", "TREATMENT", 68, 98], ["the higher rigidity", "PROBLEM", 197, 216], ["the higher transfection", "PROBLEM", 239, 262], ["higher rigidity", "OBSERVATION", 201, 216], ["higher", "OBSERVATION_MODIFIER", 243, 249], ["transfection", "OBSERVATION", 250, 262]]], ["21 We tested the probe anisotropy in the range of 20 to 80\u00b0C, focusing on the physiologically relevant temperatures.", [["the probe anisotropy", "TEST", 13, 33]]], ["In addition to the cholesterol analogs mentioned above, we also tested LNPs prepared with vitamin D2 (D2) and stigmasterol (Ster) as controls, as these previously showed high mRNA encapsulation but no transfection and poor encapsulation but improved transfection compared to Chol LNPs, respectively.", [["cholesterol", "CHEMICAL", 19, 30], ["vitamin D2", "CHEMICAL", 90, 100], ["stigmasterol", "CHEMICAL", 110, 122], ["Chol LNPs", "CHEMICAL", 275, 284], ["cholesterol", "CHEMICAL", 19, 30], ["vitamin D2", "CHEMICAL", 90, 100], ["stigmasterol", "CHEMICAL", 110, 122], ["Ster", "CHEMICAL", 124, 128], ["Chol", "CHEMICAL", 275, 279], ["cholesterol", "SIMPLE_CHEMICAL", 19, 30], ["LNPs", "SIMPLE_CHEMICAL", 71, 75], ["vitamin D2", "SIMPLE_CHEMICAL", 90, 100], ["D2", "SIMPLE_CHEMICAL", 102, 104], ["stigmasterol", "SIMPLE_CHEMICAL", 110, 122], ["Ster", "SIMPLE_CHEMICAL", 124, 128], ["Chol LNPs", "SIMPLE_CHEMICAL", 275, 284], ["the cholesterol analogs", "TREATMENT", 15, 38], ["LNPs", "TEST", 71, 75], ["vitamin D2 (D2)", "TREATMENT", 90, 105], ["stigmasterol (Ster)", "TREATMENT", 110, 129], ["high mRNA encapsulation", "PROBLEM", 170, 193], ["transfection", "PROBLEM", 201, 213], ["poor encapsulation", "PROBLEM", 218, 236], ["mRNA encapsulation", "OBSERVATION", 175, 193], ["no", "UNCERTAINTY", 198, 200], ["transfection", "OBSERVATION", 201, 213], ["poor", "OBSERVATION_MODIFIER", 218, 222], ["encapsulation", "OBSERVATION_MODIFIER", 223, 236], ["improved", "OBSERVATION_MODIFIER", 241, 249], ["transfection", "OBSERVATION", 250, 262]]], ["10 The results are shown in Figure 4A ,B. Chol and Camp LNPs demonstrated the highest anisotropy throughout the entire tested range, followed by Sito and Stig and, last, Fuco LNPs.", [["Chol", "CHEMICAL", 42, 46], ["B. Chol", "SIMPLE_CHEMICAL", 39, 46], ["Camp LNPs", "SIMPLE_CHEMICAL", 51, 60], ["Camp LNPs", "TEST", 51, 60]]], ["As mentioned before, this indicates that Fuco LNPs have the most disorganized bilayer structure.", [["Fuco LNPs", "SIMPLE_CHEMICAL", 41, 50], ["most disorganized", "OBSERVATION_MODIFIER", 60, 77], ["bilayer structure", "OBSERVATION", 78, 95]]], ["The anisotropy pattern matched for cooling and heating cycles, suggesting that the lipids do not separate during the heating process.", [["lipids", "SIMPLE_CHEMICAL", 83, 89], ["The anisotropy pattern", "PROBLEM", 0, 22], ["cooling and heating cycles", "TREATMENT", 35, 61], ["the lipids", "TEST", 79, 89]]], ["The drop in the anisotropy with increasing temperature was expected due to the increased Brownian motion ( Figure S3 ).", [["The drop", "PROBLEM", 0, 8], ["the anisotropy", "PROBLEM", 12, 26], ["increasing temperature", "PROBLEM", 32, 54], ["the increased Brownian motion", "PROBLEM", 75, 104], ["drop", "OBSERVATION_MODIFIER", 4, 8], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["Brownian motion", "OBSERVATION", 89, 104]]], ["Chol and Camp LNPs, as well as Sito and Stig LNPs, showed nearly identical anisotropy trends over the entire tested temperature range.\u25a0 RESULTS AND DISCUSSIONAt the physiologically relevant temperature (35\u00b0C), the TMA-DPH assay revealed marginal differences in anisotropy of analog LNPs, except for Fuco LNPs that showed higher anisotropy (ca.", [["Chol", "CHEMICAL", 0, 4], ["DPH", "CHEMICAL", 218, 221], ["Chol", "CHEMICAL", 0, 4], ["DPH", "CHEMICAL", 218, 221], ["Chol", "SIMPLE_CHEMICAL", 0, 4], ["Camp LNPs", "SIMPLE_CHEMICAL", 9, 18], ["LNPs", "SIMPLE_CHEMICAL", 282, 286], ["Fuco LNPs", "SIMPLE_CHEMICAL", 299, 308], ["Fuco LNPs", "PROTEIN", 299, 308], ["Camp LNPs", "TREATMENT", 9, 18], ["Stig LNPs", "TEST", 40, 49], ["the TMA", "TEST", 210, 217], ["DPH assay", "TEST", 218, 227], ["marginal differences", "PROBLEM", 237, 257], ["analog LNPs", "TEST", 275, 286], ["Fuco LNPs", "TEST", 299, 308], ["higher anisotropy (ca", "PROBLEM", 321, 342], ["Camp LNPs", "OBSERVATION", 9, 18], ["anisotropy", "OBSERVATION", 75, 85], ["marginal", "OBSERVATION_MODIFIER", 237, 245], ["higher anisotropy", "OBSERVATION", 321, 338]]], ["0.29 vs 0.27 on average for the other phytosterol LNPs).", [["phytosterol", "CHEMICAL", 38, 49], ["phytosterol", "CHEMICAL", 38, 49], ["the other phytosterol LNPs", "TREATMENT", 28, 54]]], ["Ster and D2 LNPs, previously identified outliers, showed significantly lower anisotropy at 35\u00b0C (approximately 0.25 and 0.22, respectively).", [["Ster", "SIMPLE_CHEMICAL", 0, 4], ["Ster and D2 LNPs", "DNA", 0, 16], ["significantly lower anisotropy", "PROBLEM", 57, 87], ["lower anisotropy", "OBSERVATION_MODIFIER", 71, 87]]], ["These findings suggest that there is likely a Goldilocks membrane rigidity range; the somewhat fluid lipid membrane of D2 LNPs may disintegrate before the LNPs pass the cellular barrier, while the excessively rigid membrane of Fuco LNPs perhaps fails to successfully release the cargo due to their excessive stability in the biological environment.", [["membrane", "ANATOMY", 57, 65], ["fluid lipid membrane", "ANATOMY", 95, 115], ["cellular", "ANATOMY", 169, 177], ["membrane", "ANATOMY", 215, 223], ["rigidity", "DISEASE", 66, 74], ["Fuco LNPs", "CHEMICAL", 227, 236], ["lipid membrane", "CELLULAR_COMPONENT", 101, 115], ["D2 LNPs", "SIMPLE_CHEMICAL", 119, 126], ["LNPs", "SIMPLE_CHEMICAL", 155, 159], ["cellular barrier", "TISSUE", 169, 185], ["membrane", "CELLULAR_COMPONENT", 215, 223], ["Fuco LNPs", "SIMPLE_CHEMICAL", 227, 236], ["LNPs", "CELL_TYPE", 155, 159], ["a Goldilocks membrane rigidity range", "PROBLEM", 44, 80], ["D2 LNPs", "TREATMENT", 119, 126], ["the cellular barrier", "TREATMENT", 165, 185], ["Fuco LNPs", "TREATMENT", 227, 236], ["membrane rigidity", "OBSERVATION", 57, 74], ["somewhat", "OBSERVATION_MODIFIER", 86, 94], ["fluid lipid", "OBSERVATION", 95, 106], ["D2 LNPs", "OBSERVATION", 119, 126], ["cellular barrier", "OBSERVATION", 169, 185], ["excessive", "OBSERVATION_MODIFIER", 298, 307], ["stability", "OBSERVATION", 308, 317]]], ["However, low encapsulation efficiency may compromise cellular uptake despite optimal rigidity.", [["cellular", "ANATOMY", 53, 61], ["rigidity", "DISEASE", 85, 93], ["cellular", "CELL", 53, 61], ["low encapsulation efficiency", "PROBLEM", 9, 37], ["cellular uptake", "PROBLEM", 53, 68], ["optimal rigidity", "PROBLEM", 77, 93], ["low", "OBSERVATION_MODIFIER", 9, 12], ["encapsulation efficiency", "OBSERVATION", 13, 37], ["cellular uptake", "OBSERVATION", 53, 68], ["optimal rigidity", "OBSERVATION", 77, 93]]], ["Ster LNPs demonstrated an anisotropy value more similar to the LNP baseline and were more successful at transfection than Chol LNPs; however, their encapsulation efficiency was significantly lower, likely due to the lack of free rotation of the alkyl tail.", [["Chol", "CHEMICAL", 122, 126], ["alkyl", "CHEMICAL", 245, 250], ["Chol", "CHEMICAL", 122, 126], ["Chol LNPs", "SIMPLE_CHEMICAL", 122, 131], ["alkyl tail", "PROTEIN", 245, 255], ["Ster LNPs", "TEST", 0, 9], ["an anisotropy value", "TEST", 23, 42], ["Chol LNPs", "TEST", 122, 131], ["free rotation of the alkyl tail", "PROBLEM", 224, 255], ["anisotropy", "OBSERVATION", 26, 36], ["encapsulation efficiency", "OBSERVATION", 148, 172], ["likely due to", "UNCERTAINTY", 198, 211], ["free rotation", "OBSERVATION", 224, 237], ["alkyl tail", "ANATOMY", 245, 255]]], ["22 Thermal Analysis.", [["Thermal Analysis", "TEST", 3, 19]]], ["Differential scanning calorimetry (DSC) is a thermal analysis method used to characterize phase transitions, frequently used for liposomes.", [["liposomes", "SIMPLE_CHEMICAL", 129, 138], ["Differential scanning calorimetry", "TEST", 0, 33], ["a thermal analysis method", "TEST", 43, 68], ["phase transitions", "PROBLEM", 90, 107], ["liposomes", "TREATMENT", 129, 138]]], ["23 Phospholipid-based liposomes containing Chol analogs undergo phase transitions in the physiological temperature range, 24\u221226 which change lipid organization and may even induce changes in lipid membrane curvature.", [["lipid membrane", "ANATOMY", 191, 205], ["Chol", "CHEMICAL", 43, 47], ["Chol", "CHEMICAL", 43, 47], ["Phospholipid-based liposomes", "SIMPLE_CHEMICAL", 3, 31], ["Chol analogs", "SIMPLE_CHEMICAL", 43, 55], ["lipid", "SIMPLE_CHEMICAL", 141, 146], ["lipid membrane", "CELLULAR_COMPONENT", 191, 205], ["Phospholipid-based liposomes", "TREATMENT", 3, 31], ["phase transitions", "PROBLEM", 64, 81], ["changes in lipid membrane curvature", "PROBLEM", 180, 215], ["lipid organization", "OBSERVATION", 141, 159], ["lipid membrane curvature", "OBSERVATION", 191, 215]]], ["27, 28 These properties may have implications on the nucleic acid cargo delivery; for example, complexes of cationic liposomes containing DNA show various transfection efficiencies, depending on the organization.", [["nucleic acid", "CHEMICAL", 53, 65], ["cationic liposomes", "SIMPLE_CHEMICAL", 108, 126], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["the nucleic acid cargo delivery", "TREATMENT", 49, 80], ["cationic liposomes", "TREATMENT", 108, 126], ["various transfection efficiencies", "PROBLEM", 147, 180], ["various", "OBSERVATION_MODIFIER", 147, 154], ["transfection efficiencies", "OBSERVATION", 155, 180]]], ["29 Coupled with the membrane rigidity assay, DSC could be a useful tool in understanding the effect of Chol analogs on membrane structure 23 and, potentially, deducing whether the phase transitions of LNPs occur at the membrane surface or in Figure S4 ).", [["membrane", "ANATOMY", 20, 28], ["membrane", "ANATOMY", 119, 127], ["membrane surface", "ANATOMY", 219, 235], ["rigidity", "DISEASE", 29, 37], ["Chol", "CHEMICAL", 103, 107], ["Chol", "CHEMICAL", 103, 107], ["membrane", "CELLULAR_COMPONENT", 20, 28], ["Chol", "SIMPLE_CHEMICAL", 103, 107], ["membrane", "CELLULAR_COMPONENT", 119, 127], ["LNPs", "SIMPLE_CHEMICAL", 201, 205], ["membrane surface", "CELLULAR_COMPONENT", 219, 235], ["the membrane rigidity assay", "PROBLEM", 16, 43], ["Chol analogs on membrane structure", "TREATMENT", 103, 137], ["the phase transitions of LNPs", "PROBLEM", 176, 205]]], ["Nano Letters pubs.acs.org/NanoLett Letter the bulk of the lipid material.", [["lipid material", "MULTI-TISSUE_STRUCTURE", 58, 72], ["NanoLett", "TREATMENT", 26, 34]]], ["Therefore, we decided to investigate the thermotropic behavior of LNPs containing no mRNA and compare the LNP thermal behavior to the results of the membrane rigidity assay.", [["membrane", "ANATOMY", 149, 157], ["rigidity", "DISEASE", 158, 166], ["LNPs", "SIMPLE_CHEMICAL", 66, 70], ["membrane", "CELLULAR_COMPONENT", 149, 157], ["mRNA", "RNA", 85, 89], ["mRNA", "PROBLEM", 85, 89], ["the LNP thermal behavior", "PROBLEM", 102, 126], ["the membrane rigidity assay", "TEST", 145, 172], ["membrane rigidity", "OBSERVATION", 149, 166]]], ["The results are shown in Figure 4C .\u25a0 RESULTS AND DISCUSSIONAll tested LNPs showed distinct sharp phase transition peaks.", [["DISCUSSIONAll tested LNPs", "TEST", 50, 75], ["distinct sharp phase transition peaks", "PROBLEM", 83, 120], ["distinct", "OBSERVATION_MODIFIER", 83, 91], ["sharp phase", "OBSERVATION", 92, 103], ["transition peaks", "OBSERVATION", 104, 120]]], ["Stig LNPs showed the highest phase transition temperature at 105\u00b0C, while Sito, Fuco, Chol, and Camp LNPs only had one phase transition at ca.", [["Chol", "CHEMICAL", 86, 90], ["Sito", "CHEMICAL", 74, 78], ["Fuco", "CHEMICAL", 80, 84], ["Chol", "CHEMICAL", 86, 90], ["Sito", "SIMPLE_CHEMICAL", 74, 78], ["Fuco", "SIMPLE_CHEMICAL", 80, 84], ["Chol", "SIMPLE_CHEMICAL", 86, 90], ["Camp LNPs", "SIMPLE_CHEMICAL", 96, 105], ["Stig LNPs", "TEST", 0, 9], ["the highest phase transition temperature", "PROBLEM", 17, 57], ["Camp LNPs", "TEST", 96, 105], ["one phase transition at ca", "PROBLEM", 115, 141], ["highest phase", "OBSERVATION_MODIFIER", 21, 34]]], ["Camp and Chol LNPs also exhibit glass transitions at ca.", [["Chol", "CHEMICAL", 9, 13], ["Chol", "CHEMICAL", 9, 13], ["Chol LNPs", "SIMPLE_CHEMICAL", 9, 18], ["Camp and Chol LNPs", "TEST", 0, 18], ["glass transitions at ca", "PROBLEM", 32, 55], ["Chol", "OBSERVATION", 9, 13], ["glass transitions", "OBSERVATION", 32, 49]]], ["46 and 95\u00b0C (respectively), while Stig and Fuco LNPs have additional broad transitions at ca.", [["Fuco LNPs", "SIMPLE_CHEMICAL", 43, 52], ["additional broad transitions at ca", "PROBLEM", 58, 92], ["broad transitions", "OBSERVATION", 69, 86]]], ["All of the transitions were endothermic, suggesting that these transitions correspond to melting and, thus, decreasing organization.", [["these transitions", "PROBLEM", 57, 74], ["decreasing", "OBSERVATION_MODIFIER", 108, 118]]], ["Jovanovic\u0301et al. previously reported that DPPC/Chol and Sito liposomes undergo phase transitions in a similar range, although melting temperatures depended on the lipid content.", [["DPPC", "CHEMICAL", 42, 46], ["Chol", "CHEMICAL", 47, 51], ["Sito", "CHEMICAL", 56, 60], ["DPPC", "CHEMICAL", 42, 46], ["Chol", "CHEMICAL", 47, 51], ["Sito", "CHEMICAL", 56, 60], ["DPPC", "SIMPLE_CHEMICAL", 42, 46], ["Chol", "SIMPLE_CHEMICAL", 47, 51], ["Sito liposomes", "SIMPLE_CHEMICAL", 56, 70], ["lipid", "SIMPLE_CHEMICAL", 163, 168], ["DPPC/Chol", "TREATMENT", 42, 51], ["Sito liposomes", "TREATMENT", 56, 70], ["phase transitions", "PROBLEM", 79, 96], ["melting temperatures", "PROBLEM", 126, 146], ["lipid content", "OBSERVATION", 163, 176]]], ["23 These phase transitions were attributed to the gel-to-liquid transition, and it has been demonstrated that the increasing fraction of phytosterols in the liposomal formulations induces ordering in the lipid membrane, suppressing the said transition.", [["lipid membrane", "ANATOMY", 204, 218], ["phytosterols", "CHEMICAL", 137, 149], ["liposomal", "CHEMICAL", 157, 166], ["phytosterols", "CHEMICAL", 137, 149], ["phytosterols", "SIMPLE_CHEMICAL", 137, 149], ["lipid membrane", "CELLULAR_COMPONENT", 204, 218], ["These phase transitions", "PROBLEM", 3, 26], ["phytosterols", "TREATMENT", 137, 149], ["the liposomal formulations", "TREATMENT", 153, 179], ["the lipid membrane", "TREATMENT", 200, 218], ["increasing", "OBSERVATION_MODIFIER", 114, 124], ["fraction", "OBSERVATION_MODIFIER", 125, 133], ["lipid membrane", "ANATOMY", 204, 218]]], ["18, 23 siRNA-LNP formulations with Chol-based cationic lipids undergo endothermic phase transitions in a similar range, which were identified as lamellar-to-inverted-hexagonal based on smallangle X-ray scattering.", [["Chol", "CHEMICAL", 35, 39], ["Chol", "CHEMICAL", 35, 39], ["Chol-based cationic lipids", "SIMPLE_CHEMICAL", 35, 61], ["23 siRNA-LNP formulations", "TREATMENT", 4, 29], ["Chol-based cationic lipids", "TREATMENT", 35, 61], ["endothermic phase transitions", "PROBLEM", 70, 99], ["lamellar", "TEST", 145, 153], ["endothermic phase", "OBSERVATION_MODIFIER", 70, 87]]], ["30 We have previously identified that the Chol and Sito LNPs containing mRNA possess a lamellar internal structure at 25\u00b0C, 10 which may suggest that LNPs with phytosterols undergo lamellar-to-inverted hexagonal transition when heated.\u25a0 RESULTS AND DISCUSSIONCholesterol is known to induce membrane \"stiffening\" when mixed with phospholipids, increasing the membrane fluidity below and decreasing the fluidity above the gel-to-liquid transition temperature as confirmed by both DSC and the TMA-DPH assay for DPPC/Chol vesicles.", [["membrane", "ANATOMY", 290, 298], ["membrane", "ANATOMY", 358, 366], ["Chol", "CHEMICAL", 42, 46], ["phytosterols", "CHEMICAL", 160, 172], ["DPH", "CHEMICAL", 494, 497], ["DPPC", "CHEMICAL", 508, 512], ["Chol", "CHEMICAL", 513, 517], ["Chol", "CHEMICAL", 42, 46], ["phytosterols", "CHEMICAL", 160, 172], ["DPH", "CHEMICAL", 494, 497], ["DPPC", "CHEMICAL", 508, 512], ["Chol", "CHEMICAL", 513, 517], ["Chol", "SIMPLE_CHEMICAL", 42, 46], ["Sito LNPs", "SIMPLE_CHEMICAL", 51, 60], ["LNPs", "SIMPLE_CHEMICAL", 150, 154], ["phytosterols", "SIMPLE_CHEMICAL", 160, 172], ["membrane", "CELLULAR_COMPONENT", 290, 298], ["phospholipids", "SIMPLE_CHEMICAL", 328, 341], ["membrane", "CELLULAR_COMPONENT", 358, 366], ["DPH", "SIMPLE_CHEMICAL", 494, 497], ["DPPC", "SIMPLE_CHEMICAL", 508, 512], ["Chol vesicles", "SIMPLE_CHEMICAL", 513, 526], ["Chol and Sito LNPs", "RNA", 42, 60], ["mRNA", "RNA", 72, 76], ["the Chol and Sito LNPs", "TREATMENT", 38, 60], ["a lamellar internal structure", "PROBLEM", 85, 114], ["inverted hexagonal transition", "TREATMENT", 193, 222], ["phospholipids", "TREATMENT", 328, 341], ["increasing the membrane fluidity", "PROBLEM", 343, 375], ["the gel", "TREATMENT", 416, 423], ["the TMA", "TEST", 486, 493], ["DPH assay", "TEST", 494, 503], ["DPPC", "TEST", 508, 512], ["Chol vesicles", "PROBLEM", 513, 526], ["Chol", "OBSERVATION", 42, 46], ["lamellar", "OBSERVATION_MODIFIER", 87, 95], ["internal structure", "OBSERVATION", 96, 114], ["hexagonal transition", "OBSERVATION", 202, 222], ["Chol vesicles", "ANATOMY", 513, 526]]], ["18, 31 The shifting of the transition peaks should be interpreted as a measure of intermolecular interactions in LNP formulation.", [["LNP", "SIMPLE_CHEMICAL", 113, 116], ["the transition peaks", "PROBLEM", 23, 43], ["intermolecular interactions in LNP formulation", "TREATMENT", 82, 128], ["shifting", "OBSERVATION_MODIFIER", 11, 19], ["transition peaks", "OBSERVATION", 27, 43]]], ["Reduced transition temperatures would suggest reduced intermolecular interactions.", [["Reduced transition temperatures", "PROBLEM", 0, 31], ["reduced intermolecular interactions", "PROBLEM", 46, 81], ["reduced", "OBSERVATION_MODIFIER", 46, 53], ["intermolecular interactions", "OBSERVATION", 54, 81]]], ["31 Analysis of the transition peaks among the \"empty\" phytosterol LNPs suggests that the Camp LNPs have weaker intermolecular interactions compared to Chol LNPs, while the rest of the LNPs have increasingly stronger intermolecular interactions.", [["phytosterol", "CHEMICAL", 54, 65], ["Chol", "CHEMICAL", 151, 155], ["phytosterol", "CHEMICAL", 54, 65], ["Chol", "CHEMICAL", 151, 155], ["phytosterol", "SIMPLE_CHEMICAL", 54, 65], ["Camp LNPs", "SIMPLE_CHEMICAL", 89, 98], ["Chol LNPs", "SIMPLE_CHEMICAL", 151, 160], ["LNPs", "SIMPLE_CHEMICAL", 184, 188], ["the transition peaks", "PROBLEM", 15, 35], ["the Camp LNPs", "TEST", 85, 98], ["weaker intermolecular interactions", "PROBLEM", 104, 138], ["Chol LNPs", "TREATMENT", 151, 160], ["weaker", "OBSERVATION_MODIFIER", 104, 110], ["intermolecular interactions", "OBSERVATION", 111, 138], ["stronger", "OBSERVATION_MODIFIER", 207, 215], ["intermolecular interactions", "OBSERVATION", 216, 243]]], ["This could be interpreted as the increasing LNP membrane rigidity; therefore, Camp LNPs are the least rigid, while Stig LNPs are the most rigid.", [["membrane", "ANATOMY", 48, 56], ["rigidity", "DISEASE", 57, 65], ["Camp LNPs", "SIMPLE_CHEMICAL", 78, 87], ["Stig LNPs", "SIMPLE_CHEMICAL", 115, 124], ["the increasing LNP membrane rigidity", "PROBLEM", 29, 65], ["Camp LNPs", "TEST", 78, 87], ["increasing", "OBSERVATION_MODIFIER", 33, 43], ["LNP membrane rigidity", "OBSERVATION", 44, 65], ["most rigid", "OBSERVATION_MODIFIER", 133, 143]]], ["Since membrane rigidity may concur with the multilamellarity, DSC data explains why Sito and Stig LNPs both have a high degree of lamellarity and transition peaks at ca.", [["membrane", "ANATOMY", 6, 14], ["rigidity", "DISEASE", 15, 23], ["membrane", "CELLULAR_COMPONENT", 6, 14], ["membrane rigidity", "PROBLEM", 6, 23], ["DSC data", "TEST", 62, 70], ["a high degree of lamellarity", "PROBLEM", 113, 141], ["transition peaks at ca", "PROBLEM", 146, 168], ["rigidity", "OBSERVATION", 15, 23], ["high degree", "OBSERVATION_MODIFIER", 115, 126]]], ["55\u00b0C. Stig LNPs, however, exhibit an additional, more pronounced peak at 102\u00b0C, which signifies the inherently different lipid arrangement in the formulation.", [["lipid", "SIMPLE_CHEMICAL", 121, 126], ["pronounced", "OBSERVATION_MODIFIER", 54, 64], ["peak", "OBSERVATION_MODIFIER", 65, 69], ["lipid arrangement", "OBSERVATION", 121, 138]]], ["Similarly, Fuco, Camp, and Chol LNPs show additional thermal events after the main transition; Fuco LNPs showed an additional phase transition while Chol and Camp LNPs showed glass transitions.", [["Chol", "CHEMICAL", 27, 31], ["Chol", "CHEMICAL", 149, 153], ["Chol", "CHEMICAL", 27, 31], ["Chol", "CHEMICAL", 149, 153], ["Fuco", "SIMPLE_CHEMICAL", 11, 15], ["Chol LNPs", "SIMPLE_CHEMICAL", 27, 36], ["Fuco LNPs", "SIMPLE_CHEMICAL", 95, 104], ["Chol", "SIMPLE_CHEMICAL", 149, 153], ["Camp LNPs", "SIMPLE_CHEMICAL", 158, 167], ["Camp", "TEST", 17, 21], ["Chol LNPs", "TEST", 27, 36], ["additional thermal events", "PROBLEM", 42, 67], ["Fuco LNPs", "TEST", 95, 104], ["an additional phase transition", "PROBLEM", 112, 142], ["Camp LNPs", "TEST", 158, 167], ["glass transitions", "PROBLEM", 175, 192], ["glass transitions", "OBSERVATION", 175, 192]]], ["The differences in thermotropic behavior correlate with the classification suggested on the basis of the results of cryo-EM and suggest that phytosterol LNPs may exhibit different lipid phases at physiological temperatures.\u25a0 RESULTS AND DISCUSSIONEven though empty Camp LNPs exhibit a transition at a temperature below physiological and thus could form an inverted-hexagonal phase at the temperatures above 25\u00b0C, loading of mRNA, the addition of solvent into the LNPs, and the presence of solvent may significantly affect the lipid interactions and organization as a result.", [["phytosterol", "CHEMICAL", 141, 152], ["phytosterol", "CHEMICAL", 141, 152], ["phytosterol LNPs", "SIMPLE_CHEMICAL", 141, 157], ["LNPs", "SIMPLE_CHEMICAL", 463, 467], ["lipid", "SIMPLE_CHEMICAL", 526, 531], ["mRNA", "RNA", 424, 428], ["cryo-EM", "TEST", 116, 123], ["phytosterol LNPs", "TREATMENT", 141, 157], ["an inverted-hexagonal phase", "PROBLEM", 353, 380], ["mRNA", "TREATMENT", 424, 428], ["solvent into the LNPs", "TREATMENT", 446, 467], ["hexagonal phase", "OBSERVATION_MODIFIER", 365, 380]]], ["This is evident from the DLS data shown in Figure 4D .", [["the DLS data", "TEST", 21, 33]]], ["DLS analysis revealed that LNPs containing no mRNA payload possess a smaller size with a much larger deviation compared to those with mRNA, reiterating that the presence of mRNA is instrumental in the lipid self-assembly and may influence lipid phase behavior.", [["LNPs", "SIMPLE_CHEMICAL", 27, 31], ["lipid", "SIMPLE_CHEMICAL", 201, 206], ["LNPs", "DNA", 27, 31], ["mRNA payload", "RNA", 46, 58], ["mRNA", "RNA", 134, 138], ["mRNA", "RNA", 173, 177], ["DLS analysis", "TEST", 0, 12], ["LNPs", "TEST", 27, 31], ["mRNA payload", "PROBLEM", 46, 58], ["a smaller size", "PROBLEM", 67, 81], ["a much larger deviation", "PROBLEM", 87, 110], ["no", "UNCERTAINTY", 43, 45], ["mRNA payload", "OBSERVATION", 46, 58], ["smaller", "OBSERVATION_MODIFIER", 69, 76], ["size", "OBSERVATION_MODIFIER", 77, 81], ["much", "OBSERVATION_MODIFIER", 89, 93], ["larger", "OBSERVATION_MODIFIER", 94, 100], ["deviation", "OBSERVATION", 101, 110], ["mRNA", "OBSERVATION", 173, 177], ["instrumental", "OBSERVATION_MODIFIER", 181, 193], ["lipid phase", "OBSERVATION_MODIFIER", 239, 250]]], ["This assumption is further supported by TMA-DPH assay results ( Figure S3 ), which showed no defined phase transitions between 20 and 80\u00b0C. This observation might be the result of compromised binding of the hydrophilic TMA-DPH probe to the outer membrane layer due to the PEG shield or water displacement, previously observed in response to the incorporation of cholesterol into phospholipid membranes.", [["outer membrane layer", "ANATOMY", 240, 260], ["phospholipid membranes", "ANATOMY", 379, 401], ["DPH", "CHEMICAL", 223, 226], ["PEG", "CHEMICAL", 272, 275], ["cholesterol", "CHEMICAL", 362, 373], ["DPH", "CHEMICAL", 44, 47], ["TMA", "CHEMICAL", 219, 222], ["DPH", "CHEMICAL", 223, 226], ["PEG", "CHEMICAL", 272, 275], ["cholesterol", "CHEMICAL", 362, 373], ["DPH", "SIMPLE_CHEMICAL", 223, 226], ["outer membrane layer", "CELLULAR_COMPONENT", 240, 260], ["water", "SIMPLE_CHEMICAL", 286, 291], ["cholesterol", "SIMPLE_CHEMICAL", 362, 373], ["phospholipid membranes", "CELLULAR_COMPONENT", 379, 401], ["TMA", "TEST", 40, 43], ["DPH assay", "TEST", 44, 53], ["defined phase transitions", "PROBLEM", 93, 118], ["compromised binding of the hydrophilic TMA", "PROBLEM", 180, 222], ["the PEG shield", "TREATMENT", 268, 282], ["water displacement", "PROBLEM", 286, 304], ["the incorporation of cholesterol into phospholipid membranes", "TREATMENT", 341, 401], ["no", "UNCERTAINTY", 90, 92], ["phase transitions", "OBSERVATION", 101, 118], ["compromised", "OBSERVATION", 180, 191], ["hydrophilic", "OBSERVATION_MODIFIER", 207, 218], ["TMA", "OBSERVATION", 219, 222], ["outer membrane", "ANATOMY_MODIFIER", 240, 254], ["layer", "OBSERVATION_MODIFIER", 255, 260], ["PEG shield", "OBSERVATION", 272, 282], ["water displacement", "OBSERVATION", 286, 304], ["phospholipid membranes", "OBSERVATION", 379, 401]]], ["32, 33 Although the previous cryo-TEM study indicates that the incorporation of siRNA into LNP formulations does not alter the LNP morphology, 9 future studies are needed to deconvolute further the effect of the solvent and the chemistry of RNA cargo as well as the lipid composition and ratios.\u25a0 CONCLUSIONLNPs have become the gold standard in the nonviral delivery of genes.", [["LNP", "SIMPLE_CHEMICAL", 91, 94], ["lipid", "SIMPLE_CHEMICAL", 266, 271], ["the previous cryo-TEM study", "TEST", 16, 43], ["the incorporation of siRNA into LNP formulations", "TREATMENT", 59, 107], ["future studies", "TEST", 145, 159], ["the solvent", "TREATMENT", 208, 219], ["RNA cargo", "TREATMENT", 241, 250], ["the lipid composition", "TEST", 262, 283], ["CONCLUSIONLNPs", "TREATMENT", 297, 311]]], ["However, the LNP morphology and its effect on gene delivery remain to be uncovered.", [["the LNP morphology", "TEST", 9, 27], ["gene delivery", "TREATMENT", 46, 59], ["LNP morphology", "OBSERVATION_MODIFIER", 13, 27], ["effect", "OBSERVATION_MODIFIER", 36, 42]]], ["Studies with the replacement of phospholipid, PEG-lipid, and ionizable lipids have led to the deconvolution of the size, shape, and internal structure of these clinically approved materials.", [["PEG", "CHEMICAL", 46, 49], ["PEG", "CHEMICAL", 46, 49], ["phospholipid", "SIMPLE_CHEMICAL", 32, 44], ["PEG-lipid", "SIMPLE_CHEMICAL", 46, 55], ["Studies", "TEST", 0, 7], ["the replacement of phospholipid", "TREATMENT", 13, 44], ["PEG-lipid", "TREATMENT", 46, 55], ["ionizable lipids", "TREATMENT", 61, 77], ["ionizable lipids", "OBSERVATION", 61, 77], ["size", "OBSERVATION_MODIFIER", 115, 119], ["shape", "OBSERVATION_MODIFIER", 121, 126], ["internal structure", "OBSERVATION_MODIFIER", 132, 150]]], ["34\u221236 Using the C24 alkyl derivatives of cholesterol, we expand on the understanding of features within the LNP structure.", [["34\u221236", "CHEMICAL", 0, 5], ["C24 alkyl", "CHEMICAL", 16, 25], ["cholesterol", "CHEMICAL", 41, 52], ["cholesterol", "CHEMICAL", 41, 52], ["C24 alkyl derivatives", "SIMPLE_CHEMICAL", 16, 37], ["cholesterol", "SIMPLE_CHEMICAL", 41, 52], ["the C24 alkyl derivatives of cholesterol", "TREATMENT", 12, 52], ["LNP", "ANATOMY", 108, 111]]], ["The incorporation of phytosterols in place of cholesterol has a significant impact on the LNP morphology and the consequential gene transfection in vitro.", [["phytosterols", "CHEMICAL", 21, 33], ["cholesterol", "CHEMICAL", 46, 57], ["phytosterols", "CHEMICAL", 21, 33], ["cholesterol", "CHEMICAL", 46, 57], ["phytosterols", "SIMPLE_CHEMICAL", 21, 33], ["cholesterol", "SIMPLE_CHEMICAL", 46, 57], ["The incorporation of phytosterols", "TREATMENT", 0, 33], ["phytosterols", "OBSERVATION_MODIFIER", 21, 33], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["impact", "OBSERVATION", 76, 82], ["gene transfection", "OBSERVATION", 127, 144]]], ["Overall, the LNPs containing phytosterols show different degrees of rigidity and, likely, crystallinity, which explains the differences in their lamellarity, lipid partitioning, and thermal response.", [["phytosterols", "CHEMICAL", 29, 41], ["rigidity", "DISEASE", 68, 76], ["phytosterols", "CHEMICAL", 29, 41], ["LNPs", "SIMPLE_CHEMICAL", 13, 17], ["phytosterols", "SIMPLE_CHEMICAL", 29, 41], ["lipid", "SIMPLE_CHEMICAL", 158, 163], ["the LNPs containing phytosterols", "TEST", 9, 41], ["rigidity", "PROBLEM", 68, 76], ["crystallinity", "PROBLEM", 90, 103], ["lipid partitioning", "TREATMENT", 158, 176], ["different degrees", "OBSERVATION_MODIFIER", 47, 64], ["rigidity", "OBSERVATION_MODIFIER", 68, 76], ["likely", "UNCERTAINTY", 82, 88], ["crystallinity", "OBSERVATION_MODIFIER", 90, 103], ["lipid partitioning", "OBSERVATION", 158, 176]]], ["We summarize their hypothetical structures in Figure 5 .\u25a0 CONCLUSIONSito LNPs, the best performer in the in vitro studies, showed one broad transition peak in DSC, a high degree of lamellarity, and no internal defects; Chol LNPs, the baseline, showed a phase and a glass transition while revealing hardly any structural features.", [["lamellarity", "DISEASE", 181, 192], ["Chol", "CHEMICAL", 219, 223], ["Chol", "CHEMICAL", 219, 223], ["Chol LNPs", "SIMPLE_CHEMICAL", 219, 228], ["vitro studies", "TEST", 108, 121], ["one broad transition peak in DSC", "PROBLEM", 130, 162], ["a high degree of lamellarity", "PROBLEM", 164, 192], ["internal defects", "PROBLEM", 201, 217], ["a glass transition", "TEST", 263, 281], ["broad", "OBSERVATION_MODIFIER", 134, 139], ["transition peak", "OBSERVATION", 140, 155], ["high degree", "OBSERVATION_MODIFIER", 166, 177], ["lamellarity", "OBSERVATION", 181, 192], ["no", "UNCERTAINTY", 198, 200], ["internal defects", "OBSERVATION", 201, 217], ["Chol LNPs", "OBSERVATION", 219, 228]]], ["The incorporation of Stig resulted in the largest fraction of multilamellar structures and a distinctive phase transition pattern.", [["multilamellar structures", "ANATOMY", 62, 86], ["Stig", "PROTEIN", 21, 25], ["a distinctive phase transition pattern", "PROBLEM", 91, 129], ["largest", "OBSERVATION_MODIFIER", 42, 49], ["fraction", "OBSERVATION_MODIFIER", 50, 58], ["multilamellar structures", "OBSERVATION", 62, 86], ["distinctive", "OBSERVATION_MODIFIER", 93, 104], ["phase", "OBSERVATION_MODIFIER", 105, 110], ["transition pattern", "OBSERVATION", 111, 129]]], ["Camp LNPs showed a thermal pattern similar to Chol yet possessed a much larger degree of multilamellarity and, potentially, the inverted-hexagonal phase at a physiological temperature.", [["Chol", "CHEMICAL", 46, 50], ["Chol", "CHEMICAL", 46, 50], ["Chol", "SIMPLE_CHEMICAL", 46, 50], ["Camp LNPs", "TEST", 0, 9], ["a thermal pattern", "PROBLEM", 17, 34], ["larger", "OBSERVATION_MODIFIER", 72, 78], ["degree", "OBSERVATION_MODIFIER", 79, 85], ["multilamellarity", "OBSERVATION", 89, 105], ["hexagonal phase", "OBSERVATION_MODIFIER", 137, 152]]], ["Fuco, the only phytosterol in the series containing a double bond in the alkyl chain, likely induces an entirely different lipid ordering due to the lipid separation, as evident from both the distinct fraction of internal defects and the thermal pattern.", [["Fuco", "CHEMICAL", 0, 4], ["phytosterol", "CHEMICAL", 15, 26], ["alkyl", "CHEMICAL", 73, 78], ["phytosterol", "CHEMICAL", 15, 26], ["Fuco", "SIMPLE_CHEMICAL", 0, 4], ["phytosterol", "SIMPLE_CHEMICAL", 15, 26], ["lipid", "SIMPLE_CHEMICAL", 123, 128], ["lipid", "SIMPLE_CHEMICAL", 149, 154], ["a double bond in the alkyl chain", "TREATMENT", 52, 84], ["the lipid separation", "PROBLEM", 145, 165], ["internal defects", "PROBLEM", 213, 229], ["alkyl chain", "OBSERVATION", 73, 84], ["lipid separation", "OBSERVATION", 149, 165], ["distinct", "OBSERVATION_MODIFIER", 192, 200], ["fraction", "OBSERVATION_MODIFIER", 201, 209], ["internal defects", "OBSERVATION", 213, 229], ["thermal", "OBSERVATION_MODIFIER", 238, 245], ["pattern", "OBSERVATION_MODIFIER", 246, 253]]], ["Despite the subtle variations in the chemical structures of these phytosterols, they greatly affect the lipid packing in LNP formulations.", [["phytosterols", "CHEMICAL", 66, 78], ["phytosterols", "CHEMICAL", 66, 78], ["phytosterols", "SIMPLE_CHEMICAL", 66, 78], ["lipid", "SIMPLE_CHEMICAL", 104, 109], ["LNP", "SIMPLE_CHEMICAL", 121, 124], ["the subtle variations", "PROBLEM", 8, 29], ["these phytosterols", "TREATMENT", 60, 78], ["the lipid packing in LNP formulations", "TREATMENT", 100, 137], ["subtle", "OBSERVATION_MODIFIER", 12, 18], ["variations", "OBSERVATION_MODIFIER", 19, 29], ["lipid packing", "OBSERVATION", 104, 117]]], ["Overall, we can propose that an increase in multilamellarity and polymorphic shape results in higher gene transfection, although future studies are needed to identify the lipid phases and their effect on gene delivery.\u25a0 CONCLUSIONUncovering structural modifications that occur in an in vivo environment is critical to developing highly efficient systems.", [["an increase in multilamellarity and polymorphic shape", "PROBLEM", 29, 82], ["higher gene transfection", "PROBLEM", 94, 118], ["future studies", "TEST", 129, 143], ["the lipid phases", "TEST", 167, 183], ["gene delivery", "TREATMENT", 204, 217], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["higher", "OBSERVATION_MODIFIER", 94, 100], ["gene transfection", "OBSERVATION", 101, 118]]], ["37 Moreover, the delivery of RNA-based medicines to nonhepatic targets may require adjustments to the LNP structure.", [["the delivery of RNA-based medicines", "TREATMENT", 13, 48], ["nonhepatic targets", "TREATMENT", 52, 70], ["nonhepatic", "ANATOMY", 52, 62]]], ["A case in point is the mRNA delivery to the eye, where the LNP must pass the vitreous cavity and penetrate the retinal tissue, or to the lungs, where the LNP must be nebulized to spread throughout the lung and cross the thick mucus, which are the future directions of our work.", [["eye", "ANATOMY", 44, 47], ["vitreous cavity", "ANATOMY", 77, 92], ["retinal tissue", "ANATOMY", 111, 125], ["lungs", "ANATOMY", 137, 142], ["lung", "ANATOMY", 201, 205], ["mucus", "ANATOMY", 226, 231], ["eye", "ORGAN", 44, 47], ["LNP", "GENE_OR_GENE_PRODUCT", 59, 62], ["vitreous cavity", "TISSUE", 77, 92], ["retinal tissue", "TISSUE", 111, 125], ["lungs", "ORGAN", 137, 142], ["LNP", "GENE_OR_GENE_PRODUCT", 154, 157], ["lung", "ORGAN", 201, 205], ["mucus", "MULTI-TISSUE_STRUCTURE", 226, 231], ["the mRNA delivery", "TREATMENT", 19, 36], ["the LNP", "TREATMENT", 55, 62], ["the LNP", "TREATMENT", 150, 157], ["eye", "ANATOMY", 44, 47], ["vitreous cavity", "OBSERVATION", 77, 92], ["retinal tissue", "ANATOMY", 111, 125], ["lungs", "ANATOMY", 137, 142], ["nebulized", "OBSERVATION", 166, 175], ["lung", "ANATOMY", 201, 205]]], ["The understanding of LNP morphology and lipid composition has crucial ramifications in the prevention and treatment of infectious diseases via LNP-mRNA vaccines, such as those currently in the vanguard to tackle the unraveling of the COVID-19 pandemic.* s\u0131 Supporting InformationThe Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.nanolett.0c01386.* s\u0131 Supporting InformationMaterials and methods, encapsulation efficiency, transfection, and full TMA-DPH assay data, DLS data for particles with and without mRNA payload, and author contributions (PDF)", [["infectious diseases", "DISEASE", 119, 138], ["DPH", "CHEMICAL", 494, 497], ["lipid", "SIMPLE_CHEMICAL", 40, 45], ["lipid composition", "TREATMENT", 40, 57], ["infectious diseases", "PROBLEM", 119, 138], ["LNP", "TREATMENT", 143, 146], ["mRNA vaccines", "TREATMENT", 147, 160], ["full TMA", "TEST", 485, 493], ["DPH assay data", "TEST", 494, 508], ["DLS data", "TEST", 510, 518], ["mRNA payload", "PROBLEM", 550, 562], ["infectious", "OBSERVATION", 119, 129]]]], "PMC3080933": [["Data ::: Data and MethodsParticle measurements were performed at a background measuring station on the campus of the Peking University (PKU) located in the northwestern part of Beijing in the Haidian district (Figure 1).", [["MethodsParticle measurements", "TEST", 18, 46]]], ["The campus area is primarily residential and commercial, without heavy traffic or industrial sources.", [["without", "UNCERTAINTY", 57, 64], ["heavy", "OBSERVATION_MODIFIER", 65, 70], ["industrial sources", "OBSERVATION", 82, 100]]], ["The inlet of the sampling system was placed 20 m above ground on top of a six-floor building located > 500 m away from major roads.", [["the sampling system", "TREATMENT", 13, 32], ["inlet", "OBSERVATION_MODIFIER", 4, 9]]], ["Local emission sources within a 1-km radius include vehicular traffic and fuel combustion for domestic cooking, heating, and construction.", [["domestic cooking", "TREATMENT", 94, 110], ["emission sources", "OBSERVATION", 6, 22], ["vehicular traffic", "OBSERVATION", 52, 69], ["fuel combustion", "OBSERVATION", 74, 89]]], ["A study of the spatial variability of PM2.5 mass and chemical composition in 1999\u20132002 showed only minor differences between a PKU campus site and an urban measurement site located approximately 10 km southeast from the PKU measurement site.", [["PKU", "DISEASE", 127, 130], ["PM2.5", "SIMPLE_CHEMICAL", 38, 43], ["PKU measurement site", "DNA", 220, 240], ["A study", "TEST", 0, 7], ["PM2.5 mass", "PROBLEM", 38, 48], ["chemical composition", "TEST", 53, 73], ["a PKU campus site", "PROBLEM", 125, 142], ["an urban measurement site", "PROBLEM", 147, 172], ["the PKU measurement", "TEST", 216, 235], ["mass", "OBSERVATION", 44, 48]]], ["The setup of the measurement station is described in detail elsewhere (e.g., Wehner et al. 2004, 2008).Data ::: Data and MethodsWe continuously measured aerosol number size distributions between 3 nm and 1 \u03bcm.", [["size", "OBSERVATION_MODIFIER", 168, 172]]], ["Sampling was done using a Twin Differential Mobility Particle Sizer (TDMPS; Birmili et al. 1999), consisting of two Hauke-type differential mobility analyzers and two condensation particle counters (models 3010 and 3025; TSI Inc., St. Paul, MN, USA) which covered the size range from 3 nm to 800 nm (mobility diameter) and an Aerodynamic Particle Sizer (APS; model 3321; TSI Inc.) which measured particles between 800 nm and 1 \u03bcm (aerodynamic diameter).", [["Sampling", "TEST", 0, 8], ["TSI", "TEST", 221, 224], ["an Aerodynamic Particle Sizer", "TEST", 323, 352], ["model", "TEST", 359, 364], ["TSI Inc.", "TEST", 371, 379], ["size", "OBSERVATION_MODIFIER", 268, 272], ["Aerodynamic", "OBSERVATION", 326, 337], ["Particle Sizer", "OBSERVATION", 338, 352], ["800 nm", "OBSERVATION_MODIFIER", 414, 420]]], ["To combine both measurements, APS data were transformed from aerodynamic diameter to Stokes diameter assuming an effective particle density of 1.7 g/cm3 for the particles > 800 nm, because these particles are dominated by sulfate and crustal material in Beijing (Yao et al. 2003).", [["sulfate", "CHEMICAL", 222, 229], ["sulfate", "CHEMICAL", 222, 229], ["sulfate", "SIMPLE_CHEMICAL", 222, 229], ["APS data", "TEST", 30, 38], ["an effective particle density", "PROBLEM", 110, 139], ["the particles", "TEST", 157, 170], ["Stokes", "OBSERVATION_MODIFIER", 85, 91], ["diameter", "OBSERVATION_MODIFIER", 92, 100], ["effective", "OBSERVATION_MODIFIER", 113, 122], ["particle", "OBSERVATION_MODIFIER", 123, 131], ["density", "OBSERVATION", 132, 139], ["1.7 g/cm3", "OBSERVATION_MODIFIER", 143, 152], ["crustal material", "OBSERVATION", 234, 250]]], ["A low-flow PM10 inlet was used to minimize contamination by large dust particles.", [["PM10", "CHEMICAL", 11, 15], ["A low-flow PM10 inlet", "TREATMENT", 0, 21], ["contamination", "PROBLEM", 43, 56], ["large dust particles", "PROBLEM", 60, 80], ["low", "OBSERVATION_MODIFIER", 2, 5], ["large", "OBSERVATION_MODIFIER", 60, 65], ["dust particles", "OBSERVATION", 66, 80]]], ["The ambient aerosol was dried in a diffusion drier before entering the air-conditioned laboratory to avoid condensation of water in the inlet systems during warm and humid days in summertime.", [["The ambient aerosol", "TREATMENT", 0, 19]]], ["The data were corrected for losses due to diffusion and sedimentation within the inlet line.", [["inlet line", "ANATOMY", 81, 91], ["The data", "TEST", 0, 8], ["losses", "PROBLEM", 28, 34], ["diffusion and sedimentation within the inlet line", "PROBLEM", 42, 91], ["sedimentation", "OBSERVATION", 56, 69], ["inlet line", "OBSERVATION", 81, 91]]], ["Size-dependent losses for the TDMPS inlet line were estimated using empirical particle loss corrections (diffusion and gravitation) from Willeke and Baron (1993).", [["Size-dependent losses", "PROBLEM", 0, 21], ["the TDMPS inlet line", "TREATMENT", 26, 46], ["empirical particle loss corrections", "TREATMENT", 68, 103], ["dependent", "OBSERVATION_MODIFIER", 5, 14], ["losses", "OBSERVATION", 15, 21], ["inlet line", "OBSERVATION", 36, 46], ["particle loss", "OBSERVATION", 78, 91]]], ["Losses of 4-nm and 10-nm particles were estimated to be 35% and approximately 10%, respectively.Data ::: Data and MethodsNumber size distributions were converted to particle number concentrations (PNC) and particle surface area concentrations (PSC) assuming spherical particles.", [["surface", "ANATOMY", 215, 222], ["Losses", "DISEASE", 0, 6], ["Losses", "TEST", 0, 6], ["MethodsNumber size distributions", "TREATMENT", 114, 146], ["particle number concentrations (PNC) and particle surface area concentrations", "TREATMENT", 165, 242], ["size", "OBSERVATION_MODIFIER", 128, 132], ["spherical particles", "OBSERVATION", 258, 277]]], ["For our analysis, we calculated daily means for 3\u201310 nm, 10\u201330 nm, 30\u201350 nm, 50\u2013100 nm, 100\u2013300 nm, and 300\u20131,000 nm size fractions.", [["our analysis", "TEST", 4, 16]]], ["Total particle number or surface area concentration were computed as the sum of all fractions, and UFP as the sum of particle number concentrations < 100 nm.Data ::: Data and MethodsIn addition, daily particle mass (PM10), sulfur dioxide (SO2), and nitrogen dioxide (NO2) concentrations were gathered from the monitoring network of the Beijing Environmental Protection Bureau.", [["surface area", "ANATOMY", 25, 37], ["PM10", "CHEMICAL", 216, 220], ["sulfur dioxide", "CHEMICAL", 223, 237], ["SO2", "CHEMICAL", 239, 242], ["nitrogen dioxide", "CHEMICAL", 249, 265], ["NO2", "CHEMICAL", 267, 270], ["UFP", "CHEMICAL", 99, 102], ["sulfur dioxide", "CHEMICAL", 223, 237], ["SO2", "CHEMICAL", 239, 242], ["nitrogen dioxide", "CHEMICAL", 249, 265], ["NO2", "CHEMICAL", 267, 270], ["UFP", "SIMPLE_CHEMICAL", 99, 102], ["sulfur dioxide", "SIMPLE_CHEMICAL", 223, 237], ["SO2", "SIMPLE_CHEMICAL", 239, 242], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 249, 265], ["NO2", "SIMPLE_CHEMICAL", 267, 270], ["Total particle number or surface area concentration", "TREATMENT", 0, 51], ["UFP", "TEST", 99, 102], ["MethodsIn", "TREATMENT", 175, 184], ["daily particle mass (PM10)", "TREATMENT", 195, 221], ["sulfur dioxide (SO2)", "TREATMENT", 223, 243], ["nitrogen dioxide", "TREATMENT", 249, 265], ["particle", "OBSERVATION_MODIFIER", 6, 14], ["surface", "OBSERVATION_MODIFIER", 25, 32]]], ["Measurements were obtained as averages of eight fixed monitoring sites located in different parts of the urban area (Figure 1).Data ::: Data and MethodsDaily mean meteorologic data from a measurement station near the Beijing Capital International Airport (Figure 1) were gathered from an internet weather service (Weather Underground 2009) because measurements from the meteorologic station closest to the particulate measurement station were incomplete.", [["Measurements", "TEST", 0, 12], ["eight fixed monitoring sites", "TREATMENT", 42, 70], ["different", "OBSERVATION_MODIFIER", 82, 91], ["parts", "OBSERVATION_MODIFIER", 92, 97], ["urban", "OBSERVATION_MODIFIER", 105, 110]]], ["The Pearson correlation coefficients for valid days between the two data sources were 0.99 and 0.95 for daily air temperature and relative humidity, respectively, indicating a good agreement.Data ::: Data and MethodsWe collected data on hospital emergency room visits (ERV) from the Peking University Third Hospital, located in the Haidian district (Figure 1), where patients within 10 km of the measurement site were likely to be treated (personal communication with hospital doctors).", [["patients", "ORGANISM", 367, 375], ["patients", "SPECIES", 367, 375], ["daily air temperature", "TEST", 104, 125]]], ["The data acquisition system of the hospital recorded only patients who did not stay longer than 1 day.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["A standardized form was completed by medically trained study personnel at PKU, School of Public Health, by abstracting the data from the medical records.", [["PKU", "DISEASE", 74, 77]]], ["A database was built on the basis of these files, and respiratory clinical end points were coded according to the International Classification of Diseases, 10th Revision (ICD-10) [World Health Organization (WHO) 1993] for respiratory diseases (ICD-10 codes J00\u2013J99).", [["respiratory", "ANATOMY", 222, 233], ["respiratory diseases", "DISEASE", 222, 242], ["A database", "TEST", 0, 10], ["10th Revision (ICD", "TREATMENT", 156, 174], ["respiratory diseases", "PROBLEM", 222, 242], ["ICD", "TREATMENT", 244, 247]]], ["Total respiratory ERV comprise acute upper respiratory infections (J00\u2013J06), pneumonia (J18), acute bronchitis (J20), other diseases of the upper respiratory tract (J30\u2013J39), and chronic lower respiratory diseases (J40\u2013J47).", [["respiratory", "ANATOMY", 43, 54], ["upper respiratory tract", "ANATOMY", 140, 163], ["respiratory", "ANATOMY", 193, 204], ["upper respiratory infections", "DISEASE", 37, 65], ["pneumonia", "DISEASE", 77, 86], ["J18", "DISEASE", 88, 91], ["acute bronchitis", "DISEASE", 94, 110], ["J20", "DISEASE", 112, 115], ["diseases of the upper respiratory tract", "DISEASE", 124, 163], ["chronic lower respiratory diseases", "DISEASE", 179, 213], ["upper respiratory", "ORGANISM_SUBDIVISION", 140, 157], ["tract", "ORGANISM_SUBDIVISION", 158, 163], ["Total respiratory ERV", "PROBLEM", 0, 21], ["acute upper respiratory infections", "PROBLEM", 31, 65], ["pneumonia (J18)", "PROBLEM", 77, 92], ["acute bronchitis (J20)", "PROBLEM", 94, 116], ["other diseases of the upper respiratory tract", "PROBLEM", 118, 163], ["chronic lower respiratory diseases", "PROBLEM", 179, 213], ["respiratory ERV", "OBSERVATION", 6, 21], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["upper", "ANATOMY_MODIFIER", 37, 42], ["respiratory", "ANATOMY", 43, 54], ["infections", "OBSERVATION", 55, 65], ["pneumonia", "OBSERVATION", 77, 86], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["bronchitis", "OBSERVATION", 100, 110], ["diseases", "OBSERVATION", 124, 132], ["upper", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["lower", "ANATOMY_MODIFIER", 187, 192], ["respiratory", "ANATOMY", 193, 204], ["diseases", "OBSERVATION", 205, 213]]], ["In addition, location of permanent residence was recorded for each case; based on this information, only patients from Haidian district were considered for further analysis.", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["further analysis", "TEST", 156, 172]]], ["Because of an outbreak of the severe acute respiratory syndrome in China in 2003, all patients with body temperature > 38\u00b0C were separately treated in the hospital, and these cases were excluded.", [["body", "ANATOMY", 100, 104], ["acute respiratory syndrome", "DISEASE", 37, 63], ["patients", "ORGANISM", 86, 94], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["patients", "SPECIES", 86, 94], ["the severe acute respiratory syndrome", "PROBLEM", 26, 63], ["body temperature", "TEST", 100, 116], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome", "OBSERVATION", 43, 63]]], ["Assignment of the diagnoses to ICD-10 disease categories were quality-assured by a nosological expert from the Third Hospital, resulting in a good agreement, as the percentage of misclassification was about 4%.Statistical analysis ::: Data and MethodsWe applied a time-series analysis using generalized additive Poisson regression models (Hastie and Tibshirani 1987) to estimate associations between air pollutants and respiratory ERV.Statistical analysis ::: Data and MethodsIn the first step, a base model without pollutants was built for identifying pollutant-independent variability.", [["ICD", "TREATMENT", 31, 34], ["10 disease categories", "PROBLEM", 35, 56], ["series analysis", "TEST", 269, 284], ["respiratory ERV", "TREATMENT", 419, 434], ["respiratory ERV", "OBSERVATION", 419, 434], ["independent variability", "OBSERVATION", 563, 586]]], ["As further potential confounders, we considered the meteorologic parameters air temperature, air pressure, and relative humidity.", [["the meteorologic parameters air temperature", "TEST", 48, 91], ["air pressure", "TEST", 93, 105], ["air pressure", "OBSERVATION", 93, 105], ["humidity", "OBSERVATION_MODIFIER", 120, 128]]], ["The base model was selected according to Akaike\u2019s information criterion (Akaike 1974) and statistical significance of the covariates (p < 0.05).", [["The base model", "TEST", 0, 14], ["base", "ANATOMY_MODIFIER", 4, 8]]], ["Nonlinear effects were modeled by regression splines with an automatic smoothness selection (Wood 2006).", [["Nonlinear effects", "PROBLEM", 0, 17], ["an automatic smoothness selection", "TREATMENT", 58, 91]]], ["The smoothness of the trend function was manually adjusted based on the absolute value of the sum of the partial autocorrelation function (Touloumi et al. 2006).Statistical analysis ::: Data and MethodsThe final base model consisted of the categorical variables holiday, weekend, and season, the linear influence of same-day relative air humidity, and the smooth functions of calendar time, air temperature, represented by the mean of the present and two previous days, and same-day air pressure.Statistical analysis ::: Data and MethodsThe base model was extended by including air pollutants.", [["relative air humidity", "TREATMENT", 325, 346], ["air temperature", "TEST", 391, 406], ["MethodsThe base model", "TREATMENT", 530, 551], ["smoothness", "OBSERVATION_MODIFIER", 4, 14], ["base", "OBSERVATION_MODIFIER", 212, 216], ["model", "OBSERVATION_MODIFIER", 217, 222], ["air humidity", "OBSERVATION", 334, 346], ["smooth", "OBSERVATION_MODIFIER", 356, 362], ["pressure", "OBSERVATION_MODIFIER", 487, 495], ["air pollutants", "OBSERVATION", 578, 592]]], ["Delayed effects up to a maximum of 5 days were estimated by polynomial distributed lag (PDL) models (Zanobetti et al. 2003), cumulative effects models that represented the delayed effect as a moving average, and single lag models that incorporated the delayed effect as a lagged variable into the model.", [["Delayed effects", "PROBLEM", 0, 15], ["polynomial distributed lag (PDL) models", "PROBLEM", 60, 99], ["cumulative effects models", "PROBLEM", 125, 150], ["the delayed effect", "PROBLEM", 168, 186], ["single lag models", "PROBLEM", 212, 229], ["the delayed effect", "PROBLEM", 248, 266]]], ["Two-pollutant cumulative effects models included PM10 or NO2 in addition to another air pollution variable, with each modeled according to the same lag (e.g., same-day total particle number concentration and same-day NO2 concentration).Statistical analysis ::: Data and MethodsTo explore the robustness of the models, we performed several sensitivity analyses for associations with particle number concentrations from 100 to 300 nm (PNC100\u2013300) that varied the lag pattern of temperature, relative humidity, and air pressure, and used different degrees of smoothness for the time trend function.", [["PM10", "CHEMICAL", 49, 53], ["NO2", "CHEMICAL", 57, 60], ["NO2", "CHEMICAL", 217, 220], ["PM10", "CHEMICAL", 49, 53], ["NO2", "CHEMICAL", 57, 60], ["NO2", "CHEMICAL", 217, 220], ["PM10", "SIMPLE_CHEMICAL", 49, 53], ["NO2", "SIMPLE_CHEMICAL", 57, 60], ["NO2", "SIMPLE_CHEMICAL", 217, 220], ["NO2", "TREATMENT", 57, 60], ["another air pollution", "TREATMENT", 76, 97], ["several sensitivity analyses", "TEST", 331, 359], ["air pressure", "TEST", 512, 524], ["air pollution", "OBSERVATION", 84, 97], ["air pressure", "OBSERVATION", 512, 524]]], ["Additionally, for PDL models we varied the number of the maximum lag and the degree of the polynomial order.Statistical analysis ::: Data and MethodsAll statistical analyses were done using the mgcv package in the R software (R Development Core Team 2003), version 2.90.ResultsIn total, we identified 15,981 cases of respiratory ERV in the study period, including 12,798 (80%) due to acute upper respiratory infections followed by 1,954 (12%) due to lower respiratory diseases.", [["respiratory", "ANATOMY", 396, 407], ["respiratory", "ANATOMY", 456, 467], ["upper respiratory infections", "DISEASE", 390, 418], ["respiratory diseases", "DISEASE", 456, 476], ["PDL models", "PROBLEM", 18, 28], ["All statistical analyses", "TEST", 149, 173], ["the mgcv package", "TREATMENT", 190, 206], ["acute upper respiratory infections", "PROBLEM", 384, 418], ["lower respiratory diseases", "PROBLEM", 450, 476], ["respiratory ERV", "OBSERVATION", 317, 332], ["acute", "OBSERVATION_MODIFIER", 384, 389], ["upper", "ANATOMY_MODIFIER", 390, 395], ["respiratory", "ANATOMY", 396, 407], ["infections", "OBSERVATION", 408, 418], ["lower", "ANATOMY_MODIFIER", 450, 455], ["respiratory diseases", "OBSERVATION", 456, 476]]], ["The daily mean of respiratory ERV was 15, with a minimum of 0 and a maximum of 88 patients per day (Table 1).", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["respiratory ERV", "TEST", 18, 33], ["respiratory ERV", "OBSERVATION", 18, 33]]], ["Because of technical difficulties and maintenance, 218 days of particle size\u2013segregated measurements were missing.", [["technical difficulties", "PROBLEM", 11, 33], ["particle size\u2013segregated measurements", "TEST", 63, 100]]], ["Consequently, effect estimates for particulate air pollutants other than PM10 are based on 818 days of data (13,055 respiratory ERV were recorded in this period).", [["PM10", "CHEMICAL", 73, 77], ["PM10", "SIMPLE_CHEMICAL", 73, 77], ["particulate air pollutants", "PROBLEM", 35, 61], ["respiratory ERV", "TEST", 116, 131]]], ["Particle number concentrations were dominated by particles < 300 nm and particle surface area concentrations by particles in the range of 50\u20131,000 nm (Table 1).", [["particle surface area concentrations", "TEST", 72, 108], ["particles", "OBSERVATION_MODIFIER", 112, 121]]], ["The time series of respiratory ERV showed a seasonal and weekly pattern, with more cases during the cold season and a peak on the weekend and on holidays (data not shown).ResultsSize-segregated particle number and surface area concentrations were correlated with meteorologic and other air pollution variables [Table 2; see also Supplemental Material, Table 1 (doi:10.1289/ehp.1002203)].", [["surface area", "ANATOMY", 214, 226], ["respiratory ERV", "TEST", 19, 34], ["other air pollution variables", "TEST", 280, 309], ["particle", "OBSERVATION_MODIFIER", 194, 202]]], ["Particle number concentrations of smaller particles (< 50 nm) and UFP were negatively correlated with air temperature, relative air humidity, and SO2.", [["SO2", "CHEMICAL", 146, 149], ["UFP", "CHEMICAL", 66, 69], ["SO2", "CHEMICAL", 146, 149], ["UFP", "SIMPLE_CHEMICAL", 66, 69], ["SO2", "SIMPLE_CHEMICAL", 146, 149], ["smaller particles", "PROBLEM", 34, 51], ["UFP", "TEST", 66, 69], ["air temperature", "TEST", 102, 117], ["relative air humidity", "TEST", 119, 140], ["concentrations", "OBSERVATION_MODIFIER", 16, 30], ["smaller", "OBSERVATION_MODIFIER", 34, 41], ["particles", "OBSERVATION_MODIFIER", 42, 51], ["air humidity", "OBSERVATION", 128, 140]]], ["UFP and NO2 concentrations were not correlated when all days were included in the analysis (Table 2) but were moderately correlated when restricted to summer (r = 0.45), winter (r = \u22120.33), or transitional months (r = 0.16).", [["UFP", "CHEMICAL", 0, 3], ["NO2", "CHEMICAL", 8, 11], ["UFP", "CHEMICAL", 0, 3], ["NO2", "CHEMICAL", 8, 11], ["UFP", "SIMPLE_CHEMICAL", 0, 3], ["NO2", "SIMPLE_CHEMICAL", 8, 11], ["NO2 concentrations", "TEST", 8, 26], ["the analysis", "TEST", 78, 90]]], ["There were small negative correlations between NO2 and PNC3\u201310 (\u22120.16) and PNC10\u201330 (\u22120.09) and a moderate positive correlation between NO2 and PNC30\u201350 (0.22) and PNC50\u2013100 (r = 0.43).", [["NO2", "CHEMICAL", 47, 50], ["NO2", "CHEMICAL", 136, 139], ["NO2", "CHEMICAL", 47, 50], ["PNC3\u201310", "CHEMICAL", 55, 62], ["PNC10\u201330", "CHEMICAL", 75, 83], ["NO2", "CHEMICAL", 136, 139], ["PNC30\u201350", "CHEMICAL", 144, 152], ["PNC50\u2013100", "CHEMICAL", 164, 173], ["NO2", "SIMPLE_CHEMICAL", 47, 50], ["NO2", "SIMPLE_CHEMICAL", 136, 139], ["NO2", "TEST", 47, 50], ["PNC3\u201310", "TEST", 55, 62], ["PNC10\u201330", "TEST", 75, 83], ["a moderate positive correlation", "PROBLEM", 96, 127], ["NO2", "TEST", 136, 139], ["PNC30\u201350", "TEST", 144, 152], ["PNC50", "TEST", 164, 169], ["small", "OBSERVATION_MODIFIER", 11, 16], ["negative", "OBSERVATION", 17, 25], ["moderate", "OBSERVATION_MODIFIER", 98, 106], ["positive", "OBSERVATION", 107, 115]]], ["Particle number and surface area concentrations of larger particles (> 100 nm) as well as PSCtotal were moderately correlated with relative air humidity, NO2, and PM10.", [["Particle", "ANATOMY", 0, 8], ["surface area", "ANATOMY", 20, 32], ["NO2", "CHEMICAL", 154, 157], ["PM10", "CHEMICAL", 163, 167], ["NO2", "CHEMICAL", 154, 157], ["PM10", "CHEMICAL", 163, 167], ["NO2", "SIMPLE_CHEMICAL", 154, 157], ["PM10", "SIMPLE_CHEMICAL", 163, 167], ["larger particles", "PROBLEM", 51, 67], ["PSCtotal", "TEST", 90, 98], ["relative air humidity", "TREATMENT", 131, 152], ["surface", "OBSERVATION_MODIFIER", 20, 27], ["area", "OBSERVATION_MODIFIER", 28, 32], ["concentrations", "OBSERVATION_MODIFIER", 33, 47], ["larger", "OBSERVATION_MODIFIER", 51, 57], ["particles", "OBSERVATION_MODIFIER", 58, 67], ["moderately", "OBSERVATION_MODIFIER", 104, 114], ["air humidity", "OBSERVATION", 140, 152]]], ["PNCtotal was moderately correlated with all meteorologic (air temperature, relative air humidity, and air pressure) and air pollutant (SO2, NO2, and PM10) variables.", [["SO2", "CHEMICAL", 135, 138], ["NO2", "CHEMICAL", 140, 143], ["PM10", "CHEMICAL", 149, 153], ["SO2", "CHEMICAL", 135, 138], ["NO2", "CHEMICAL", 140, 143], ["PM10", "CHEMICAL", 149, 153], ["SO2", "SIMPLE_CHEMICAL", 135, 138], ["NO2", "SIMPLE_CHEMICAL", 140, 143], ["air temperature", "TEST", 58, 73], ["relative air humidity", "TEST", 75, 96], ["air pressure", "TEST", 102, 114], ["air pollutant (SO2", "TEST", 120, 138], ["moderately", "OBSERVATION_MODIFIER", 13, 23], ["air humidity", "OBSERVATION", 84, 96], ["air pressure", "OBSERVATION", 102, 114], ["air pollutant", "OBSERVATION", 120, 133]]], ["In addition, correlations between adjacent particle size classes were high.ResultsRespiratory ERV increased by 5% [RR = 1.05 (95% CI, 1.02\u20131.08)] with an IQR increase (4,400 cm\u22123) in PNC100\u2013300 with a 1-day lag (PDL model) [Table 3; see also Supplemental Material, Table 2 (doi:10.1289/ehp.1002203)].", [["adjacent particle size classes", "TEST", 34, 64], ["ResultsRespiratory ERV", "TEST", 75, 97], ["RR", "TEST", 115, 117], ["CI", "TEST", 130, 132], ["an IQR increase", "PROBLEM", 151, 166], ["PNC100", "TEST", 183, 189], ["particle", "OBSERVATION_MODIFIER", 43, 51], ["size", "OBSERVATION_MODIFIER", 52, 56], ["high", "OBSERVATION_MODIFIER", 70, 74]]], ["Effect estimates for an IQR increase in NO2 were similar in magnitude to estimates for IQR increases in particle number and surface area concentrations of particles > 100 nm.", [["surface area", "ANATOMY", 124, 136], ["NO2", "CHEMICAL", 40, 43], ["NO2", "CHEMICAL", 40, 43], ["NO2", "SIMPLE_CHEMICAL", 40, 43], ["an IQR increase", "PROBLEM", 21, 36]]], ["Some inverse associations were observed with UFP and particle number concentrations of fractions < 50 nm.", [["UFP", "CHEMICAL", 45, 48], ["UFP", "CHEMICAL", 45, 48], ["UFP", "SIMPLE_CHEMICAL", 45, 48], ["fractions", "TEST", 87, 96]]], ["In most cases PNC50\u2013100 was positively associated with respiratory ERV based on PDL models, although some single lag model associations were inverse.ResultsEffect estimates for PNC, PSC, and NO2 were mostly higher in magnitude after adjustment for PM10 [Table 4; see also Supplemental Material, Table 3 (doi:10.1289/ehp.1002203)].", [["PNC50\u2013100", "CHEMICAL", 14, 23], ["NO2", "CHEMICAL", 191, 194], ["PM10", "CHEMICAL", 248, 252], ["PNC50\u2013100", "CHEMICAL", 14, 23], ["NO2", "CHEMICAL", 191, 194], ["PNC", "SIMPLE_CHEMICAL", 177, 180], ["PSC", "SIMPLE_CHEMICAL", 182, 185], ["NO2", "SIMPLE_CHEMICAL", 191, 194], ["respiratory ERV", "DNA", 55, 70], ["respiratory ERV", "PROBLEM", 55, 70], ["PDL models", "TEST", 80, 90], ["PNC", "PROBLEM", 177, 180], ["PSC", "TEST", 182, 185], ["NO2", "TREATMENT", 191, 194], ["respiratory ERV", "OBSERVATION", 55, 70]]], ["Associations with PNC and PSC were comparable in magnitude but less precise after adjustment for NO2, with borderline p-values (p < 0.09) only for PNC100\u2013300 and PSC100\u2013300 cumulative effects over 3 days (present and previous 2 days).", [["NO2", "CHEMICAL", 97, 100], ["NO2", "CHEMICAL", 97, 100], ["NO2", "SIMPLE_CHEMICAL", 97, 100], ["PNC", "TREATMENT", 18, 21], ["PSC", "TREATMENT", 26, 29], ["NO2", "TEST", 97, 100], ["borderline p-values", "PROBLEM", 107, 126], ["PNC100", "TEST", 147, 153], ["PSC100", "TREATMENT", 162, 168], ["PSC", "OBSERVATION", 26, 29]]], ["In two-pollutant models, associations between respiratory ERV and NO2 were more consistent than those for other pollutants.ResultsAssociations with PNC100\u2013300 were robust to variations in model parameters [see Supplemental Material, Table 4 (doi:10.1289/ehp.1002203)] in the sensitivity analyses.DiscussionWe observed adverse associations between respiratory ERV and NO2 and particle number and surface area concentrations in several size ranges.", [["surface area", "ANATOMY", 395, 407], ["NO2", "CHEMICAL", 66, 69], ["PNC100\u2013300", "CHEMICAL", 148, 158], ["NO2", "CHEMICAL", 367, 370], ["NO2", "CHEMICAL", 66, 69], ["NO2", "CHEMICAL", 367, 370], ["NO2", "SIMPLE_CHEMICAL", 66, 69], ["NO2", "SIMPLE_CHEMICAL", 367, 370], ["respiratory ERV", "TEST", 46, 61], ["ResultsAssociations", "TEST", 123, 142], ["PNC100", "TEST", 148, 154], ["model parameters", "TEST", 188, 204], ["doi:", "TEST", 242, 246], ["the sensitivity analyses", "TEST", 271, 295], ["respiratory ERV", "TREATMENT", 347, 362], ["NO2 and particle number and surface area concentrations", "TREATMENT", 367, 422], ["respiratory ERV", "OBSERVATION", 46, 61], ["respiratory ERV", "OBSERVATION", 347, 362], ["several", "OBSERVATION_MODIFIER", 426, 433], ["size", "OBSERVATION_MODIFIER", 434, 438]]], ["Effects estimates for IQR increases in both particle number and surface area concentrations of 100\u2013300 nm and 300\u20131,000 nm particles were comparable with estimated effects for IQR increases in NO2 concentrations, and effect estimates for NO2 were more consistent than those for other exposures in two-pollutant models.", [["surface area", "ANATOMY", 64, 76], ["NO2", "CHEMICAL", 193, 196], ["NO2", "CHEMICAL", 238, 241], ["NO2", "CHEMICAL", 193, 196], ["NO2", "CHEMICAL", 238, 241], ["NO2", "SIMPLE_CHEMICAL", 193, 196], ["NO2", "SIMPLE_CHEMICAL", 238, 241], ["IQR increases", "PROBLEM", 22, 35], ["surface area concentrations", "TEST", 64, 91], ["NO2 concentrations", "TEST", 193, 211], ["NO2", "PROBLEM", 238, 241], ["NO2 concentrations", "OBSERVATION", 193, 211]]], ["In most cases, particles < 50 nm were not positively associated with respiratory ERV, whereas particles in the size range of 50\u2013100 nm were adversely associated with respiratory ERV, both being fractions of UFP.DiscussionOur findings are consistent with results from other studies reporting that levels of air pollution, often represented by PM10, PM2.5, NO2, SO2, O3, or UFP, are associated with short-term increases in ERV for respiratory complaints (Knol et al. 2009; Peel et al. 2005; Stieb et al. 2009; Tolbert et al. 2007).DiscussionInterestingly, we did not observe adverse associations of respiratory ERV with small particles (< 50 nm) but did observe positive associations with particle number concentration for particles > 100 nm.", [["respiratory", "ANATOMY", 429, 440], ["respiratory", "ANATOMY", 597, 608], ["UFP", "CHEMICAL", 207, 210], ["PM10", "CHEMICAL", 342, 346], ["PM2.5", "CHEMICAL", 348, 353], ["NO2", "CHEMICAL", 355, 358], ["SO2", "CHEMICAL", 360, 363], ["O3", "CHEMICAL", 365, 367], ["UFP", "CHEMICAL", 372, 375], ["respiratory complaints", "DISEASE", 429, 451], ["UFP", "CHEMICAL", 207, 210], ["PM10", "CHEMICAL", 342, 346], ["PM2.5", "CHEMICAL", 348, 353], ["NO2", "CHEMICAL", 355, 358], ["SO2", "CHEMICAL", 360, 363], ["O3", "CHEMICAL", 365, 367], ["UFP", "CHEMICAL", 372, 375], ["UFP", "SIMPLE_CHEMICAL", 207, 210], ["PM10", "SIMPLE_CHEMICAL", 342, 346], ["PM2.5", "SIMPLE_CHEMICAL", 348, 353], ["NO2", "SIMPLE_CHEMICAL", 355, 358], ["SO2", "SIMPLE_CHEMICAL", 360, 363], ["O3", "SIMPLE_CHEMICAL", 365, 367], ["UFP", "SIMPLE_CHEMICAL", 372, 375], ["respiratory ERV", "PROBLEM", 69, 84], ["respiratory ERV", "PROBLEM", 166, 181], ["other studies", "TEST", 267, 280], ["air pollution", "PROBLEM", 306, 319], ["NO2", "TEST", 355, 358], ["short-term increases", "PROBLEM", 397, 417], ["respiratory complaints", "PROBLEM", 429, 451], ["small particles", "PROBLEM", 618, 633], ["respiratory ERV", "OBSERVATION", 69, 84], ["size", "OBSERVATION_MODIFIER", 111, 115], ["respiratory ERV", "OBSERVATION", 166, 181], ["consistent with", "UNCERTAINTY", 238, 253], ["air pollution", "OBSERVATION", 306, 319], ["respiratory ERV", "OBSERVATION", 597, 612]]], ["Andersen et al. (2008) investigated the association between short-term exposure to size-segregated particles and hospital admissions due to respiratory diseases in Copenhagen among the elderly (age > 65 years).", [["respiratory", "ANATOMY", 140, 151], ["respiratory diseases", "DISEASE", 140, 160], ["respiratory diseases", "PROBLEM", 140, 160], ["size", "OBSERVATION_MODIFIER", 83, 87], ["respiratory", "ANATOMY", 140, 151], ["diseases", "OBSERVATION", 152, 160]]], ["They reported associations between total particle number concentrations and respiratory disease admissions (RR = 1.04; 95% CI, 1.00\u20131.07) comparable with the associations of PNC100\u2013300 and PNC300\u20131,000 that we found.DiscussionParticle surface area concentrations also were adversely associated with total respiratory ERV, in agreement with Sager and Castranova (2009).", [["respiratory", "ANATOMY", 76, 87], ["surface", "ANATOMY", 235, 242], ["respiratory disease", "DISEASE", 76, 95], ["total particle number concentrations", "PROBLEM", 35, 71], ["respiratory disease admissions", "PROBLEM", 76, 106], ["RR", "TEST", 108, 110], ["CI", "TEST", 123, 125], ["PNC100", "TREATMENT", 174, 180], ["PNC300", "TREATMENT", 189, 195], ["total respiratory ERV", "TREATMENT", 299, 320], ["respiratory disease", "OBSERVATION", 76, 95]]], ["This would be expected, as we derived particle surface area concentrations from particle number concentrations.", [["surface", "ANATOMY", 47, 54], ["particle", "OBSERVATION_MODIFIER", 80, 88], ["number concentrations", "OBSERVATION", 89, 110]]], ["Toxicologic studies report that surface area plays an important role in determining the biological activity of smaller particles, as they occupy less volume, resulting in a larger number of particles with a greater surface area per unit mass and an increased potential for biological interaction and absorption of chemical compounds (Oberd\u00f6rster et al. 2005).", [["surface area", "ANATOMY", 32, 44], ["surface", "ANATOMY", 215, 222], ["Toxicologic studies", "TEST", 0, 19], ["a larger number of particles", "PROBLEM", 171, 199], ["unit mass", "PROBLEM", 232, 241], ["biological interaction", "PROBLEM", 273, 295], ["larger", "OBSERVATION_MODIFIER", 173, 179], ["particles", "OBSERVATION_MODIFIER", 190, 199], ["greater", "OBSERVATION_MODIFIER", 207, 214], ["surface", "OBSERVATION_MODIFIER", 215, 222], ["mass", "OBSERVATION", 237, 241], ["increased", "OBSERVATION_MODIFIER", 249, 258]]], ["However, it is not yet possible to measure particle surface area directly on a continuous scale.DiscussionAdverse associations between total respiratory ERV and both particle number and surface area concentrations remained after adjustment for particle mass (PM10).", [["surface area", "ANATOMY", 52, 64], ["surface area", "ANATOMY", 186, 198], ["a continuous scale", "TREATMENT", 77, 95], ["total respiratory ERV", "TREATMENT", 135, 156], ["both particle number and surface area concentrations", "TREATMENT", 161, 213], ["particle mass", "PROBLEM", 244, 257], ["not yet possible", "UNCERTAINTY", 15, 31], ["particle", "OBSERVATION_MODIFIER", 43, 51], ["surface", "OBSERVATION_MODIFIER", 52, 59], ["respiratory ERV", "OBSERVATION", 141, 156]]], ["In two studies of respiratory health outcomes and air pollution, associations with particle number concentrations diminished after controlling for PM2.5 (Andersen et al. 2008; Halonen et al. 2008).", [["PM2.5", "CHEMICAL", 147, 152], ["air pollution", "PROBLEM", 50, 63], ["respiratory", "ANATOMY", 18, 29], ["air pollution", "OBSERVATION", 50, 63]]], ["Unfortunately, we did not have PM2.5 data available.DiscussionNO2 was associated with total respiratory ERV, in agreement with other studies (Peel et al. 2005; Stieb et al. 2009; Tolbert et al. 2007).", [["PM2.5 data", "TEST", 31, 41], ["total respiratory ERV", "TREATMENT", 86, 107], ["other studies", "TEST", 127, 140]]], ["NO2 itself has adverse health effects at high concentrations (> 200 \u03bcg/m3) (WHO 2005), but such levels are rare in Beijing.", [["NO2", "CHEMICAL", 0, 3], ["NO2", "CHEMICAL", 0, 3], ["NO2", "SIMPLE_CHEMICAL", 0, 3], ["adverse", "OBSERVATION_MODIFIER", 15, 22]]], ["NO2 originates mainly from combustion processes and traffic, which are major sources of air pollution in Beijing (Sun et al. 2004), and NO2 is often correlated with other pollutants.", [["NO2", "CHEMICAL", 0, 3], ["NO2", "CHEMICAL", 136, 139], ["NO2", "CHEMICAL", 0, 3], ["NO2", "CHEMICAL", 136, 139], ["NO2", "SIMPLE_CHEMICAL", 0, 3], ["NO2", "SIMPLE_CHEMICAL", 136, 139], ["NO2", "PROBLEM", 0, 3], ["air pollution", "PROBLEM", 88, 101], ["combustion processes", "OBSERVATION", 27, 47], ["air pollution", "OBSERVATION", 88, 101]]], ["Traffic-related air pollution has been associated with respiratory diseases in several studies (Brunekreef et al. 2009).", [["respiratory", "ANATOMY", 55, 66], ["respiratory diseases", "DISEASE", 55, 75], ["Traffic-related air pollution", "PROBLEM", 0, 29], ["respiratory diseases", "PROBLEM", 55, 75], ["several studies", "TEST", 79, 94], ["air pollution", "OBSERVATION", 16, 29], ["associated with", "UNCERTAINTY", 39, 54], ["respiratory diseases", "OBSERVATION", 55, 75]]], ["In our two-pollutant models, associations with NO2 were most consistent.", [["NO2", "CHEMICAL", 47, 50], ["NO2", "CHEMICAL", 47, 50], ["NO2", "SIMPLE_CHEMICAL", 47, 50], ["NO2", "TREATMENT", 47, 50]]], ["When controlling for NO2, associations with 100\u2013300 nm stayed moderately significant (p < 0.09).", [["NO2", "CHEMICAL", 21, 24], ["NO2", "CHEMICAL", 21, 24], ["NO2", "SIMPLE_CHEMICAL", 21, 24]]], ["A pollutant that exhibits a relatively strong association in a multipollutant model may be acting as a surrogate for an unmeasured or poorly measured pollutant (Peel et al. 2005).", [["a multipollutant model", "TREATMENT", 61, 83], ["pollutant", "OBSERVATION", 2, 11], ["relatively", "OBSERVATION_MODIFIER", 28, 38], ["strong", "OBSERVATION_MODIFIER", 39, 45]]], ["In addition, associations with pollutants based on single-pollutant models may be attributable to an association with another pollutant that is correlated with the measured pollutant.", [["pollutants", "TREATMENT", 31, 41]]], ["Typically, epidemiologic studies (including ours) cannot verify to what extent associations with NO2 are attributable to NO2 itself or to other pollutants correlated with NO2.", [["NO2", "CHEMICAL", 97, 100], ["NO2", "CHEMICAL", 121, 124], ["NO2", "CHEMICAL", 171, 174], ["NO2", "CHEMICAL", 97, 100], ["NO2", "CHEMICAL", 121, 124], ["NO2", "CHEMICAL", 171, 174], ["NO2", "SIMPLE_CHEMICAL", 97, 100], ["NO2", "SIMPLE_CHEMICAL", 121, 124], ["NO2", "SIMPLE_CHEMICAL", 171, 174], ["epidemiologic studies", "TEST", 11, 32], ["NO2", "PROBLEM", 97, 100]]], ["Therefore, we cannot rule out the possibility that observed associations for NO2 were due to NO2-correlated air pollution.DiscussionWe gathered daily concentrations of SO2, NO2, and PM10 from the Beijing Environmental Protection Bureau, but PM2.5 concentrations were not available.", [["NO2", "CHEMICAL", 77, 80], ["NO2", "CHEMICAL", 93, 96], ["SO2", "CHEMICAL", 168, 171], ["NO2", "CHEMICAL", 173, 176], ["PM10", "CHEMICAL", 182, 186], ["PM2.5", "CHEMICAL", 241, 246], ["NO2", "CHEMICAL", 77, 80], ["NO2", "CHEMICAL", 93, 96], ["SO2", "CHEMICAL", 168, 171], ["NO2", "CHEMICAL", 173, 176], ["PM10", "CHEMICAL", 182, 186], ["PM2.5", "CHEMICAL", 241, 246], ["NO2", "SIMPLE_CHEMICAL", 77, 80], ["NO2", "SIMPLE_CHEMICAL", 93, 96], ["SO2", "SIMPLE_CHEMICAL", 168, 171], ["NO2", "SIMPLE_CHEMICAL", 173, 176], ["PM10", "SIMPLE_CHEMICAL", 182, 186], ["PM2.5", "SIMPLE_CHEMICAL", 241, 246], ["NO2", "PROBLEM", 77, 80], ["NO2-correlated air pollution", "PROBLEM", 93, 121], ["SO2", "TREATMENT", 168, 171], ["NO2", "TREATMENT", 173, 176], ["air pollution", "OBSERVATION", 108, 121]]], ["Because of size limitations, we did not investigate associations with disease-specific outcomes.", [["disease", "PROBLEM", 70, 77], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Associations within population subgroups, such as the elderly or children, and disease specific analyses have suggested variation in effects and susceptibilities (Halonen et al. 2008).", [["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["disease specific analyses", "PROBLEM", 79, 104]]], ["Associations between cardiovascular diseases and particle mass concentrations were not in the scope of our study, but are under investigation.", [["cardiovascular", "ANATOMY", 21, 35], ["cardiovascular diseases", "DISEASE", 21, 44], ["cardiovascular", "ANATOMICAL_SYSTEM", 21, 35], ["cardiovascular diseases", "PROBLEM", 21, 44], ["particle mass concentrations", "PROBLEM", 49, 77], ["our study", "TEST", 103, 112], ["cardiovascular", "ANATOMY", 21, 35], ["diseases", "OBSERVATION", 36, 44], ["particle", "OBSERVATION_MODIFIER", 49, 57], ["mass", "OBSERVATION", 58, 62]]], ["Guo et al. (2009) reported that PM2.5, NO2, and SO2 concentrations were associated with hospital ERV for cardiovascular diseases in Beijing.DiscussionExposure assessment and misclassification of exposure is a well-recognized limitation of epidemiologic time-series studies.", [["cardiovascular", "ANATOMY", 105, 119], ["PM2.5", "CHEMICAL", 32, 37], ["NO2", "CHEMICAL", 39, 42], ["SO2", "CHEMICAL", 48, 51], ["cardiovascular diseases", "DISEASE", 105, 128], ["PM2.5", "CHEMICAL", 32, 37], ["NO2", "CHEMICAL", 39, 42], ["SO2", "CHEMICAL", 48, 51], ["PM2.5", "SIMPLE_CHEMICAL", 32, 37], ["NO2", "SIMPLE_CHEMICAL", 39, 42], ["SO2", "SIMPLE_CHEMICAL", 48, 51], ["cardiovascular", "ANATOMICAL_SYSTEM", 105, 119], ["SO2 concentrations", "PROBLEM", 48, 66], ["cardiovascular diseases", "PROBLEM", 105, 128], ["Exposure assessment", "TEST", 150, 169], ["epidemiologic time", "TEST", 239, 257], ["series studies", "TEST", 258, 272], ["cardiovascular", "ANATOMY", 105, 119], ["diseases", "OBSERVATION", 120, 128]]], ["Measurements from only one station were used for the particle size distribution data, and we were not able to assess spatial variation in particle number concentrations.", [["Measurements", "TEST", 0, 12], ["the particle size distribution data", "TEST", 49, 84]]], ["Our measurement site may be considered as an urban background station because of its location (20 m height and > 500 m from a major road).", [["Our measurement site", "TEST", 0, 20], ["may be considered", "UNCERTAINTY", 21, 38]]], ["Average particle number size distributions at a PKU measurement site and another regional measurement site, located approximately 50 km south of the PKU, were similar (Yue et al. 2009), confirming that our measurement site may be considered as an urban background station.", [["particle", "ANATOMY", 8, 16], ["PKU", "DISEASE", 149, 152], ["PKU measurement site", "DNA", 48, 68], ["a PKU measurement", "TEST", 46, 63], ["the PKU", "TEST", 145, 152], ["particle", "OBSERVATION_MODIFIER", 8, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["size", "OBSERVATION_MODIFIER", 24, 28], ["distributions", "OBSERVATION_MODIFIER", 29, 42]]], ["In Beijing, concentrations of fine PM (PM2.5 and PM10) are evenly distributed over the urban area, including the Haidian district (Cheng et al. 2007; Wang et al. 2009).", [["PM10", "CHEMICAL", 49, 53], ["PM10", "CHEMICAL", 49, 53], ["evenly", "OBSERVATION_MODIFIER", 59, 65], ["distributed", "OBSERVATION_MODIFIER", 66, 77]]], ["In urban areas, differences of absolute particle number concentrations between different measurement sites can be great (Krudysz et al. 2009), with the largest variations in ultrafine (< 100 nm) and coarse (2,500\u201310,000 nm) particles and more homogenous spatial distributions of accumulation mode particles (100\u20132,000 nm) (Monn 2001).", [["absolute particle number concentrations", "TREATMENT", 31, 70], ["coarse", "TEST", 199, 205], ["accumulation mode particles", "TEST", 279, 306], ["absolute particle", "OBSERVATION_MODIFIER", 31, 48], ["largest", "OBSERVATION_MODIFIER", 152, 159], ["homogenous", "OBSERVATION_MODIFIER", 243, 253], ["spatial distributions", "OBSERVATION", 254, 275], ["accumulation mode", "OBSERVATION", 279, 296]]], ["The low correlation between NO2\u2014as an urban average, representing traffic exhaust levels and the main source of UFP\u2014and UFP might suggest low correlation between UFP at the measurement site and UFP levels elsewhere in the city.", [["UFP", "CHEMICAL", 120, 123], ["UFP", "CHEMICAL", 162, 165], ["UFP", "CHEMICAL", 194, 197], ["UFP", "SIMPLE_CHEMICAL", 162, 165], ["UFP", "SIMPLE_CHEMICAL", 194, 197], ["traffic exhaust levels", "TEST", 66, 88], ["UFP levels", "TEST", 194, 204], ["low", "OBSERVATION_MODIFIER", 4, 7], ["traffic exhaust", "OBSERVATION", 66, 81], ["main", "OBSERVATION_MODIFIER", 97, 101], ["low correlation", "OBSERVATION_MODIFIER", 138, 153]]], ["On the other hand, moderate correlations between UFP and NO2 were observed for subgroups, for example, seasons or particle subfractions of UFP.", [["UFP", "CHEMICAL", 49, 52], ["NO2", "CHEMICAL", 57, 60], ["UFP", "CHEMICAL", 139, 142], ["UFP", "CHEMICAL", 49, 52], ["NO2", "CHEMICAL", 57, 60], ["UFP", "SIMPLE_CHEMICAL", 49, 52], ["NO2", "SIMPLE_CHEMICAL", 57, 60], ["UFP", "SIMPLE_CHEMICAL", 139, 142], ["UFP", "TEST", 49, 52], ["NO2", "TEST", 57, 60], ["moderate", "OBSERVATION_MODIFIER", 19, 27]]], ["Personal levels of UFP can differ substantially, such as in proximity to traffic (Kaminsky et al. 2009).", [["UFP", "CHEMICAL", 19, 22], ["UFP", "SIMPLE_CHEMICAL", 19, 22]]], ["However, Buzorius et al. (1999), Cyrys et al. (2008), and Puustinen et al. (2007) showed that daily temporal correlations of particle number concentration time series between different monitoring sites are high.", [["high", "OBSERVATION_MODIFIER", 206, 210]]], ["The authors concluded that using one carefully chosen monitoring site is a reasonable approach to characterize exposure of particle number concentrations in epidemiologic time-series studies.", [["series studies", "TEST", 176, 190]]], ["When associations are estimated by Poisson regression model in time-series studies, Lipfert and Wyzga (1995) argued that exposure misclassification will reduce the precision of effect estimates, resulting in wider CIs, but will not bias estimates.", [["series studies", "TEST", 68, 82]]], ["On the other hand, bias away from the null can occur in time-series studies of multiple pollutants, such as this one, when measurement errors of different pollutants are correlated (Zeger et al. 2000).DiscussionThe air pollution mixture in Beijing is different from that of Western cities.", [["multiple pollutants", "PROBLEM", 79, 98], ["different pollutants", "PROBLEM", 145, 165], ["The air pollution mixture", "TREATMENT", 211, 236], ["air pollution", "OBSERVATION", 215, 228]]], ["The main sources of particulate air pollution in Beijing are coal burning, traffic, and dust from long-range transport (Sun et al. 2004).", [["particulate air pollution", "PROBLEM", 20, 45], ["coal burning", "PROBLEM", 61, 73], ["main", "OBSERVATION_MODIFIER", 4, 8], ["particulate", "OBSERVATION_MODIFIER", 20, 31], ["air pollution", "OBSERVATION", 32, 45], ["coal burning", "OBSERVATION", 61, 73]]], ["The mean particle number concentrations in urban areas in Europe or North America are 60\u201380% of the Beijing values, and particulate mass concentrations in Beijing are about three times higher than in Europe (Wehner et al. 2008).", [["particulate mass concentrations", "PROBLEM", 120, 151], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["particle", "OBSERVATION_MODIFIER", 9, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["concentrations", "OBSERVATION_MODIFIER", 25, 39], ["urban", "OBSERVATION_MODIFIER", 43, 48], ["areas", "OBSERVATION_MODIFIER", 49, 54], ["particulate", "OBSERVATION_MODIFIER", 120, 131], ["mass", "OBSERVATION", 132, 136], ["concentrations", "OBSERVATION_MODIFIER", 137, 151]]], ["In addition, the possibility that some effects might have occurred by chance cannot be excluded.", [["cannot be excluded", "UNCERTAINTY", 77, 95]]], ["To verify our findings with respect to different pollutants and particle fractions, further studies should be conducted, including analyzing the spatial correlation of pollutant time series.ConclusionsPresent levels of air pollution were associated with respiratory ERV in Beijing, China.", [["different pollutants and particle fractions", "PROBLEM", 39, 82], ["further studies", "TEST", 84, 99], ["air pollution", "PROBLEM", 219, 232], ["particle fractions", "OBSERVATION", 64, 82], ["air pollution", "OBSERVATION", 219, 232], ["respiratory ERV", "OBSERVATION", 254, 269]]], ["NO2 concentrations in Beijing appeared to be a better surrogate measure than PM10 or particle number concentrations for evaluating respiratory health effects of an air pollution mixture.", [["respiratory", "ANATOMY", 131, 142], ["NO2", "CHEMICAL", 0, 3], ["PM10", "CHEMICAL", 77, 81], ["NO2", "CHEMICAL", 0, 3], ["NO2", "SIMPLE_CHEMICAL", 0, 3], ["PM10", "SIMPLE_CHEMICAL", 77, 81], ["NO2 concentrations", "PROBLEM", 0, 18], ["an air pollution mixture", "TREATMENT", 161, 185], ["air pollution", "OBSERVATION", 164, 177]]]], "1d720a06cad9b69f7f45a4e7549142738114287e": [["IntroductionAntibiotics have been widely used in the swine industry for more than 50 years.", [["swine", "SPECIES", 53, 58], ["swine", "SPECIES", 53, 58], ["IntroductionAntibiotics", "TREATMENT", 0, 23]]], ["The efficacy of antibiotics in increasing growth rate, improving feed utilization, and reducing incidence of disease is well documented [1] .", [["antibiotics", "TREATMENT", 16, 27], ["increasing growth rate", "PROBLEM", 31, 53], ["disease", "PROBLEM", 109, 116], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["growth", "OBSERVATION_MODIFIER", 42, 48], ["disease", "OBSERVATION", 109, 116]]], ["In general, sub-therapeutic levels of antibiotics in swine diets increase the growth rate by an average of 16 % in weanling pigs, 11 % in growing pigs, and 4 % in growing-finishing pigs [1] .", [["swine", "ORGANISM", 53, 58], ["weanling pigs", "ORGANISM", 115, 128], ["pigs", "ORGANISM", 146, 150], ["pigs", "ORGANISM", 181, 185], ["swine", "SPECIES", 53, 58], ["weanling pigs", "SPECIES", 115, 128], ["pigs", "SPECIES", 146, 150], ["pigs", "SPECIES", 181, 185], ["swine", "SPECIES", 53, 58], ["pigs", "SPECIES", 124, 128], ["pigs", "SPECIES", 146, 150], ["antibiotics in swine diets", "TREATMENT", 38, 64], ["the growth rate", "TEST", 74, 89], ["weanling pigs", "TREATMENT", 115, 128]]], ["In addition, antibiotics are also used for disease prevention (prophylactic doses) and treatment (therapeutic doses).", [["antibiotics", "TREATMENT", 13, 24], ["disease prevention", "TREATMENT", 43, 61], ["prophylactic doses)", "TREATMENT", 63, 82], ["treatment (therapeutic doses", "TREATMENT", 87, 115]]], ["However, serious concerns have arisen with regard to the potential risks for human health including drug residues in meat products and increased bacterial resistance due to the use and misuse of in-feed antibiotics [2] .", [["meat", "ANATOMY", 117, 121], ["human", "ORGANISM", 77, 82], ["meat", "ORGANISM_SUBDIVISION", 117, 121], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["drug residues in meat products", "TREATMENT", 100, 130], ["increased bacterial resistance", "PROBLEM", 135, 165], ["antibiotics", "TREATMENT", 203, 214], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["bacterial resistance", "OBSERVATION", 145, 165]]], ["As a result, the European Union has totally banned the use of antibiotics for growth promotion since January 2006 [3] , while the US Food and Administration (FDA) has been phasing out non-medical antibiotic use for livestock since December 2013 [4] .IntroductionDiarrheal disease is a frequent cause of heavy economic losses for swine producers.", [["Diarrheal disease", "DISEASE", 262, 279], ["swine", "SPECIES", 329, 334], ["swine", "SPECIES", 329, 334], ["antibiotics", "TREATMENT", 62, 73], ["Diarrheal disease", "PROBLEM", 262, 279], ["heavy economic losses", "PROBLEM", 303, 324], ["swine producers", "TREATMENT", 329, 344], ["disease", "OBSERVATION", 272, 279], ["heavy", "OBSERVATION_MODIFIER", 303, 308], ["economic losses", "OBSERVATION", 309, 324]]], ["A major challenge currently facing the swine industry is to develop alternative means for controlling diarrhea in young pigs (particularly neonatal and early-weaned piglets) that are not only cost effective, but also allow for sustainable pork production.", [["diarrhea", "DISEASE", 102, 110], ["pigs", "ORGANISM", 120, 124], ["piglets", "ORGANISM", 165, 172], ["pork", "ORGANISM_SUBDIVISION", 239, 243], ["pigs", "SPECIES", 120, 124], ["piglets", "SPECIES", 165, 172], ["swine", "SPECIES", 39, 44], ["pigs", "SPECIES", 120, 124], ["pork", "SPECIES", 239, 243], ["A major challenge", "TREATMENT", 0, 17], ["controlling diarrhea", "PROBLEM", 90, 110]]], ["In the past two decades, a variety of materials have been tested as effective alternatives to antibiotics to maintain swine health and performance.", [["swine", "SPECIES", 118, 123], ["swine", "SPECIES", 118, 123], ["a variety of materials", "TREATMENT", 25, 47], ["antibiotics", "TREATMENT", 94, 105]]], ["The most widely researched alternatives include enzymes [5] , organic acids [6] , pro-and prebiotics [7] [8] [9] , herbal extracts [10, 11] and neutraceuticals such as copper and zinc [12, 13] .", [["extracts", "ANATOMY", 122, 130], ["[5] , organic acids [6] , pro-and prebiotics [7] [8] [9] , herbal extracts [10, 11]", "CHEMICAL", 56, 139], ["copper", "CHEMICAL", 168, 174], ["zinc", "CHEMICAL", 179, 183], ["copper", "CHEMICAL", 168, 174], ["zinc", "CHEMICAL", 179, 183], ["[5]", "SIMPLE_CHEMICAL", 56, 59], ["organic acids [6]", "SIMPLE_CHEMICAL", 62, 79], ["pro-and prebiotics [7] [8] [9]", "SIMPLE_CHEMICAL", 82, 112], ["10, 11]", "SIMPLE_CHEMICAL", 132, 139], ["neutraceuticals", "SIMPLE_CHEMICAL", 144, 159], ["copper", "SIMPLE_CHEMICAL", 168, 174], ["zinc [12, 13]", "SIMPLE_CHEMICAL", 179, 192], ["enzymes", "TEST", 48, 55], ["organic acids", "TEST", 62, 75], ["prebiotics", "TEST", 90, 100], ["herbal extracts", "TEST", 115, 130], ["neutraceuticals", "TEST", 144, 159], ["zinc", "TEST", 179, 183]]], ["However, these alternatives produce limited growth promotion and protection against pathogens.IntroductionRecently, egg yolk antibodies, generally referred to as IgY, have attracted considerable interest as an alternative to antibiotics for growth promotion in the presence of disease causing organisms [14] .", [["egg yolk", "ANATOMY", 116, 124], ["egg yolk antibodies", "GENE_OR_GENE_PRODUCT", 116, 135], ["IgY", "GENE_OR_GENE_PRODUCT", 162, 165], ["egg yolk antibodies", "PROTEIN", 116, 135], ["IgY", "PROTEIN", 162, 165], ["pathogens", "PROBLEM", 84, 93], ["egg yolk antibodies", "PROBLEM", 116, 135], ["antibiotics", "TREATMENT", 225, 236], ["growth promotion", "TREATMENT", 241, 257], ["disease causing organisms", "PROBLEM", 277, 302], ["disease", "OBSERVATION", 277, 284]]], ["IgY possesses a large number of advantages over mammalian IgG such as cost-effectiveness, convenience, and high yield [15] .", [["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 58, 61], ["IgY", "PROTEIN", 0, 3], ["mammalian IgG", "PROTEIN", 48, 61], ["mammalian IgG", "TREATMENT", 48, 61], ["large", "OBSERVATION_MODIFIER", 16, 21], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["Oral administration of specific IgY antibodies has been shown to be highly effective against a variety of intestinal pathogens which cause diarrhea in animals and human such as enterotoxigenic Escherichia coli (ETEC), Salmonella spp., bovine and human rotaviruses, bovine coronavirus, porcine transmissible gastroenteritis virus (TGEV), and porcine epidemic diarrhea virus (PEDV) [14, 16] .IntroductionFollowing a brief description of IgY technology and the advantages of IgY, this review will focus on the potential to use specific IgY as a production enhancer in swine production, and discuss the potential obstacles to the adoption of IgY technology.IgY technologyAs described more than 100 years ago, Klemperer [17] first demonstrated that avian maternal antibodies are transferred from serum to egg yolk in order to protect the developing embryo from potential pathogens but at that time there was no scientific application for this knowledge.", [["Oral", "ANATOMY", 0, 4], ["intestinal", "ANATOMY", 106, 116], ["serum", "ANATOMY", 791, 796], ["egg yolk", "ANATOMY", 800, 808], ["embryo", "ANATOMY", 844, 850], ["diarrhea", "DISEASE", 139, 147], ["enterotoxigenic Escherichia coli", "DISEASE", 177, 209], ["bovine coronavirus", "DISEASE", 265, 283], ["transmissible gastroenteritis", "DISEASE", 293, 322], ["porcine epidemic diarrhea virus", "DISEASE", 341, 372], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 32, 46], ["intestinal", "ORGAN", 106, 116], ["human", "ORGANISM", 163, 168], ["enterotoxigenic Escherichia coli", "ORGANISM", 177, 209], ["ETEC", "ORGANISM", 211, 215], ["Salmonella spp.", "ORGANISM", 218, 233], ["bovine", "ORGANISM", 235, 241], ["human", "ORGANISM", 246, 251], ["rotaviruses", "ORGANISM", 252, 263], ["bovine coronavirus", "ORGANISM", 265, 283], ["porcine transmissible gastroenteritis virus", "ORGANISM", 285, 328], ["TGEV", "ORGANISM", 330, 334], ["porcine epidemic diarrhea virus", "ORGANISM", 341, 372], ["IgY", "GENE_OR_GENE_PRODUCT", 472, 475], ["IgY", "GENE_OR_GENE_PRODUCT", 533, 536], ["swine", "ORGANISM", 565, 570], ["IgY", "GENE_OR_GENE_PRODUCT", 638, 641], ["IgY", "GENE_OR_GENE_PRODUCT", 653, 656], ["avian", "ORGANISM", 744, 749], ["serum", "ORGANISM_SUBSTANCE", 791, 796], ["egg yolk", "ORGANISM_SUBSTANCE", 800, 808], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 844, 850], ["IgY antibodies", "PROTEIN", 32, 46], ["IgY", "PROTEIN", 435, 438], ["IgY", "PROTEIN", 472, 475], ["IgY", "PROTEIN", 533, 536], ["IgY", "PROTEIN", 638, 641], ["avian maternal antibodies", "PROTEIN", 744, 769], ["human", "SPECIES", 163, 168], ["Escherichia coli", "SPECIES", 193, 209], ["Salmonella spp.", "SPECIES", 218, 233], ["bovine", "SPECIES", 235, 241], ["human", "SPECIES", 246, 251], ["rotaviruses", "SPECIES", 252, 263], ["bovine", "SPECIES", 265, 271], ["coronavirus", "SPECIES", 272, 283], ["porcine transmissible gastroenteritis virus", "SPECIES", 285, 328], ["TGEV", "SPECIES", 330, 334], ["porcine epidemic diarrhea virus", "SPECIES", 341, 372], ["swine", "SPECIES", 565, 570], ["human", "SPECIES", 163, 168], ["Escherichia coli", "SPECIES", 193, 209], ["ETEC", "SPECIES", 211, 215], ["Salmonella spp.", "SPECIES", 218, 233], ["bovine", "SPECIES", 235, 241], ["human rotaviruses", "SPECIES", 246, 263], ["bovine coronavirus", "SPECIES", 265, 283], ["porcine transmissible gastroenteritis virus", "SPECIES", 285, 328], ["TGEV", "SPECIES", 330, 334], ["porcine epidemic diarrhea virus", "SPECIES", 341, 372], ["PEDV", "SPECIES", 374, 378], ["swine", "SPECIES", 565, 570], ["Oral administration", "TREATMENT", 0, 19], ["specific IgY antibodies", "TREATMENT", 23, 46], ["intestinal pathogens", "PROBLEM", 106, 126], ["diarrhea", "PROBLEM", 139, 147], ["enterotoxigenic Escherichia coli", "PROBLEM", 177, 209], ["Salmonella spp.", "PROBLEM", 218, 233], ["bovine and human rotaviruses", "TREATMENT", 235, 263], ["bovine coronavirus", "PROBLEM", 265, 283], ["porcine transmissible gastroenteritis virus", "PROBLEM", 285, 328], ["porcine epidemic diarrhea virus", "PROBLEM", 341, 372], ["a production enhancer", "PROBLEM", 540, 561], ["IgY technology", "TREATMENT", 638, 652], ["avian maternal antibodies", "PROBLEM", 744, 769], ["the developing embryo", "PROBLEM", 829, 850], ["potential pathogens", "PROBLEM", 856, 875], ["intestinal", "ANATOMY", 106, 116], ["pathogens", "OBSERVATION", 117, 126], ["bovine coronavirus", "OBSERVATION", 265, 283], ["embryo", "OBSERVATION", 844, 850]]], ["However, when animal welfare became a matter of serious ethical concern for the scientific community, the results of Klemperer began to receive more interest, particularly since the 1980s.IgY technologySince 1996, IgY technology (i.e. the production and use of IgY) has become an internationally accepted practice [18] .", [["IgY", "PROTEIN", 261, 264]]], ["In 1996, the European Centre for the Validation of Alternative Methods (ECVAM) workshop strongly recommended that IgY should be used as an alternative to mammalian antibodies [19] .", [["IgY", "GENE_OR_GENE_PRODUCT", 114, 117], ["IgY", "PROTEIN", 114, 117], ["mammalian antibodies", "PROTEIN", 154, 174], ["IgY", "TREATMENT", 114, 117]]], ["In 1999, IgY technology was approved as an alternative method for supporting animal welfare by the Veterinary Office of the Swiss Government (Office V\u00e9t\u00e9rinaire F\u00e9d\u00e9ral).IgY technologyDetails concerning the production of specific IgY have been reviewed by Schade et al. (2005) [20] .", [["IgY", "GENE_OR_GENE_PRODUCT", 170, 173], ["IgY", "GENE_OR_GENE_PRODUCT", 230, 233], ["IgY", "PROTEIN", 230, 233]]], ["Briefly, in order to produce specific IgY antibodies, laying hens are immunized with specific foreign pathogens which induce immune responses, including the production of antibodies with activity against these specific disease conditions.", [["IgY", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgY antibodies", "PROTEIN", 38, 52], ["antibodies", "PROTEIN", 171, 181], ["specific IgY antibodies", "PROBLEM", 29, 52], ["specific foreign pathogens", "PROBLEM", 85, 111], ["the production of antibodies", "PROBLEM", 153, 181], ["these specific disease conditions", "PROBLEM", 204, 237]]], ["These antibodies are then transferred to the egg yolk and deposited in large quantities.", [["egg yolk", "ANATOMY", 45, 53], ["egg yolk", "ORGANISM_SUBSTANCE", 45, 53], ["antibodies", "PROTEIN", 6, 16], ["large quantities", "OBSERVATION_MODIFIER", 71, 87]]], ["Booster immunizations are usually given to ensure continued transfer of antibodies from the hen's serum to the egg yolk.", [["serum", "ANATOMY", 98, 103], ["egg yolk", "ANATOMY", 111, 119], ["hen", "ORGANISM", 92, 95], ["serum", "ORGANISM_SUBSTANCE", 98, 103], ["egg yolk", "ORGAN", 111, 119], ["antibodies", "PROTEIN", 72, 82], ["hen", "SPECIES", 92, 95], ["hen", "SPECIES", 92, 95], ["Booster immunizations", "TREATMENT", 0, 21], ["antibodies", "TREATMENT", 72, 82]]], ["These antibodies are then extracted from the egg yolk and processed to be administered directly to the animal or incorporated into diets.IgY technologyAntibodies can be administered in several forms including whole egg powder, whole yolk powder, a water-soluble fraction powder or purified IgY.", [["egg yolk", "ANATOMY", 45, 53], ["egg", "ANATOMY", 215, 218], ["yolk", "ANATOMY", 233, 237], ["egg yolk", "ORGANISM_SUBSTANCE", 45, 53], ["IgY", "GENE_OR_GENE_PRODUCT", 137, 140], ["egg", "ORGANISM_SUBDIVISION", 215, 218], ["yolk", "ORGANISM_SUBDIVISION", 233, 237], ["IgY", "GENE_OR_GENE_PRODUCT", 290, 293], ["antibodies", "PROTEIN", 6, 16], ["purified IgY", "PROTEIN", 281, 293], ["the egg yolk", "TREATMENT", 41, 53], ["Antibodies", "TREATMENT", 151, 161], ["whole egg powder", "TREATMENT", 209, 225], ["whole yolk powder", "TREATMENT", 227, 244], ["a water-soluble fraction powder", "TREATMENT", 246, 277]]], ["Antibody production and titer development as a result of immunization are not very predictable.", [["Antibody production", "PROBLEM", 0, 19], ["immunization", "TREATMENT", 57, 69]]], ["Variables influencing immunization include the antigen (dose, MW), type of adjuvant used, route of immunization, immunization frequency and the chicken itself (such as housing conditions, age, breed, egg laying capacity).Advantages of IgYThe use of chickens as the immunization host for antibody production provide a number of advantages over production methods using mammals.", [["IgYThe", "CHEMICAL", 235, 241], ["chicken", "ORGANISM", 144, 151], ["IgYThe", "SIMPLE_CHEMICAL", 235, 241], ["chickens", "ORGANISM", 249, 257], ["chicken", "SPECIES", 144, 151], ["chickens", "SPECIES", 249, 257], ["chicken", "SPECIES", 144, 151], ["chickens", "SPECIES", 249, 257], ["Variables influencing immunization", "TREATMENT", 0, 34], ["adjuvant", "TREATMENT", 75, 83], ["immunization", "TREATMENT", 99, 111], ["immunization frequency", "TREATMENT", 113, 135], ["chickens", "TREATMENT", 249, 257], ["the immunization host", "TREATMENT", 261, 282], ["antibody production", "TREATMENT", 287, 306]]], ["The most significant advantage is that egg collection is non-invasive compared with the stressful bleeding of animals to obtain serum.", [["egg", "ANATOMY", 39, 42], ["serum", "ANATOMY", 128, 133], ["bleeding", "DISEASE", 98, 106], ["egg", "ORGANISM_SUBSTANCE", 39, 42], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["egg collection", "PROBLEM", 39, 53], ["the stressful bleeding of animals", "PROBLEM", 84, 117], ["serum", "TEST", 128, 133], ["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["In addition, the high and long-lasting titer produced in chickens reduces the need for frequent booster injections.", [["chickens", "ORGANISM", 57, 65], ["chickens", "SPECIES", 57, 65], ["chickens", "SPECIES", 57, 65], ["the high and long-lasting titer", "PROBLEM", 13, 44], ["frequent booster injections", "TREATMENT", 87, 114], ["high", "OBSERVATION_MODIFIER", 17, 21]]], ["Another advantage is that the production of IgY antibodies against highly conserved mammalian proteins is more successful in chickens than in other mammals [21] and requires much less antigen to induce an efficient immune response due to the phylogenetic distance between chickens and mammals [22] .Advantages of IgYA hen can be considered as a small \"factory\" for antibody production.", [["IgY antibodies", "GENE_OR_GENE_PRODUCT", 44, 58], ["chickens", "ORGANISM", 125, 133], ["chickens", "ORGANISM", 272, 280], ["IgYA hen", "ORGANISM", 313, 321], ["IgY antibodies", "PROTEIN", 44, 58], ["mammalian proteins", "PROTEIN", 84, 102], ["chickens", "SPECIES", 125, 133], ["chickens", "SPECIES", 272, 280], ["hen", "SPECIES", 318, 321], ["chickens", "SPECIES", 125, 133], ["chickens", "SPECIES", 272, 280], ["hen", "SPECIES", 318, 321], ["IgY antibodies", "TREATMENT", 44, 58], ["antibody production", "PROBLEM", 365, 384]]], ["One hen can produce more than 22.5 g of total IgY per year of which 2 to 10 % are specific antibodies [14] .", [["hen", "ORGANISM", 4, 7], ["IgY", "GENE_OR_GENE_PRODUCT", 46, 49], ["IgY", "PROTEIN", 46, 49], ["specific antibodies", "TEST", 82, 101]]], ["This extraordinary quantity is equivalent to the production of 4.3 rabbits over the course of a year.", [["rabbits", "ORGANISM", 67, 74], ["rabbits", "SPECIES", 67, 74], ["extraordinary", "OBSERVATION_MODIFIER", 5, 18], ["quantity", "OBSERVATION_MODIFIER", 19, 27], ["equivalent", "OBSERVATION_MODIFIER", 31, 41], ["4.3 rabbits", "OBSERVATION_MODIFIER", 63, 74]]], ["The cost for maintaining laying hens are also lower than those for mammals such as rabbits [20] .", [["rabbits", "ORGANISM", 83, 90], ["rabbits", "SPECIES", 83, 90]]], ["Therefore, egg yolk offers a more hygienic, costefficient, convenient and rich source of antibodies compared with traditional production methods using mammals.", [["egg yolk", "ANATOMY", 11, 19], ["egg yolk", "MULTI-TISSUE_STRUCTURE", 11, 19], ["antibodies", "PROTEIN", 89, 99], ["antibodies", "PROBLEM", 89, 99], ["traditional production methods", "TREATMENT", 114, 144]]], ["In contrast to antibiotics, the use of IgY is environmentally-friendly and elicits no undesirable side effects, disease resistance or toxic residues [23] .Advantages of IgYIn terms of function, unlike mammalian IgG, IgY does not activate mammalian complement and also does not interact with mammalian Fc and complement receptors.", [["IgY", "GENE_OR_GENE_PRODUCT", 39, 42], ["IgYIn", "GENE_OR_GENE_PRODUCT", 169, 174], ["IgG", "GENE_OR_GENE_PRODUCT", 211, 214], ["IgY", "GENE_OR_GENE_PRODUCT", 216, 219], ["Fc", "GENE_OR_GENE_PRODUCT", 301, 303], ["complement receptors", "GENE_OR_GENE_PRODUCT", 308, 328], ["IgY", "PROTEIN", 39, 42], ["IgYIn", "PROTEIN", 169, 174], ["mammalian IgG", "PROTEIN", 201, 214], ["IgY", "PROTEIN", 216, 219], ["mammalian Fc", "PROTEIN", 291, 303], ["complement receptors", "PROTEIN", 308, 328], ["antibiotics", "TREATMENT", 15, 26], ["undesirable side effects", "PROBLEM", 86, 110], ["disease resistance", "PROBLEM", 112, 130], ["toxic residues", "PROBLEM", 134, 148]]], ["As well, IgY does not bind to protein A, protein G or rheumatoid factor [15] .", [["IgY", "GENE_OR_GENE_PRODUCT", 9, 12], ["protein A", "GENE_OR_GENE_PRODUCT", 30, 39], ["protein G", "GENE_OR_GENE_PRODUCT", 41, 50], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 54, 71], ["IgY", "PROTEIN", 9, 12], ["protein A", "PROTEIN", 30, 39], ["protein G", "PROTEIN", 41, 50], ["rheumatoid factor", "PROTEIN", 54, 71], ["rheumatoid factor", "PROBLEM", 54, 71]]], ["These differences provide great advantages for the successful application of IgY technology in many research areas, diagnostics [24] , antibioticalternative therapy [15] and xenotransplantation [25] .Mode of actionThe exact mechanisms through which IgY counteracts pathogen activity have not been determined.", [["IgY", "GENE_OR_GENE_PRODUCT", 249, 252], ["IgY", "PROTEIN", 249, 252], ["IgY technology", "TREATMENT", 77, 91], ["antibioticalternative therapy", "TREATMENT", 135, 164], ["xenotransplantation", "TREATMENT", 174, 193]]], ["However, several mechanisms have been proposed by Xu et al. (2011) [14] including agglutination of bacteria, inhibition of adhesion, as well as opsonization followed by phagocytosis and toxin neutralization.", [["bacteria", "PROBLEM", 99, 107], ["inhibition of adhesion", "TREATMENT", 109, 131], ["opsonization", "TREATMENT", 144, 156], ["phagocytosis", "PROBLEM", 169, 181], ["toxin neutralization", "PROBLEM", 186, 206]]], ["Among these, inhibition of adhesion is considered the primary mechanism by which specific IgY functions.", [["IgY", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgY", "PROTEIN", 90, 93], ["adhesion", "OBSERVATION", 27, 35]]], ["Briefly, IgY antibodies generated against intestinal disease causing organisms may reduce the incidence of disease by preventing the attachment of pathogens to the intestine, such as blocking the mucosal receptor, interfering with binding to mucins, or neutralizing the colonization factor (such as the outer membrane protein, lipopolysaccharide, fimbriae (or pili), and flagella) [26] .", [["intestinal", "ANATOMY", 42, 52], ["intestine", "ANATOMY", 164, 173], ["mucosal", "ANATOMY", 196, 203], ["outer membrane", "ANATOMY", 303, 317], ["intestinal disease", "DISEASE", 42, 60], ["lipopolysaccharide", "CHEMICAL", 327, 345], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 9, 23], ["intestinal", "ORGAN", 42, 52], ["intestine", "ORGAN", 164, 173], ["mucosal receptor", "GENE_OR_GENE_PRODUCT", 196, 212], ["mucins", "GENE_OR_GENE_PRODUCT", 242, 248], ["outer membrane protein", "GENE_OR_GENE_PRODUCT", 303, 325], ["lipopolysaccharide", "GENE_OR_GENE_PRODUCT", 327, 345], ["fimbriae", "GENE_OR_GENE_PRODUCT", 347, 355], ["pili", "GENE_OR_GENE_PRODUCT", 360, 364], ["IgY antibodies", "PROTEIN", 9, 23], ["mucosal receptor", "PROTEIN", 196, 212], ["colonization factor", "PROTEIN", 270, 289], ["outer membrane protein", "PROTEIN", 303, 325], ["fimbriae", "PROTEIN", 347, 355], ["pili", "PROTEIN", 360, 364], ["IgY antibodies", "TREATMENT", 9, 23], ["intestinal disease", "PROBLEM", 42, 60], ["organisms", "PROBLEM", 69, 78], ["disease", "PROBLEM", 107, 114], ["the attachment of pathogens to the intestine", "PROBLEM", 129, 173], ["blocking the mucosal receptor", "TREATMENT", 183, 212], ["binding to mucins", "PROBLEM", 231, 248], ["neutralizing the colonization factor", "PROBLEM", 253, 289], ["the outer membrane protein", "TREATMENT", 299, 325], ["intestinal", "ANATOMY", 42, 52], ["disease", "OBSERVATION", 53, 60], ["disease", "OBSERVATION", 107, 114], ["intestine", "ANATOMY", 164, 173], ["mucosal receptor", "ANATOMY", 196, 212]]], ["The possible primary mode of action by which IgY protects pigs against E coli K88 induced diarrhea is illustrated in Fig. 1 .IgY applications in swine productionDiarrhoea in neonatal and post-weaning pigs can be caused by a number of causative agents and has become a serious problem in the swine industry due to the trend towards large intensive herds and early weaning (i.e. 14-21 rather than 21-28 days of age).", [["diarrhea", "DISEASE", 90, 98], ["Diarrhoea", "DISEASE", 161, 170], ["IgY", "GENE_OR_GENE_PRODUCT", 45, 48], ["pigs", "ORGANISM", 58, 62], ["E coli K88", "ORGANISM", 71, 81], ["IgY", "GENE_OR_GENE_PRODUCT", 125, 128], ["swine", "ORGANISM", 145, 150], ["pigs", "ORGANISM", 200, 204], ["IgY", "PROTEIN", 45, 48], ["pigs", "SPECIES", 58, 62], ["E coli", "SPECIES", 71, 77], ["swine", "SPECIES", 145, 150], ["pigs", "SPECIES", 200, 204], ["swine", "SPECIES", 291, 296], ["pigs", "SPECIES", 58, 62], ["E coli", "SPECIES", 71, 77], ["swine", "SPECIES", 145, 150], ["pigs", "SPECIES", 200, 204], ["swine", "SPECIES", 291, 296], ["IgY protects pigs", "TREATMENT", 45, 62], ["E coli K88", "TREATMENT", 71, 81], ["diarrhea", "PROBLEM", 90, 98], ["IgY applications", "TREATMENT", 125, 141], ["Diarrhoea", "PROBLEM", 161, 170], ["weaning pigs", "TREATMENT", 192, 204], ["causative agents", "TREATMENT", 234, 250], ["a serious problem", "PROBLEM", 266, 283], ["large intensive herds", "TREATMENT", 331, 352], ["early weaning", "TREATMENT", 357, 370]]], ["The potential applications for using orally administered IgY in the control of enteric infections of either bacterial or viral origin in piglets have been studied at length and are summarized in Tables 1 and 2 .Antimicrobial and performance effectsEnterotoxigenic Escherichia coli Diarrhea due to enterotoxigenic Escherichia coli (ETEC) is by far the most common enteric colibacillosis encountered in neonatal and post-weaned pigs [27] [28] [29] .", [["enteric infections", "DISEASE", 79, 97], ["Diarrhea", "DISEASE", 281, 289], ["enterotoxigenic Escherichia coli", "DISEASE", 297, 329], ["ETEC", "DISEASE", 331, 335], ["colibacillosis", "DISEASE", 371, 385], ["IgY", "GENE_OR_GENE_PRODUCT", 57, 60], ["piglets", "ORGANISM", 137, 144], ["Escherichia coli", "ORGANISM", 264, 280], ["enterotoxigenic Escherichia coli", "ORGANISM", 297, 329], ["ETEC", "ORGANISM", 331, 335], ["pigs", "ORGANISM", 426, 430], ["IgY", "PROTEIN", 57, 60], ["piglets", "SPECIES", 137, 144], ["Escherichia coli", "SPECIES", 264, 280], ["enterotoxigenic Escherichia coli", "SPECIES", 297, 329], ["pigs", "SPECIES", 426, 430], ["Escherichia coli", "SPECIES", 264, 280], ["Escherichia coli", "SPECIES", 313, 329], ["ETEC", "SPECIES", 331, 335], ["The potential applications", "TREATMENT", 0, 26], ["orally", "TREATMENT", 37, 43], ["IgY", "TREATMENT", 57, 60], ["enteric infections", "PROBLEM", 79, 97], ["Antimicrobial", "TREATMENT", 211, 224], ["Enterotoxigenic Escherichia coli Diarrhea", "PROBLEM", 248, 289], ["enterotoxigenic Escherichia coli", "PROBLEM", 297, 329], ["enteric", "ANATOMY", 79, 86], ["infections", "OBSERVATION", 87, 97], ["bacterial", "OBSERVATION_MODIFIER", 108, 117], ["viral origin", "OBSERVATION", 121, 133], ["Escherichia coli", "OBSERVATION", 264, 280], ["enterotoxigenic", "OBSERVATION_MODIFIER", 297, 312], ["Escherichia coli", "OBSERVATION", 313, 329], ["colibacillosis", "OBSERVATION", 371, 385]]], ["ETEC can cause diarrhea in piglets by colonization in the small intestine and thereafter through the production of either one or two enterotoxins namely heat-labile enterotoxin (LT) and heat-stable enterotoxins (ST), which induce massive fluid and electrolyte secretion into the gut lumen [30] .Antimicrobial and performance effectsThe strains of E. coli associated with intestinal colonization which cause severe diarrhea are those expressing the K88 (or F4), K99 (or F5), 987P (or F6), F18 and F41 fimbrial adhesions.", [["small intestine", "ANATOMY", 58, 73], ["fluid", "ANATOMY", 238, 243], ["gut lumen", "ANATOMY", 279, 288], ["intestinal", "ANATOMY", 371, 381], ["ETEC", "CHEMICAL", 0, 4], ["diarrhea", "DISEASE", 15, 23], ["diarrhea", "DISEASE", 414, 422], ["piglets", "ORGANISM", 27, 34], ["small intestine", "ORGAN", 58, 73], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 165, 176], ["fluid", "ORGANISM_SUBSTANCE", 238, 243], ["gut lumen", "MULTI-TISSUE_STRUCTURE", 279, 288], ["E. coli", "ORGANISM", 347, 354], ["intestinal", "ORGAN", 371, 381], ["K88", "GENE_OR_GENE_PRODUCT", 448, 451], ["K99", "GENE_OR_GENE_PRODUCT", 461, 464], ["enterotoxin", "PROTEIN", 165, 176], ["LT", "PROTEIN", 178, 180], ["enterotoxins", "PROTEIN", 198, 210], ["ST", "PROTEIN", 212, 214], ["piglets", "SPECIES", 27, 34], ["E. coli", "SPECIES", 347, 354], ["ETEC", "SPECIES", 0, 4], ["E. coli", "SPECIES", 347, 354], ["ETEC", "PROBLEM", 0, 4], ["diarrhea", "PROBLEM", 15, 23], ["colonization in the small intestine", "PROBLEM", 38, 73], ["labile enterotoxin", "PROBLEM", 158, 176], ["massive fluid and electrolyte secretion into the gut lumen", "PROBLEM", 230, 288], ["Antimicrobial", "TREATMENT", 295, 308], ["E. coli", "PROBLEM", 347, 354], ["intestinal colonization", "PROBLEM", 371, 394], ["severe diarrhea", "PROBLEM", 407, 422], ["fimbrial adhesions", "PROBLEM", 500, 518], ["diarrhea", "OBSERVATION", 15, 23], ["small intestine", "ANATOMY", 58, 73], ["stable", "OBSERVATION_MODIFIER", 191, 197], ["enterotoxins", "OBSERVATION", 198, 210], ["massive", "OBSERVATION_MODIFIER", 230, 237], ["fluid", "OBSERVATION", 238, 243], ["electrolyte secretion", "OBSERVATION", 248, 269], ["gut", "ANATOMY", 279, 282], ["lumen", "ANATOMY_MODIFIER", 283, 288], ["E. coli", "OBSERVATION", 347, 354], ["intestinal", "ANATOMY", 371, 381], ["colonization", "OBSERVATION", 382, 394], ["severe", "OBSERVATION_MODIFIER", 407, 413], ["diarrhea", "OBSERVATION", 414, 422], ["adhesions", "OBSERVATION", 509, 518]]], ["These fimbrial adhesions mediate the adhesion of E. coli to the epithelial mucosa lining of the intestine and thereby contribute to their virulence.", [["fimbrial adhesions", "ANATOMY", 6, 24], ["epithelial mucosa", "ANATOMY", 64, 81], ["intestine", "ANATOMY", 96, 105], ["E. coli", "ORGANISM", 49, 56], ["epithelial mucosa lining", "TISSUE", 64, 88], ["intestine", "ORGAN", 96, 105], ["E. coli", "SPECIES", 49, 56], ["E. coli", "SPECIES", 49, 56], ["These fimbrial adhesions", "PROBLEM", 0, 24], ["E. coli", "PROBLEM", 49, 56], ["their virulence", "PROBLEM", 132, 147], ["fimbrial", "OBSERVATION_MODIFIER", 6, 14], ["adhesions", "OBSERVATION", 15, 24], ["adhesion", "OBSERVATION_MODIFIER", 37, 45], ["E. coli", "OBSERVATION", 49, 56], ["epithelial mucosa", "ANATOMY", 64, 81], ["intestine", "ANATOMY", 96, 105], ["virulence", "OBSERVATION", 138, 147]]], ["Among the different ETEC, those expressing the K88+ fimbrial antigen are the most prevalent forms causing E. coli infection world-wide [31] .", [["E. coli infection", "DISEASE", 106, 123], ["K88", "GENE_OR_GENE_PRODUCT", 47, 50], ["fimbrial antigen", "GENE_OR_GENE_PRODUCT", 52, 68], ["E. coli", "ORGANISM", 106, 113], ["K88", "PROTEIN", 47, 50], ["fimbrial antigen", "PROTEIN", 52, 68], ["E. coli", "SPECIES", 106, 113], ["E. coli", "SPECIES", 106, 113], ["the K88", "TEST", 43, 50], ["fimbrial antigen", "PROBLEM", 52, 68], ["E. coli infection", "PROBLEM", 106, 123], ["most prevalent", "OBSERVATION_MODIFIER", 77, 91], ["coli infection", "OBSERVATION", 109, 123]]], ["It has been estimated that K88 + ETEC are responsible for more than half of the piglet mortality which occurs annually [32] .Antimicrobial and performance effectsOral administration of IgY offers a potential prophylactic and therapeutic approach for controlling E. coli-induced diarrhea in piglets.", [["piglet", "ANATOMY", 80, 86], ["Oral", "ANATOMY", 162, 166], ["ETEC", "DISEASE", 33, 37], ["diarrhea", "DISEASE", 278, 286], ["K88 + ETEC", "GENE_OR_GENE_PRODUCT", 27, 37], ["piglet", "ORGANISM", 80, 86], ["Oral", "ORGANISM_SUBDIVISION", 162, 166], ["IgY", "GENE_OR_GENE_PRODUCT", 185, 188], ["E. coli-induced diarrhea", "ORGANISM", 262, 286], ["piglets", "ORGANISM", 290, 297], ["IgY", "PROTEIN", 185, 188], ["piglets", "SPECIES", 290, 297], ["E. coli-induced diarrhea", "SPECIES", 262, 286], ["K88", "PROBLEM", 27, 30], ["ETEC", "PROBLEM", 33, 37], ["Antimicrobial", "TREATMENT", 125, 138], ["a potential prophylactic", "TREATMENT", 196, 220], ["therapeutic approach", "TREATMENT", 225, 245], ["E. coli-induced diarrhea in piglets", "PROBLEM", 262, 297], ["coli-induced", "OBSERVATION_MODIFIER", 265, 277], ["diarrhea", "OBSERVATION", 278, 286]]], ["IgY has been shown to successfully control intestinal infections of E. coli K88, K99, 987P, and F18 in young pigs [27, 33, 34] .", [["intestinal", "ANATOMY", 43, 53], ["intestinal infections", "DISEASE", 43, 64], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["intestinal", "ORGAN", 43, 53], ["E. coli", "ORGANISM", 68, 75], ["K88", "ORGANISM", 76, 79], ["K99", "GENE_OR_GENE_PRODUCT", 81, 84], ["987P", "GENE_OR_GENE_PRODUCT", 86, 90], ["F18", "GENE_OR_GENE_PRODUCT", 96, 99], ["pigs", "ORGANISM", 109, 113], ["IgY", "PROTEIN", 0, 3], ["E. coli", "SPECIES", 68, 75], ["pigs", "SPECIES", 109, 113], ["E. coli", "SPECIES", 68, 75], ["intestinal infections of E. coli K88", "PROBLEM", 43, 79], ["intestinal", "ANATOMY", 43, 53], ["infections", "OBSERVATION", 54, 64], ["E. coli", "OBSERVATION", 68, 75]]], ["Yokoyama et al. [27] showed that orally administered crude IgY (the water-soluble fraction) generated against E. coli K88, K99, or 987P fimbriaes was protective against infection from three homologous strains of E. coli in a dosedependent manner in colostrum-deprived piglets.", [["infection", "DISEASE", 169, 178], ["IgY", "GENE_OR_GENE_PRODUCT", 59, 62], ["E. coli", "ORGANISM", 110, 117], ["K88", "ORGANISM", 118, 121], ["K99", "GENE_OR_GENE_PRODUCT", 123, 126], ["987P", "GENE_OR_GENE_PRODUCT", 131, 135], ["E. coli", "ORGANISM", 212, 219], ["colostrum", "ORGANISM", 249, 258], ["piglets", "ORGANISM", 268, 275], ["crude IgY", "PROTEIN", 53, 62], ["E. coli", "SPECIES", 110, 117], ["E. coli", "SPECIES", 212, 219], ["piglets", "SPECIES", 268, 275], ["E. coli", "SPECIES", 110, 117], ["E. coli", "SPECIES", 212, 219], ["crude IgY", "TREATMENT", 53, 62], ["the water-soluble fraction", "TREATMENT", 64, 90], ["E. coli K88", "TEST", 110, 121], ["K99", "TEST", 123, 126], ["infection", "PROBLEM", 169, 178], ["E. coli", "PROBLEM", 212, 219], ["E. coli", "OBSERVATION", 212, 219]]], ["In vitro, E. coli K88, K99, and 987P strains adhered equally to porcine epithelial cells from the duodenum and ileum but failed to so in the presence of homologous antifimbrial IgY [27] .Antimicrobial and performance effectsThe group of Marquardt [26, 34] from the University of Manitoba in Canada carried out some excellent studies on the passive protective effects of IgY against ETEC K88 fimbriae in neonatal and early-weaned piglets.", [["K99", "ANATOMY", 23, 26], ["epithelial cells", "ANATOMY", 72, 88], ["duodenum", "ANATOMY", 98, 106], ["ileum", "ANATOMY", 111, 116], ["E. coli", "ORGANISM", 10, 17], ["K88", "ORGANISM", 18, 21], ["K99", "CELL", 23, 26], ["porcine", "ORGANISM", 64, 71], ["epithelial cells", "CELL", 72, 88], ["duodenum", "ORGAN", 98, 106], ["ileum", "ORGAN", 111, 116], ["IgY", "GENE_OR_GENE_PRODUCT", 370, 373], ["ETEC K88 fimbriae", "GENE_OR_GENE_PRODUCT", 382, 399], ["piglets", "ORGANISM", 429, 436], ["porcine epithelial cells", "CELL_TYPE", 64, 88], ["antifimbrial IgY", "PROTEIN", 164, 180], ["IgY", "PROTEIN", 370, 373], ["ETEC K88 fimbriae", "PROTEIN", 382, 399], ["E. coli", "SPECIES", 10, 17], ["porcine", "SPECIES", 64, 71], ["piglets", "SPECIES", 429, 436], ["E. coli", "SPECIES", 10, 17], ["porcine", "SPECIES", 64, 71], ["ETEC", "SPECIES", 382, 386], ["E. coli K88", "TEST", 10, 21], ["K99", "TEST", 23, 26], ["P strains", "PROBLEM", 35, 44], ["Antimicrobial", "TREATMENT", 187, 200], ["the passive protective effects", "TREATMENT", 336, 366], ["IgY", "TREATMENT", 370, 373], ["ETEC K88 fimbriae", "TREATMENT", 382, 399], ["epithelial cells", "OBSERVATION", 72, 88], ["duodenum", "ANATOMY", 98, 106], ["ileum", "ANATOMY", 111, 116]]], ["In an animal feeding study, 21-day old pigs were orally challenged with high doses of ETEC K88 at 0 and 5 h of the experiment.", [["ETEC", "CHEMICAL", 86, 90], ["pigs", "ORGANISM", 39, 43], ["pigs", "SPECIES", 39, 43], ["pigs", "SPECIES", 39, 43], ["an animal feeding study", "TEST", 3, 26], ["ETEC K88", "TREATMENT", 86, 94]]], ["They were then oral administered with crude IgY (the water-soluble fraction) three times a day for two consecutive days after the first E. coli challenge.", [["oral", "ANATOMY", 15, 19], ["oral", "ORGANISM_SUBDIVISION", 15, 19], ["E. coli", "ORGANISM", 136, 143], ["crude IgY", "PROTEIN", 38, 47], ["E. coli", "SPECIES", 136, 143], ["E. coli", "SPECIES", 136, 143], ["crude IgY", "TREATMENT", 38, 47], ["the water-soluble fraction", "TREATMENT", 49, 75], ["the first E. coli challenge", "TREATMENT", 126, 153]]], ["Control piglets (treated with IgY from non-immunized hens) had severe diarrhea within 12 h and lost weight and 30 % of the pigs died within 48 h of infection.", [["diarrhea", "DISEASE", 70, 78], ["infection", "DISEASE", 148, 157], ["piglets", "ORGANISM", 8, 15], ["pigs", "ORGANISM", 123, 127], ["IgY", "PROTEIN", 30, 33], ["piglets", "SPECIES", 8, 15], ["pigs", "SPECIES", 123, 127], ["pigs", "SPECIES", 123, 127], ["IgY", "TREATMENT", 30, 33], ["severe diarrhea", "PROBLEM", 63, 78], ["weight", "TEST", 100, 106], ["infection", "PROBLEM", 148, 157], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["diarrhea", "OBSERVATION", 70, 78], ["infection", "OBSERVATION", 148, 157]]], ["In contrast, the pigs given IgY from immunized hens exhibited no signs of diarrhea 24 and 48 h after treatment, and had a positive weight gain.", [["diarrhea", "DISEASE", 74, 82], ["weight gain", "DISEASE", 131, 142], ["pigs", "ORGANISM", 17, 21], ["IgY", "GENE_OR_GENE_PRODUCT", 28, 31], ["IgY", "PROTEIN", 28, 31], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 17, 21], ["the pigs", "TREATMENT", 13, 21], ["IgY", "TREATMENT", 28, 31], ["diarrhea", "PROBLEM", 74, 82], ["treatment", "TREATMENT", 101, 110], ["a positive weight gain", "PROBLEM", 120, 142]]], ["Furthermore, this group performed studies on the practical use of IgY in a field trial.", [["IgY", "GENE_OR_GENE_PRODUCT", 66, 69], ["IgY", "PROTEIN", 66, 69]]], ["Their experiment showed suppression of the incidence and severity of diarrhea in 14-18-day-old weaned [85] piglets fed specific IgY powder, which were much lower than those fed a commercial diet containing an antibiotic.", [["diarrhea", "DISEASE", 69, 77], ["piglets", "ORGANISM", 107, 114], ["IgY", "ORGANISM", 128, 131], ["piglets", "SPECIES", 107, 114], ["diarrhea", "PROBLEM", 69, 77], ["specific IgY powder", "TREATMENT", 119, 138], ["an antibiotic", "TREATMENT", 206, 219]]], ["The number of pigs in this study was not large and it would be desirable to repeat this study with a greater number of animals.Antimicrobial and performance effectsIn another study with F18+ E. coli, it was shown that the F18 antibodies diminished the incidence of diarrhea and death in weaned piglets infected with F18+ E. coli [33] .", [["diarrhea", "DISEASE", 265, 273], ["death", "DISEASE", 278, 283], ["pigs", "ORGANISM", 14, 18], ["F18+ E. coli", "ORGANISM", 186, 198], ["F18 antibodies", "GENE_OR_GENE_PRODUCT", 222, 236], ["piglets", "ORGANISM", 294, 301], ["E. coli", "ORGANISM", 321, 328], ["F18 antibodies", "PROTEIN", 222, 236], ["pigs", "SPECIES", 14, 18], ["E. coli", "SPECIES", 191, 198], ["piglets", "SPECIES", 294, 301], ["E. coli", "SPECIES", 321, 328], ["pigs", "SPECIES", 14, 18], ["E. coli", "SPECIES", 191, 198], ["E. coli", "SPECIES", 321, 328], ["this study", "TEST", 22, 32], ["this study", "TEST", 83, 93], ["Antimicrobial", "TREATMENT", 127, 140], ["another study", "TEST", 167, 180], ["E. coli", "PROBLEM", 191, 198], ["the F18 antibodies", "TEST", 218, 236], ["diarrhea", "PROBLEM", 265, 273], ["death", "PROBLEM", 278, 283], ["E. coli", "PROBLEM", 321, 328], ["pigs", "OBSERVATION", 14, 18], ["large", "OBSERVATION", 41, 46], ["diarrhea", "OBSERVATION", 265, 273]]], ["Zuniga et al. [35] also reported that weaned pigs fed a basal feed plus 5 % (w/w) egg powder with IgY antibodies against the same fimbrial variant (F18ab or F18ac) were fully protected when the pigs were challenged with F18+ E. coli.Antimicrobial and performance effectsIn addition to reducing the incidence and severity of piglet diarrhea, several studies have shown that IgY has growth promoting effects in early-weaned pigs, similar to spray-dried animal plasma and spray-dried porcine plasma [36] [37] [38] [39] .", [["plasma", "ANATOMY", 458, 464], ["plasma", "ANATOMY", 489, 495], ["piglet diarrhea", "DISEASE", 324, 339], ["pigs", "ORGANISM", 45, 49], ["egg", "ORGANISM", 82, 85], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 98, 112], ["fimbrial", "GENE_OR_GENE_PRODUCT", 130, 138], ["pigs", "ORGANISM", 194, 198], ["E. coli", "ORGANISM", 225, 232], ["piglet", "ORGANISM_SUBDIVISION", 324, 330], ["IgY", "GENE_OR_GENE_PRODUCT", 373, 376], ["pigs", "ORGANISM", 422, 426], ["plasma", "ORGANISM_SUBSTANCE", 458, 464], ["porcine", "ORGANISM", 481, 488], ["plasma", "ORGANISM_SUBSTANCE", 489, 495], ["IgY antibodies", "PROTEIN", 98, 112], ["fimbrial variant", "PROTEIN", 130, 146], ["F18ab", "PROTEIN", 148, 153], ["F18ac", "PROTEIN", 157, 162], ["F18", "PROTEIN", 220, 223], ["IgY", "PROTEIN", 373, 376], ["pigs", "SPECIES", 45, 49], ["pigs", "SPECIES", 194, 198], ["E. coli", "SPECIES", 225, 232], ["pigs", "SPECIES", 422, 426], ["pigs", "SPECIES", 45, 49], ["pigs", "SPECIES", 194, 198], ["E. coli", "SPECIES", 225, 232], ["piglet", "SPECIES", 324, 330], ["pigs", "SPECIES", 422, 426], ["a basal feed", "TREATMENT", 54, 66], ["w/w) egg powder", "TREATMENT", 77, 92], ["IgY antibodies", "TREATMENT", 98, 112], ["E. coli", "PROBLEM", 225, 232], ["Antimicrobial", "TREATMENT", 233, 246], ["piglet diarrhea", "PROBLEM", 324, 339], ["several studies", "TEST", 341, 356], ["dried animal plasma and spray-dried porcine plasma", "TREATMENT", 445, 495], ["coli", "OBSERVATION", 228, 232]]], ["Table 3 shows the results of an experiment where the performance of pigs fed specific anti-K88 antibodies was compared with that of pigs fed diets supplemented with zinc oxide, fumaric acid or antibiotics after oral ETEC K88 challenge [37] .", [["oral", "ANATOMY", 211, 215], ["zinc oxide", "CHEMICAL", 165, 175], ["fumaric acid", "CHEMICAL", 177, 189], ["ETEC K88", "CHEMICAL", 216, 224], ["zinc oxide", "CHEMICAL", 165, 175], ["fumaric acid", "CHEMICAL", 177, 189], ["pigs", "ORGANISM", 68, 72], ["anti-K88 antibodies", "GENE_OR_GENE_PRODUCT", 86, 105], ["pigs", "ORGANISM", 132, 136], ["zinc oxide", "SIMPLE_CHEMICAL", 165, 175], ["fumaric acid", "SIMPLE_CHEMICAL", 177, 189], ["oral", "ORGANISM_SUBDIVISION", 211, 215], ["anti-K88 antibodies", "PROTEIN", 86, 105], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 132, 136], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 132, 136], ["pigs fed specific anti-K88 antibodies", "TREATMENT", 68, 105], ["pigs fed diets", "TREATMENT", 132, 146], ["zinc oxide", "TREATMENT", 165, 175], ["fumaric acid", "TREATMENT", 177, 189], ["antibiotics", "TREATMENT", 193, 204], ["oral ETEC K88 challenge", "TREATMENT", 211, 234]]], ["All four feed additives successfully increased pig performance compared with unsupplemented pigs with significant reductions observed in scour score and piglet mortality.", [["piglet", "ANATOMY", 153, 159], ["pig", "ORGANISM", 47, 50], ["pigs", "ORGANISM", 92, 96], ["piglet", "ORGANISM_SUBDIVISION", 153, 159], ["pig", "SPECIES", 47, 50], ["pigs", "SPECIES", 92, 96], ["pig", "SPECIES", 47, 50], ["pigs", "SPECIES", 92, 96], ["All four feed additives", "TREATMENT", 0, 23], ["increased pig performance", "TREATMENT", 37, 62], ["unsupplemented pigs", "TREATMENT", 77, 96], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["reductions", "OBSERVATION_MODIFIER", 114, 124], ["piglet mortality", "OBSERVATION", 153, 169]]], ["In this experiment, IgY was equal to antibiotics in enhancing pig performance.", [["IgY", "GENE_OR_GENE_PRODUCT", 20, 23], ["pig", "ORGANISM", 62, 65], ["IgY", "PROTEIN", 20, 23], ["pig", "SPECIES", 62, 65], ["pig", "SPECIES", 62, 65], ["antibiotics", "TREATMENT", 37, 48]]], ["Table 4 shows the effects of adding egg yolk containing specific anti-K88 antibodies (EGG), EGG-exchange, or spray dried porcine plasma to a corn-soybean meal-based (CON) diet on performance, plasma urea and weight of pancreas of weaned pigs that were not challenged with ETEC K88 challenge [39] .", [["egg yolk", "ANATOMY", 36, 44], ["plasma", "ANATOMY", 129, 135], ["plasma", "ANATOMY", 192, 198], ["pancreas", "ANATOMY", 218, 226], ["urea", "CHEMICAL", 199, 203], ["ETEC K88", "CHEMICAL", 272, 280], ["urea", "CHEMICAL", 199, 203], ["egg yolk", "ORGANISM_SUBSTANCE", 36, 44], ["anti-K88 antibodies", "GENE_OR_GENE_PRODUCT", 65, 84], ["EGG", "SIMPLE_CHEMICAL", 92, 95], ["porcine", "ORGANISM", 121, 128], ["plasma", "ORGANISM_SUBSTANCE", 129, 135], ["plasma", "ORGANISM_SUBSTANCE", 192, 198], ["urea", "SIMPLE_CHEMICAL", 199, 203], ["pancreas", "ORGAN", 218, 226], ["pigs", "ORGANISM", 237, 241], ["anti-K88 antibodies", "PROTEIN", 65, 84], ["EGG", "PROTEIN", 86, 89], ["porcine", "SPECIES", 121, 128], ["corn-soybean", "SPECIES", 141, 153], ["pigs", "SPECIES", 237, 241], ["porcine", "SPECIES", 121, 128], ["pigs", "SPECIES", 237, 241], ["egg yolk", "TREATMENT", 36, 44], ["specific anti-K88 antibodies", "TREATMENT", 56, 84], ["EGG-exchange", "TREATMENT", 92, 104], ["spray dried porcine plasma", "TREATMENT", 109, 135], ["a corn-soybean meal", "TREATMENT", 139, 158], ["plasma urea", "TEST", 192, 203], ["weaned pigs", "TREATMENT", 230, 241], ["ETEC K88 challenge", "TREATMENT", 272, 290], ["pancreas", "ANATOMY", 218, 226]]], ["The results show that addition of EGG to the CON diets reduced plasma urea nitrogen concentration, and increased feed intake by 23 % and tended to increase weight gain by 28 % in phase II.", [["plasma", "ANATOMY", 63, 69], ["urea nitrogen", "CHEMICAL", 70, 83], ["weight gain", "DISEASE", 156, 167], ["urea", "CHEMICAL", 70, 74], ["nitrogen", "CHEMICAL", 75, 83], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["urea", "SIMPLE_CHEMICAL", 70, 74], ["nitrogen", "SIMPLE_CHEMICAL", 75, 83], ["EGG", "PROBLEM", 34, 37], ["plasma urea nitrogen concentration", "TREATMENT", 63, 97], ["increased feed intake", "TREATMENT", 103, 124]]], ["This study indicates that inclusion of EGG in the diets for pigs immediately after weaning can significantly affect their future growth performance.", [["pigs", "ORGANISM", 60, 64], ["pigs", "SPECIES", 60, 64], ["pigs", "SPECIES", 60, 64], ["This study", "TEST", 0, 10], ["EGG", "TREATMENT", 39, 42]]], ["Unfortunately, limited numbers of pigs were used in this study and a repeat with greater numbers would certainly be welcomed.", [["pigs", "ORGANISM", 34, 38], ["pigs", "SPECIES", 34, 38], ["pigs", "SPECIES", 34, 38], ["pigs", "TREATMENT", 34, 38], ["this study", "TEST", 52, 62], ["a repeat", "TEST", 67, 75]]], ["Although adhesin-mediated colonization is a precondition for ETEC pathogenesis, enterotoxins are thought to be the central virulence determinants leading to diarrhea diseases and may also play a role in the colonization process [30, 40, 41] .", [["diarrhea", "DISEASE", 157, 165], ["adhesin", "GENE_OR_GENE_PRODUCT", 9, 16], ["ETEC", "GENE_OR_GENE_PRODUCT", 61, 65], ["adhesin", "PROTEIN", 9, 16], ["enterotoxins", "PROTEIN", 80, 92], ["ETEC", "SPECIES", 61, 65], ["adhesin-mediated colonization", "PROBLEM", 9, 38], ["ETEC pathogenesis", "PROBLEM", 61, 78], ["enterotoxins", "PROBLEM", 80, 92], ["diarrhea diseases", "PROBLEM", 157, 174], ["colonization", "OBSERVATION", 26, 38], ["thought to be", "UNCERTAINTY", 97, 110], ["diarrhea", "OBSERVATION", 157, 165]]], ["Therefore, the ideal protective agent against ETEC infection should include protection against both adhesin antigens and enterotoxins [30] .", [["ETEC", "CHEMICAL", 46, 50], ["infection", "DISEASE", 51, 60], ["ETEC", "ORGANISM", 46, 50], ["adhesin antigens", "GENE_OR_GENE_PRODUCT", 100, 116], ["adhesin antigens", "PROTEIN", 100, 116], ["enterotoxins", "PROTEIN", 121, 133], ["ETEC", "SPECIES", 46, 50], ["the ideal protective agent", "TREATMENT", 11, 37], ["ETEC infection", "PROBLEM", 46, 60], ["protection", "TREATMENT", 76, 86], ["enterotoxins", "PROBLEM", 121, 133]]], ["In contrast with LTB and STa, enterotoxins STa and STb are poorly immunogenic because of their small size, but they can attain immunogenicity when coupled chemically or genetically to an appropriate carrier [42, 43] .", [["STa", "CHEMICAL", 43, 46], ["STb", "CHEMICAL", 51, 54], ["LTB", "GENE_OR_GENE_PRODUCT", 17, 20], ["STa", "GENE_OR_GENE_PRODUCT", 25, 28], ["STa", "GENE_OR_GENE_PRODUCT", 43, 46], ["STb", "SIMPLE_CHEMICAL", 51, 54], ["LTB", "PROTEIN", 17, 20], ["STa", "PROTEIN", 25, 28], ["enterotoxins", "PROTEIN", 30, 42], ["STb", "PROTEIN", 51, 54], ["LTB", "TREATMENT", 17, 20], ["enterotoxins STa", "PROBLEM", 30, 46], ["STb", "PROBLEM", 51, 54], ["LTB", "ANATOMY", 17, 20], ["STa", "ANATOMY", 25, 28], ["small", "OBSERVATION_MODIFIER", 95, 100], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["In order to make useful toxoids, we constructed polyvalent enterotoxin STa-LTB-STb DNA and protein vaccines endowing immunogenicity to both STa and STb [44] .", [["STa", "CHEMICAL", 71, 74], ["STa", "GENE_OR_GENE_PRODUCT", 71, 74], ["STb", "ORGANISM", 79, 82], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["STa", "GENE_OR_GENE_PRODUCT", 140, 143], ["polyvalent enterotoxin STa-LTB-STb DNA", "DNA", 48, 86], ["useful toxoids", "TREATMENT", 17, 31], ["polyvalent enterotoxin STa", "TREATMENT", 48, 74], ["LTB", "PROBLEM", 75, 78], ["STb DNA", "TREATMENT", 79, 86], ["protein vaccines", "TREATMENT", 91, 107]]], ["Laying hens were immunized with DNA vaccines and obtained antitoxic antibodies from egg yolks and this was confirmed by indirect ELISA.", [["egg yolks", "ANATOMY", 84, 93], ["hens", "ORGANISM", 7, 11], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["egg yolks", "ORGANISM_SUBSTANCE", 84, 93], ["antitoxic antibodies", "PROTEIN", 58, 78], ["DNA vaccines", "TREATMENT", 32, 44], ["antitoxic antibodies", "TREATMENT", 58, 78], ["egg yolks", "TREATMENT", 84, 93]]], ["The polyvalent DNA vaccine pCI-STa-LTB-STb expressed the STa-LTB-STb fusion peptide in vitro in cultured Hela cells.", [["Hela cells", "ANATOMY", 105, 115], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["STa", "GENE_OR_GENE_PRODUCT", 57, 60], ["LTB", "GENE_OR_GENE_PRODUCT", 61, 64], ["STb", "GENE_OR_GENE_PRODUCT", 65, 68], ["Hela cells", "CELL", 105, 115], ["pCI", "PROTEIN", 27, 30], ["STa-LTB", "DNA", 31, 38], ["STb", "DNA", 39, 42], ["STa", "PROTEIN", 57, 60], ["LTB", "PROTEIN", 61, 64], ["STb", "PROTEIN", 65, 68], ["cultured Hela cells", "CELL_LINE", 96, 115], ["The polyvalent DNA vaccine pCI", "TREATMENT", 0, 30], ["STa-LTB", "TEST", 31, 38], ["STb", "PROBLEM", 39, 42], ["the STa", "TEST", 53, 60], ["LTB", "PROBLEM", 61, 64], ["STb fusion peptide", "TREATMENT", 65, 83], ["vitro in cultured Hela cells", "TREATMENT", 87, 115], ["LTB", "ANATOMY", 61, 64], ["Hela cells", "OBSERVATION", 105, 115]]], ["These egg yolk antibodies were able to neutralize the natural toxicity of STa and LTb with the highest dilution of 1/2 and 1/32 in a suckling mouse assay [45] .", [["egg yolk", "ANATOMY", 6, 14], ["toxicity", "DISEASE", 62, 70], ["STa", "CHEMICAL", 74, 77], ["egg yolk", "ORGANISM_SUBSTANCE", 6, 14], ["STa", "SIMPLE_CHEMICAL", 74, 77], ["LTb", "SIMPLE_CHEMICAL", 82, 85], ["mouse", "ORGANISM", 142, 147], ["egg yolk antibodies", "PROTEIN", 6, 25], ["mouse", "SPECIES", 142, 147], ["mouse", "SPECIES", 142, 147], ["These egg yolk antibodies", "TEST", 0, 25], ["the highest dilution", "TEST", 91, 111]]], ["These results indicate that the recombinant STa-LTB-STb protein has the potential to serve as an effective and convenient polyvalent toxoid which can provide broad protection against ETECinduced diarrhea.", [["STa", "CHEMICAL", 44, 47], ["diarrhea", "DISEASE", 195, 203], ["STa", "GENE_OR_GENE_PRODUCT", 44, 47], ["LTB", "GENE_OR_GENE_PRODUCT", 48, 51], ["STb", "GENE_OR_GENE_PRODUCT", 52, 55], ["STa", "PROTEIN", 44, 47], ["LTB", "PROTEIN", 48, 51], ["STb protein", "PROTEIN", 52, 63], ["the recombinant STa", "TEST", 28, 47], ["STb protein", "PROBLEM", 52, 63], ["convenient polyvalent toxoid", "TREATMENT", 111, 139], ["ETECinduced diarrhea", "PROBLEM", 183, 203]]], ["This study was conducted with mice and a piglet study should be conducted to confirm these findings.SalmonellaSalmonella infection has been recognized as one of the most common foodborne diseases in humans, causing 1.4 million cases with an estimated economic impact of $2.4 billion each year in the United States [46, 47] .", [["SalmonellaSalmonella infection", "DISEASE", 100, 130], ["foodborne diseases", "DISEASE", 177, 195], ["mice", "ORGANISM", 30, 34], ["piglet", "ORGANISM", 41, 47], ["humans", "ORGANISM", 199, 205], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 199, 205], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 199, 205], ["This study", "TEST", 0, 10], ["a piglet study", "TEST", 39, 53], ["SalmonellaSalmonella infection", "PROBLEM", 100, 130], ["infection", "OBSERVATION", 121, 130], ["most common", "OBSERVATION_MODIFIER", 165, 176], ["foodborne", "OBSERVATION_MODIFIER", 177, 186], ["diseases", "OBSERVATION", 187, 195]]], ["This disease can occur via foodborne transmission, animal contact, or environmental spread [48, 49] , and farm Owusu-Asiedu et al. [37] animals are the most likely source of human salmonellosis [50, 51] .", [["salmonellosis", "DISEASE", 180, 193], ["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["This disease", "PROBLEM", 0, 12], ["human salmonellosis", "PROBLEM", 174, 193], ["most likely", "UNCERTAINTY", 152, 163], ["salmonellosis", "OBSERVATION", 180, 193]]], ["Therefore, it is important to control this disease, not only to reduce productive losses in domestic livestock, but also to prevent its transmission into the human food chain.", [["human", "ORGANISM", 158, 163], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163], ["this disease", "PROBLEM", 38, 50], ["productive losses in domestic livestock", "PROBLEM", 71, 110]]], ["Salmonella species, S. enteritidis and S. typhimurium, in particular, are thought to be the major agents of human salmonellosis [46] .", [["S. enteritidis", "DISEASE", 20, 34], ["salmonellosis", "DISEASE", 114, 127], ["Salmonella species", "ORGANISM", 0, 18], ["S. enteritidis", "ORGANISM", 20, 34], ["S. typhimurium", "ORGANISM", 39, 53], ["human", "ORGANISM", 108, 113], ["S. enteritidis", "SPECIES", 20, 34], ["S. typhimurium", "SPECIES", 39, 53], ["human", "SPECIES", 108, 113], ["S. enteritidis", "SPECIES", 20, 34], ["S. typhimurium", "SPECIES", 39, 53], ["human", "SPECIES", 108, 113], ["Salmonella species", "PROBLEM", 0, 18], ["S. enteritidis", "PROBLEM", 20, 34], ["S. typhimurium", "PROBLEM", 39, 53], ["human salmonellosis", "PROBLEM", 108, 127], ["thought to be", "UNCERTAINTY", 74, 87]]], ["They are non-host serotypes which can cause disease syndromes like gastroenteritis and systemic infectious in a wide range of animal species, including humans.", [["gastroenteritis", "DISEASE", 67, 82], ["humans", "ORGANISM", 152, 158], ["humans", "SPECIES", 152, 158], ["humans", "SPECIES", 152, 158], ["non-host serotypes", "PROBLEM", 9, 27], ["disease syndromes", "PROBLEM", 44, 61], ["gastroenteritis", "PROBLEM", 67, 82], ["systemic infectious", "PROBLEM", 87, 106], ["animal species", "PROBLEM", 126, 140], ["non-host serotypes", "OBSERVATION", 9, 27], ["gastroenteritis", "OBSERVATION", 67, 82], ["systemic", "OBSERVATION_MODIFIER", 87, 95], ["infectious", "OBSERVATION_MODIFIER", 96, 106], ["wide range", "OBSERVATION_MODIFIER", 112, 122], ["animal species", "OBSERVATION", 126, 140]]], ["Studies by Yokoyama et al. [52] investigated the efficacy of IgY antibodies specific for outer membrane protein (OMP), lipopolysaccharide (LPS), or flagella (Fla) for controlling S. typhimurium or S. enteritidis.", [["outer membrane", "ANATOMY", 89, 103], ["lipopolysaccharide", "CHEMICAL", 119, 137], ["LPS", "CHEMICAL", 139, 142], ["Fla", "CHEMICAL", 158, 161], ["S. enteritidis", "DISEASE", 197, 211], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 61, 75], ["outer membrane protein", "GENE_OR_GENE_PRODUCT", 89, 111], ["OMP", "GENE_OR_GENE_PRODUCT", 113, 116], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 119, 137], ["LPS", "SIMPLE_CHEMICAL", 139, 142], ["Fla", "GENE_OR_GENE_PRODUCT", 158, 161], ["S. typhimurium", "ORGANISM", 179, 193], ["S. enteritidis", "ORGANISM", 197, 211], ["IgY antibodies", "PROTEIN", 61, 75], ["outer membrane protein", "PROTEIN", 89, 111], ["OMP", "PROTEIN", 113, 116], ["S. typhimurium", "SPECIES", 179, 193], ["S. enteritidis", "SPECIES", 197, 211], ["S. typhimurium", "SPECIES", 179, 193], ["S. enteritidis", "SPECIES", 197, 211], ["IgY antibodies", "TEST", 61, 75], ["outer membrane protein", "TEST", 89, 111], ["lipopolysaccharide (LPS)", "TREATMENT", 119, 143], ["flagella", "PROBLEM", 148, 156], ["S. typhimurium", "PROBLEM", 179, 193], ["S. enteritidis", "PROBLEM", 197, 211], ["enteritidis", "OBSERVATION", 200, 211]]], ["They treated mice orally with an appropriate placebo or purified IgY following a challenge with S. enteritidis.", [["S. enteritidis", "DISEASE", 96, 110], ["mice", "ORGANISM", 13, 17], ["IgY", "GENE_OR_GENE_PRODUCT", 65, 68], ["S. enteritidis", "ORGANISM", 96, 110], ["purified IgY", "PROTEIN", 56, 68], ["mice", "SPECIES", 13, 17], ["S. enteritidis", "SPECIES", 96, 110], ["mice", "SPECIES", 13, 17], ["S. enteritidis", "SPECIES", 96, 110], ["an appropriate placebo", "TREATMENT", 30, 52], ["S. enteritidis", "PROBLEM", 96, 110], ["enteritidis", "OBSERVATION", 99, 110]]], ["Antibody treatment resulted in survival rates of 80, 47 and 60 % using OMP-, LPS-, and Fla-specific antibodies, in contrast to survival rates of only 20 % in control mice.", [["OMP", "SIMPLE_CHEMICAL", 71, 74], ["LPS", "SIMPLE_CHEMICAL", 77, 80], ["mice", "ORGANISM", 166, 170], ["OMP", "PROTEIN", 71, 74], ["Fla-specific antibodies", "PROTEIN", 87, 110], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 166, 170], ["Antibody treatment", "TREATMENT", 0, 18], ["survival rates", "TEST", 31, 45], ["OMP", "TEST", 71, 74], ["LPS", "TEST", 77, 80], ["Fla-specific antibodies", "TEST", 87, 110], ["survival rates", "TEST", 127, 141]]], ["In the S. typhimurium trial, the survival rate was 40, 30 and 20 % using OMP-, LPS-, or Fla-specific antibodies, in contrast to 0 % in the control mice.", [["LPS", "CHEMICAL", 79, 82], ["S. typhimurium", "ORGANISM", 7, 21], ["OMP", "SIMPLE_CHEMICAL", 73, 76], ["LPS", "SIMPLE_CHEMICAL", 79, 82], ["mice", "ORGANISM", 147, 151], ["OMP", "PROTEIN", 73, 76], ["Fla-specific antibodies", "PROTEIN", 88, 111], ["S. typhimurium", "SPECIES", 7, 21], ["mice", "SPECIES", 147, 151], ["S. typhimurium", "SPECIES", 7, 21], ["mice", "SPECIES", 147, 151], ["the survival rate", "TEST", 29, 46], ["OMP", "TEST", 73, 76], ["LPS", "TEST", 79, 82], ["Fla-specific antibodies", "TEST", 88, 111]]], ["These preliminary results suggest that antibodies against specific Salmonella proteins can control salmonellosis when orally administrated to mice.SalmonellaStudies with pigs have been reported [53, 54] .", [["salmonellosis", "DISEASE", 99, 112], ["mice", "ORGANISM", 142, 146], ["pigs", "ORGANISM", 170, 174], ["antibodies", "PROTEIN", 39, 49], ["Salmonella proteins", "PROTEIN", 67, 86], ["mice", "SPECIES", 142, 146], ["pigs", "SPECIES", 170, 174], ["Salmonella", "SPECIES", 67, 77], ["salmonellosis", "SPECIES", 99, 112], ["mice", "SPECIES", 142, 146], ["antibodies", "TREATMENT", 39, 49], ["specific Salmonella proteins", "PROBLEM", 58, 86], ["salmonellosis", "PROBLEM", 99, 112], ["SalmonellaStudies", "TREATMENT", 147, 164], ["pigs", "TREATMENT", 170, 174]]], ["Unfortunately, reports where similar benefits of IgY to those found in mice were not obtained with pigs.", [["IgY", "GENE_OR_GENE_PRODUCT", 49, 52], ["mice", "ORGANISM", 71, 75], ["pigs", "ORGANISM", 99, 103], ["IgY", "PROTEIN", 49, 52], ["mice", "SPECIES", 71, 75], ["pigs", "SPECIES", 99, 103], ["mice", "SPECIES", 71, 75], ["pigs", "SPECIES", 99, 103], ["IgY", "TREATMENT", 49, 52]]], ["Mathew et al. [53] found that feeding egg yolk powder containing anti-Salmonella IgY antibodies may not be particularly effective in reducing Salmonella shedding in pigs.", [["egg yolk", "ANATOMY", 38, 46], ["egg yolk powder", "ORGANISM_SUBSTANCE", 38, 53], ["pigs", "ORGANISM", 165, 169], ["anti-Salmonella IgY antibodies", "PROTEIN", 65, 95], ["pigs", "SPECIES", 165, 169], ["Salmonella", "SPECIES", 142, 152], ["pigs", "SPECIES", 165, 169], ["feeding egg yolk powder", "TREATMENT", 30, 53], ["anti-Salmonella IgY antibodies", "TREATMENT", 65, 95]]], ["In this experiment, specific egg yolk powder derived from chickens challenged with purified Salmonella typhimurium antigens (fimbrial protein, OMP, and LPS) was included in swine feed.", [["egg yolk", "ANATOMY", 29, 37], ["LPS", "CHEMICAL", 152, 155], ["egg yolk powder", "ORGANISM_SUBSTANCE", 29, 44], ["chickens", "ORGANISM", 58, 66], ["Salmonella typhimurium antigens", "ORGANISM", 92, 123], ["fimbrial protein", "GENE_OR_GENE_PRODUCT", 125, 141], ["OMP", "GENE_OR_GENE_PRODUCT", 143, 146], ["LPS", "SIMPLE_CHEMICAL", 152, 155], ["swine", "ORGANISM", 173, 178], ["purified Salmonella typhimurium antigens", "PROTEIN", 83, 123], ["fimbrial protein", "PROTEIN", 125, 141], ["OMP", "PROTEIN", 143, 146], ["chickens", "SPECIES", 58, 66], ["Salmonella typhimurium", "SPECIES", 92, 114], ["swine", "SPECIES", 173, 178], ["chickens", "SPECIES", 58, 66], ["Salmonella typhimurium", "SPECIES", 92, 114], ["swine", "SPECIES", 173, 178], ["specific egg yolk powder", "TREATMENT", 20, 44], ["purified Salmonella typhimurium antigens", "TREATMENT", 83, 123]]], ["Treatments were provided beginning on day 3 of the experiment, and all pigs were challenged with Salmonella typhimurium on day 7.", [["pigs", "ORGANISM", 71, 75], ["Salmonella typhimurium", "ORGANISM", 97, 119], ["pigs", "SPECIES", 71, 75], ["Salmonella typhimurium", "SPECIES", 97, 119], ["pigs", "SPECIES", 71, 75], ["Salmonella typhimurium", "SPECIES", 97, 119], ["Treatments", "TREATMENT", 0, 10], ["all pigs", "TREATMENT", 67, 75], ["Salmonella typhimurium", "TREATMENT", 97, 119]]], ["Fecal samples were collected on days 0, 7, 8, 12, 14, 21, 58, 88, and 118 to determine shedding of Salmonella.", [["Fecal samples", "ANATOMY", 0, 13], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Salmonella", "SPECIES", 99, 109], ["Fecal samples", "TEST", 0, 13], ["Salmonella", "PROBLEM", 99, 109], ["Salmonella", "OBSERVATION", 99, 109]]], ["The results showed that in-feed IgY antibodies did not diminish the shedding of Salmonella, and was inferior to antibiotic treatment.", [["IgY antibodies", "PROTEIN", 32, 46], ["Salmonella", "SPECIES", 80, 90], ["Salmonella", "PROBLEM", 80, 90], ["antibiotic treatment", "TREATMENT", 112, 132]]], ["The failure of IgY to improve performance is suspected to be due to the fact that the invasive nature of Salmonella allowed the organism to by-pass the gut and the dietary treatments by moving through vascular and/or lymphatic routes directly into the colon [55] [56] [57] .", [["gut", "ANATOMY", 152, 155], ["vascular", "ANATOMY", 201, 209], ["lymphatic", "ANATOMY", 217, 226], ["colon", "ANATOMY", 252, 257], ["IgY", "GENE_OR_GENE_PRODUCT", 15, 18], ["gut", "ORGANISM_SUBDIVISION", 152, 155], ["vascular", "MULTI-TISSUE_STRUCTURE", 201, 209], ["lymphatic routes", "MULTI-TISSUE_STRUCTURE", 217, 233], ["colon", "ORGAN", 252, 257], ["IgY", "PROTEIN", 15, 18], ["Salmonella", "SPECIES", 105, 115], ["The failure of IgY", "PROBLEM", 0, 18], ["Salmonella", "PROBLEM", 105, 115], ["the dietary treatments", "TREATMENT", 160, 182], ["failure", "OBSERVATION", 4, 11], ["invasive", "OBSERVATION_MODIFIER", 86, 94], ["vascular", "ANATOMY", 201, 209], ["colon", "ANATOMY", 252, 257]]], ["However, available data are still too limited to allow reliable conclusions regarding the possible efficacy of IgY to control Salmonella infection in swine.Porcine transmissible gastroenteritis virusPorcine transmissible gastroenteritis virus (TGEV), a porcine coronavirus, can cause a highly contagious enteric infection in swine of all ages [58] .", [["Salmonella infection", "DISEASE", 126, 146], ["transmissible gastroenteritis", "DISEASE", 164, 193], ["transmissible gastroenteritis", "DISEASE", 207, 236], ["TGEV", "DISEASE", 244, 248], ["porcine coronavirus", "DISEASE", 253, 272], ["enteric infection", "DISEASE", 304, 321], ["IgY", "GENE_OR_GENE_PRODUCT", 111, 114], ["swine", "ORGANISM", 150, 155], ["Porcine transmissible gastroenteritis virusPorcine transmissible gastroenteritis virus", "ORGANISM", 156, 242], ["TGEV", "ORGANISM", 244, 248], ["porcine coronavirus", "ORGANISM", 253, 272], ["IgY", "PROTEIN", 111, 114], ["swine", "SPECIES", 150, 155], ["Porcine", "SPECIES", 156, 163], ["transmissible gastroenteritis virus", "SPECIES", 207, 242], ["TGEV", "SPECIES", 244, 248], ["porcine coronavirus", "SPECIES", 253, 272], ["swine", "SPECIES", 325, 330], ["Salmonella", "SPECIES", 126, 136], ["swine", "SPECIES", 150, 155], ["Porcine transmissible gastroenteritis virusPorcine transmissible gastroenteritis virus", "SPECIES", 156, 242], ["TGEV", "SPECIES", 244, 248], ["porcine coronavirus", "SPECIES", 253, 272], ["swine", "SPECIES", 325, 330], ["IgY", "TREATMENT", 111, 114], ["Salmonella infection", "PROBLEM", 126, 146], ["Porcine transmissible gastroenteritis virusPorcine transmissible gastroenteritis virus", "PROBLEM", 156, 242], ["a porcine coronavirus", "PROBLEM", 251, 272], ["a highly contagious enteric infection", "PROBLEM", 284, 321], ["infection", "OBSERVATION", 137, 146], ["transmissible", "OBSERVATION_MODIFIER", 164, 177], ["gastroenteritis", "OBSERVATION", 178, 193], ["porcine coronavirus", "OBSERVATION", 253, 272], ["highly", "OBSERVATION_MODIFIER", 286, 292], ["contagious", "OBSERVATION_MODIFIER", 293, 303], ["infection", "OBSERVATION", 312, 321]]], ["The infected piglets develop significant clinical signs, including vomiting, emaciation and severe diarrhea.", [["vomiting", "DISEASE", 67, 75], ["emaciation", "DISEASE", 77, 87], ["diarrhea", "DISEASE", 99, 107], ["piglets", "ORGANISM", 13, 20], ["piglets", "SPECIES", 13, 20], ["The infected piglets", "PROBLEM", 0, 20], ["significant clinical signs", "PROBLEM", 29, 55], ["vomiting", "PROBLEM", 67, 75], ["emaciation", "PROBLEM", 77, 87], ["severe diarrhea", "PROBLEM", 92, 107], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["diarrhea", "OBSERVATION", 99, 107]]], ["The disease is especially severe in the animals less than 2 weeks old with a mortality of nearly 100 % [59, 60] .", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["severe", "OBSERVATION_MODIFIER", 26, 32]]], ["With the lack of successful vaccines to prevent a TGE outbreak, the disease occurs frequently in swine farms.", [["TGE", "DISEASE", 50, 53], ["swine", "SPECIES", 97, 102], ["swine", "SPECIES", 97, 102], ["successful vaccines", "TREATMENT", 17, 36], ["a TGE outbreak", "PROBLEM", 48, 62], ["the disease", "PROBLEM", 64, 75], ["disease", "OBSERVATION", 68, 75]]], ["It has been shown that specific IgY has great potential as an alternative prophylactic approach like colostral antibodies against TGEV [61, 62] .", [["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["colostral", "ORGANISM", 101, 110], ["TGEV", "ORGANISM", 130, 134], ["IgY", "PROTEIN", 32, 35], ["colostral antibodies", "PROTEIN", 101, 121], ["TGEV", "SPECIES", 130, 134], ["an alternative prophylactic approach", "TREATMENT", 59, 95], ["colostral antibodies", "TEST", 101, 121], ["TGEV", "PROBLEM", 130, 134]]], ["In a prophylactic efficacy experiment, oral administration with IgY significantly increased newborn piglet survival rate (87.5 %) after challenge exposure compared with the control (43 %), whereas the therapeutic effects demonstrate that mortality was dramatically reduced by orally administered IgY in two farms that showed TGEV positive results [61] .", [["oral", "ANATOMY", 39, 43], ["piglet", "ANATOMY", 100, 106], ["oral", "ORGANISM_SUBDIVISION", 39, 43], ["IgY", "GENE_OR_GENE_PRODUCT", 64, 67], ["piglet", "ORGAN", 100, 106], ["IgY", "GENE_OR_GENE_PRODUCT", 296, 299], ["TGEV", "ORGANISM", 325, 329], ["IgY", "PROTEIN", 64, 67], ["IgY", "PROTEIN", 296, 299], ["TGEV", "SPECIES", 325, 329], ["a prophylactic efficacy experiment", "TREATMENT", 3, 37], ["oral administration", "TREATMENT", 39, 58], ["challenge exposure", "TREATMENT", 136, 154], ["TGEV positive results", "PROBLEM", 325, 346]]], ["Unfortunately, piglet performance was not monitored in this study.Porcine epidemic diarrhea virusPorcine epidemic diarrhea virus (PEDV) is another important enteric viral pathogen that is responsible for neonatal piglet diarrhea [63, 64] .", [["piglet", "ANATOMY", 15, 21], ["piglet", "ANATOMY", 213, 219], ["diarrhea virusPorcine epidemic diarrhea", "DISEASE", 83, 122], ["piglet diarrhea", "DISEASE", 213, 228], ["piglet", "ORGAN", 15, 21], ["Porcine epidemic diarrhea virusPorcine epidemic diarrhea virus", "ORGANISM", 66, 128], ["piglet", "ORGANISM_SUBDIVISION", 213, 219], ["Porcine", "SPECIES", 66, 73], ["diarrhea virusPorcine epidemic diarrhea virus", "SPECIES", 83, 128], ["Porcine epidemic diarrhea virusPorcine epidemic diarrhea virus", "SPECIES", 66, 128], ["PEDV", "SPECIES", 130, 134], ["piglet performance", "TEST", 15, 33], ["this study", "TEST", 55, 65], ["Porcine epidemic diarrhea", "PROBLEM", 66, 91], ["virusPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 92, 134], ["another important enteric viral pathogen", "PROBLEM", 139, 179], ["neonatal piglet diarrhea", "PROBLEM", 204, 228], ["viral pathogen", "OBSERVATION", 165, 179]]], ["Although the clinical symptoms of PEDV infection are similar to TGEV infection, PEDV is antigenically different from TGEV.", [["infection", "DISEASE", 39, 48], ["TGEV infection", "DISEASE", 64, 78], ["PEDV", "ORGANISM", 34, 38], ["TGEV", "ORGANISM", 64, 68], ["PEDV", "GENE_OR_GENE_PRODUCT", 80, 84], ["TGEV", "ORGANISM", 117, 121], ["PEDV", "SPECIES", 34, 38], ["TGEV", "SPECIES", 64, 68], ["PEDV", "SPECIES", 80, 84], ["TGEV", "SPECIES", 117, 121], ["the clinical symptoms", "PROBLEM", 9, 30], ["PEDV infection", "PROBLEM", 34, 48], ["TGEV infection", "PROBLEM", 64, 78], ["PEDV", "PROBLEM", 80, 84], ["infection", "OBSERVATION", 39, 48], ["TGEV", "OBSERVATION_MODIFIER", 64, 68], ["infection", "OBSERVATION", 69, 78]]], ["Epidemiological observations have indicated that the spread of disease seems to be slower, but rather persistent compared with a TGEV outbreak [65] .", [["TGEV", "DISEASE", 129, 133], ["TGEV", "SPECIES", 129, 133], ["Epidemiological observations", "TEST", 0, 28], ["the spread of disease", "PROBLEM", 49, 70], ["slower", "OBSERVATION_MODIFIER", 83, 89], ["persistent", "OBSERVATION_MODIFIER", 102, 112]]], ["It has been shown that IgY can be an alternative method for conferring protection in piglets against PEDV [62, 66, 67] .", [["PEDV", "CHEMICAL", 101, 105], ["IgY", "GENE_OR_GENE_PRODUCT", 23, 26], ["piglets", "ORGANISM", 85, 92], ["IgY", "PROTEIN", 23, 26], ["piglets", "SPECIES", 85, 92], ["piglets", "SPECIES", 85, 92], ["PEDV", "SPECIES", 101, 105], ["an alternative method", "TREATMENT", 34, 55], ["PEDV", "PROBLEM", 101, 105]]], ["IgY was found to reduce mortality in piglets after challenge exposures.", [["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["piglets", "ORGANISM", 37, 44], ["IgY", "PROTEIN", 0, 3], ["piglets", "SPECIES", 37, 44]]], ["The field application of IgY from three farms also revealed the survival rate was increased significantly in pigs treated with IgY (49.24 %) compared with a control group (33.71 %).RotavirusRotavirus is a major pathogen of infectious gastroenteritis, not only in children and infants, but also in domestic animals.", [["RotavirusRotavirus", "CHEMICAL", 181, 199], ["infectious gastroenteritis", "DISEASE", 223, 249], ["IgY", "GENE_OR_GENE_PRODUCT", 25, 28], ["pigs", "ORGANISM", 109, 113], ["IgY", "GENE_OR_GENE_PRODUCT", 127, 130], ["children", "ORGANISM", 263, 271], ["infants", "ORGANISM", 276, 283], ["IgY", "PROTEIN", 25, 28], ["IgY", "PROTEIN", 127, 130], ["pigs", "SPECIES", 109, 113], ["children", "SPECIES", 263, 271], ["infants", "SPECIES", 276, 283], ["pigs", "SPECIES", 109, 113], ["the survival rate", "TEST", 60, 77], ["IgY", "TREATMENT", 127, 130], ["infectious gastroenteritis", "PROBLEM", 223, 249], ["major", "OBSERVATION_MODIFIER", 205, 210], ["pathogen", "OBSERVATION_MODIFIER", 211, 219], ["infectious", "OBSERVATION_MODIFIER", 223, 233], ["gastroenteritis", "OBSERVATION", 234, 249]]], ["In humans alone, it has been estimated that rotavirus infections result in several million deaths each year [68] .", [["rotavirus infections", "DISEASE", 44, 64], ["deaths", "DISEASE", 91, 97], ["humans", "ORGANISM", 3, 9], ["rotavirus", "ORGANISM", 44, 53], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["rotavirus", "SPECIES", 44, 53], ["rotavirus infections", "PROBLEM", 44, 64], ["rotavirus", "OBSERVATION_MODIFIER", 44, 53], ["infections", "OBSERVATION", 54, 64]]], ["Animals are also seriously affected by this virus.", [["Animals", "ORGANISM", 0, 7], ["this virus", "PROBLEM", 39, 49]]], ["Rotavirus from calves, pigs, mice, foals, infant humans, lambs, chickens, and turkey are antigenically related [69] .", [["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["calves", "ORGANISM", 15, 21], ["pigs", "ORGANISM", 23, 27], ["mice", "ORGANISM", 29, 33], ["foals", "ORGANISM", 35, 40], ["humans", "ORGANISM", 49, 55], ["lambs", "ORGANISM", 57, 62], ["chickens", "ORGANISM", 64, 72], ["turkey", "ORGANISM", 78, 84], ["calves", "SPECIES", 15, 21], ["pigs", "SPECIES", 23, 27], ["mice", "SPECIES", 29, 33], ["foals", "SPECIES", 35, 40], ["infant", "SPECIES", 42, 48], ["humans", "SPECIES", 49, 55], ["lambs", "SPECIES", 57, 62], ["chickens", "SPECIES", 64, 72], ["turkey", "SPECIES", 78, 84], ["pigs", "SPECIES", 23, 27], ["mice", "SPECIES", 29, 33], ["humans", "SPECIES", 49, 55], ["chickens", "SPECIES", 64, 72], ["turkey", "SPECIES", 78, 84], ["Rotavirus", "PROBLEM", 0, 9]]], ["Therefore, the appropriate anti-rotavirus antibodies will react with the virus present in any of these species.", [["anti-rotavirus antibodies", "PROTEIN", 27, 52], ["anti-rotavirus", "SPECIES", 27, 41], ["the appropriate anti-rotavirus antibodies", "TREATMENT", 11, 52], ["the virus", "PROBLEM", 69, 78]]], ["IgY has been shown to successfully control intestinal infection of rotavirus in newborn calves and mice [70] [71] [72] [73] .", [["intestinal", "ANATOMY", 43, 53], ["intestinal infection", "DISEASE", 43, 63], ["rotavirus", "DISEASE", 67, 76], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["intestinal", "ORGAN", 43, 53], ["rotavirus", "ORGANISM", 67, 76], ["calves", "ORGANISM", 88, 94], ["mice", "ORGANISM", 99, 103], ["IgY", "PROTEIN", 0, 3], ["calves", "SPECIES", 88, 94], ["mice", "SPECIES", 99, 103], ["rotavirus", "SPECIES", 67, 76], ["mice", "SPECIES", 99, 103], ["intestinal infection of rotavirus", "PROBLEM", 43, 76], ["intestinal", "ANATOMY", 43, 53], ["infection", "OBSERVATION", 54, 63]]], ["Studies with pigs have been reported and similar positive results were obtained [74] .", [["pigs", "ORGANISM", 13, 17], ["pigs", "SPECIES", 13, 17], ["pigs", "SPECIES", 13, 17]]], ["A passive treatment based on human rotavirus specific IgY antibodies not only prevented gnotobiotic piglets from developing diarrhea caused by the prevalent strain of Wa G1P [8] HRV, but also significantly reduced the amount of infectious virus shed compared with a negative control group.Current challengesThere are many obstacles that can limit the use of IgY for the control of diarrhea diseases in swine.", [["diarrhea", "DISEASE", 124, 132], ["diarrhea diseases", "DISEASE", 381, 398], ["human", "ORGANISM", 29, 34], ["rotavirus", "ORGANISM", 35, 44], ["IgY", "GENE_OR_GENE_PRODUCT", 54, 57], ["gnotobiotic piglets", "ORGANISM", 88, 107], ["IgY", "GENE_OR_GENE_PRODUCT", 358, 361], ["swine", "ORGANISM", 402, 407], ["human rotavirus specific IgY antibodies", "PROTEIN", 29, 68], ["IgY", "PROTEIN", 358, 361], ["human", "SPECIES", 29, 34], ["piglets", "SPECIES", 100, 107], ["swine", "SPECIES", 402, 407], ["human", "SPECIES", 29, 34], ["rotavirus", "SPECIES", 35, 44], ["piglets", "SPECIES", 100, 107], ["swine", "SPECIES", 402, 407], ["A passive treatment", "TREATMENT", 0, 19], ["human rotavirus specific IgY antibodies", "TREATMENT", 29, 68], ["gnotobiotic piglets", "PROBLEM", 88, 107], ["developing diarrhea", "PROBLEM", 113, 132], ["HRV", "PROBLEM", 178, 181], ["infectious virus", "PROBLEM", 228, 244], ["Current challenges", "TREATMENT", 289, 307], ["IgY", "TREATMENT", 358, 361], ["diarrhea diseases", "PROBLEM", 381, 398], ["diarrhea", "OBSERVATION", 124, 132], ["amount", "OBSERVATION_MODIFIER", 218, 224], ["infectious", "OBSERVATION", 228, 238], ["many", "OBSERVATION_MODIFIER", 317, 321], ["obstacles", "OBSERVATION", 322, 331]]], ["The most important issues which need to be addressed are as follows.Current challengesThe stability of IgY in the gastrointestinal tract when they are fed to swine Although the beneficial effects of pathogen-specific IgY in animals have been known for about 20 years, results on the experimental application of these antibodies in swine have not always been consistent.", [["gastrointestinal tract", "ANATOMY", 114, 136], ["IgY", "GENE_OR_GENE_PRODUCT", 103, 106], ["gastrointestinal tract", "ORGAN", 114, 136], ["IgY", "GENE_OR_GENE_PRODUCT", 217, 220], ["swine", "ORGANISM", 331, 336], ["IgY", "PROTEIN", 103, 106], ["IgY", "PROTEIN", 217, 220], ["antibodies", "PROTEIN", 317, 327], ["swine", "SPECIES", 158, 163], ["swine", "SPECIES", 331, 336], ["swine", "SPECIES", 158, 163], ["swine", "SPECIES", 331, 336], ["Current challenges", "TREATMENT", 68, 86], ["pathogen", "PROBLEM", 199, 207], ["these antibodies", "TEST", 311, 327], ["stability", "OBSERVATION_MODIFIER", 90, 99], ["gastrointestinal tract", "ANATOMY", 114, 136]]], ["There are several reports where IgY failed to improve pig performance [75, 76] .", [["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["pig", "ORGANISM", 54, 57], ["IgY", "PROTEIN", 32, 35], ["pig", "SPECIES", 54, 57]]], ["The most likely explanation for the failure of the treatment is that the antibody failed to survive passage through the gastrointestinal tract as a result of its susceptibility to proteolysis [77] .", [["gastrointestinal tract", "ANATOMY", 120, 142], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 120, 142], ["the treatment", "TREATMENT", 47, 60], ["the antibody", "PROBLEM", 69, 81], ["passage through the gastrointestinal tract", "PROBLEM", 100, 142], ["its susceptibility to proteolysis", "PROBLEM", 158, 191], ["most likely explanation for", "UNCERTAINTY", 4, 31], ["gastrointestinal tract", "ANATOMY", 120, 142]]], ["IgY, being a glycoprotein, is sensitive to the same denaturing conditions as most proteins.", [["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgY", "PROTEIN", 0, 3], ["glycoprotein", "PROTEIN", 13, 25], ["the same denaturing conditions", "PROBLEM", 43, 73]]], ["It has been reported that IgY is fairly resistant to digestion by intestinal proteases, but the activity of IgY was decreased at pH 3.5 or lower and almost completely lost with irreversible change at pH 3 [78] .", [["intestinal", "ANATOMY", 66, 76], ["IgY", "GENE_OR_GENE_PRODUCT", 26, 29], ["intestinal", "ORGAN", 66, 76], ["IgY", "GENE_OR_GENE_PRODUCT", 108, 111], ["IgY", "PROTEIN", 26, 29], ["intestinal proteases", "PROTEIN", 66, 86], ["IgY", "PROTEIN", 108, 111], ["intestinal proteases", "PROBLEM", 66, 86], ["pH", "TEST", 129, 131], ["irreversible change at pH", "PROBLEM", 177, 202], ["fairly", "OBSERVATION_MODIFIER", 33, 39], ["resistant", "OBSERVATION", 40, 49], ["intestinal proteases", "ANATOMY", 66, 86], ["irreversible", "OBSERVATION_MODIFIER", 177, 189]]], ["In addition, the inactivation at low pH is further enhanced by the presence of pepsin.", [["pepsin", "GENE_OR_GENE_PRODUCT", 79, 85], ["pepsin", "PROTEIN", 79, 85], ["the inactivation at low pH", "PROBLEM", 13, 39], ["pepsin", "TREATMENT", 79, 85]]], ["In contrast to very young pigs, the stomach of older pigs has a low pH and pepsin, and therefore IgY may not be effective in controlling post-weaning E. coli diarrhea in older animals.Current challengesYokoyama et al. [79] , in an excellent study, detected the rate of IgY passage through the gastrointestinal tract of pigs and its ability to retain its activity in the different sections of the tract.", [["stomach", "ANATOMY", 36, 43], ["gastrointestinal tract", "ANATOMY", 293, 315], ["sections", "ANATOMY", 380, 388], ["tract", "ANATOMY", 396, 401], ["diarrhea", "DISEASE", 158, 166], ["pigs", "ORGANISM", 26, 30], ["stomach", "ORGAN", 36, 43], ["pigs", "ORGANISM", 53, 57], ["pepsin", "GENE_OR_GENE_PRODUCT", 75, 81], ["IgY", "GENE_OR_GENE_PRODUCT", 97, 100], ["E. coli", "ORGANISM", 150, 157], ["IgY", "GENE_OR_GENE_PRODUCT", 269, 272], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 293, 315], ["pigs", "ORGANISM", 319, 323], ["tract", "ORGANISM_SUBDIVISION", 396, 401], ["IgY", "PROTEIN", 97, 100], ["IgY", "PROTEIN", 269, 272], ["pigs", "SPECIES", 26, 30], ["pigs", "SPECIES", 53, 57], ["E. coli", "SPECIES", 150, 157], ["pigs", "SPECIES", 319, 323], ["pigs", "SPECIES", 26, 30], ["pigs", "SPECIES", 53, 57], ["E. coli", "SPECIES", 150, 157], ["pigs", "SPECIES", 319, 323], ["pepsin", "TREATMENT", 75, 81], ["IgY", "TREATMENT", 97, 100], ["E. coli diarrhea", "PROBLEM", 150, 166], ["Current challenges", "TREATMENT", 184, 202], ["an excellent study", "TEST", 228, 246], ["stomach", "ANATOMY", 36, 43], ["low pH", "OBSERVATION_MODIFIER", 64, 70], ["coli diarrhea", "OBSERVATION", 153, 166], ["gastrointestinal tract", "ANATOMY", 293, 315], ["activity", "OBSERVATION_MODIFIER", 354, 362], ["tract", "ANATOMY", 396, 401]]], ["Their results demonstrated that IgY is readily absorbed within 24 h by the newly born pig.", [["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["pig", "ORGANISM", 86, 89], ["IgY", "PROTEIN", 32, 35], ["pig", "SPECIES", 86, 89], ["pig", "SPECIES", 86, 89]]], ["IgY has a serum half-life of 1.85 days in newborn pigs, which is shorter than the reported serum half-life of 12 to 14 days for homologous IgG (colostral antibodies).", [["serum", "ANATOMY", 10, 15], ["serum", "ANATOMY", 91, 96], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["pigs", "ORGANISM", 50, 54], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["colostral antibodies", "GENE_OR_GENE_PRODUCT", 144, 164], ["IgY", "PROTEIN", 0, 3], ["homologous IgG", "PROTEIN", 128, 142], ["colostral antibodies", "PROTEIN", 144, 164], ["pigs", "SPECIES", 50, 54], ["pigs", "SPECIES", 50, 54], ["homologous IgG (colostral antibodies", "TEST", 128, 164]]], ["The amount of IgY absorbed into the circulation when administered in pigs decreased with increasing age of pigs.Current challengesSince the primary target site of IgY is the small intestine, in order for it to function, it must be able to survive passage through the harsh environmental conditions found in the stomach.", [["small intestine", "ANATOMY", 174, 189], ["stomach", "ANATOMY", 311, 318], ["IgY", "GENE_OR_GENE_PRODUCT", 14, 17], ["pigs", "ORGANISM", 69, 73], ["pigs", "ORGANISM", 107, 111], ["IgY", "GENE_OR_GENE_PRODUCT", 163, 166], ["small intestine", "ORGAN", 174, 189], ["stomach", "ORGAN", 311, 318], ["IgY", "PROTEIN", 14, 17], ["IgY", "PROTEIN", 163, 166], ["pigs", "SPECIES", 69, 73], ["pigs", "SPECIES", 107, 111], ["pigs", "SPECIES", 69, 73], ["pigs", "SPECIES", 107, 111], ["Current challenges", "TREATMENT", 112, 130], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["IgY absorbed", "OBSERVATION_MODIFIER", 14, 26], ["circulation", "ANATOMY", 36, 47], ["small", "OBSERVATION_MODIFIER", 174, 179], ["intestine", "ANATOMY", 180, 189], ["stomach", "ANATOMY", 311, 318]]], ["Microencapsulation techniques have been developed to protect IgY from gastric inactivation [77, [80] [81] [82] [83] .", [["gastric", "ANATOMY", 70, 77], ["IgY", "GENE_OR_GENE_PRODUCT", 61, 64], ["gastric", "ORGAN", 70, 77], ["IgY", "PROTEIN", 61, 64], ["Microencapsulation techniques", "TREATMENT", 0, 29], ["gastric inactivation", "TEST", 70, 90], ["gastric", "ANATOMY", 70, 77]]], ["Table 5 shows the results of an experiment where chitosan-alginate microcapsules were used for oral delivery of egg yolk immunoglobulin in weaned pigs challenged with enterotoxigenic E. coli K88 [83] .", [["oral", "ANATOMY", 95, 99], ["egg yolk", "ANATOMY", 112, 120], ["chitosan-alginate", "CHEMICAL", 49, 66], ["chitosan-alginate microcapsules", "SIMPLE_CHEMICAL", 49, 80], ["oral", "ORGANISM_SUBDIVISION", 95, 99], ["egg yolk", "ORGANISM_SUBSTANCE", 112, 120], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 121, 135], ["pigs", "ORGANISM", 146, 150], ["E. coli", "ORGANISM", 183, 190], ["egg yolk immunoglobulin", "PROTEIN", 112, 135], ["pigs", "SPECIES", 146, 150], ["E. coli", "SPECIES", 183, 190], ["pigs", "SPECIES", 146, 150], ["E. coli", "SPECIES", 183, 190], ["an experiment where chitosan-alginate microcapsules", "TREATMENT", 29, 80], ["oral delivery of egg yolk immunoglobulin", "TREATMENT", 95, 135], ["weaned pigs", "TREATMENT", 139, 150], ["enterotoxigenic E. coli K88", "TREATMENT", 167, 194]]], ["The percentage of pigs with diarrhea 24 h after treatment and the diarrhea score were improved in pigs receiving encapsulated IgY compared with non- All pigs except negative control were orally challenged with 5 mL of viable E. coli K88 organisms (10 11 cfu/mL per pig) at time 0 h.", [["diarrhea", "DISEASE", 28, 36], ["diarrhea", "DISEASE", 66, 74], ["pigs", "ORGANISM", 18, 22], ["pigs", "ORGANISM", 98, 102], ["IgY", "GENE_OR_GENE_PRODUCT", 126, 129], ["pigs", "ORGANISM", 153, 157], ["E. coli", "ORGANISM", 225, 232], ["pig", "ORGANISM", 265, 268], ["pigs", "SPECIES", 18, 22], ["pigs", "SPECIES", 98, 102], ["pigs", "SPECIES", 153, 157], ["E. coli", "SPECIES", 225, 232], ["pig", "SPECIES", 265, 268], ["pigs", "SPECIES", 18, 22], ["pigs", "SPECIES", 98, 102], ["E. coli", "SPECIES", 225, 232], ["pig", "SPECIES", 265, 268], ["diarrhea", "PROBLEM", 28, 36], ["treatment", "TREATMENT", 48, 57], ["the diarrhea score", "PROBLEM", 62, 80], ["All pigs", "TREATMENT", 149, 157], ["viable E. coli K88 organisms", "TREATMENT", 218, 246], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Challenged pigs were left untreated (positive control) or treated three times (\u22121, 4 and 9 h after bacterial challenge) on the first day and twice a day for two consecutive days each time with 0.4 g non-encapsulated IgY, 2 g of microencapsulated IgY (equivalent to 0.4 g of IgY) or 0.25 g of aureomycin.", [["aureomycin", "CHEMICAL", 292, 302], ["aureomycin", "CHEMICAL", 292, 302], ["pigs", "ORGANISM", 11, 15], ["IgY", "GENE_OR_GENE_PRODUCT", 246, 249], ["aureomycin", "SIMPLE_CHEMICAL", 292, 302], ["microencapsulated IgY", "PROTEIN", 228, 249], ["IgY", "PROTEIN", 274, 277], ["pigs", "SPECIES", 11, 15], ["pigs", "SPECIES", 11, 15], ["Challenged pigs", "TREATMENT", 0, 15], ["microencapsulated IgY", "TREATMENT", 228, 249], ["aureomycin", "TREATMENT", 292, 302]]], ["Diarrhea and weight gain were assessed for 3 days after challenge 2 FC score is the mean fecal consistency score: 0, normal; 1, soft feces; 2, mild diarrhea; 3, severe diarrhea.", [["soft feces", "ANATOMY", 128, 138], ["Diarrhea", "DISEASE", 0, 8], ["weight gain", "DISEASE", 13, 24], ["diarrhea", "DISEASE", 148, 156], ["diarrhea", "DISEASE", 168, 176], ["Diarrhea", "PROBLEM", 0, 8], ["weight gain", "PROBLEM", 13, 24], ["challenge 2 FC score", "TEST", 56, 76], ["the mean fecal consistency score", "TEST", 80, 112], ["mild diarrhea", "PROBLEM", 143, 156], ["severe diarrhea", "PROBLEM", 161, 176], ["normal", "OBSERVATION", 117, 123], ["mild", "OBSERVATION_MODIFIER", 143, 147], ["diarrhea", "OBSERVATION", 148, 156], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["diarrhea", "OBSERVATION", 168, 176]]], ["Pigs with a fecal score of < 1 were considered not to have diarrhea 3 Means in a column followed by same or no letter do not differ (P > 0.05) encapsulated IgY.", [["fecal", "ANATOMY", 12, 17], ["diarrhea", "DISEASE", 59, 67], ["Pigs", "ORGANISM", 0, 4], ["IgY", "GENE_OR_GENE_PRODUCT", 156, 159], ["IgY", "PROTEIN", 156, 159], ["Pigs", "SPECIES", 0, 4], ["a fecal score", "TEST", 10, 23], ["diarrhea", "PROBLEM", 59, 67]]], ["In addition, weight gain over the three day period was significantly higher in pigs receiving encapsulated IgY compared with non-encapsulated IgY.", [["weight gain", "DISEASE", 13, 24], ["pigs", "ORGANISM", 79, 83], ["IgY", "GENE_OR_GENE_PRODUCT", 107, 110], ["IgY", "GENE_OR_GENE_PRODUCT", 142, 145], ["IgY", "PROTEIN", 107, 110], ["non-encapsulated IgY", "PROTEIN", 125, 145], ["pigs", "SPECIES", 79, 83], ["pigs", "SPECIES", 79, 83], ["weight gain", "PROBLEM", 13, 24], ["higher", "OBSERVATION_MODIFIER", 69, 75]]], ["Both encapsulated and non-encapsulated IgY treatments were numerically superior to an aureomycin treated group.", [["aureomycin", "CHEMICAL", 86, 96], ["aureomycin", "CHEMICAL", 86, 96], ["IgY", "GENE_OR_GENE_PRODUCT", 39, 42], ["aureomycin", "SIMPLE_CHEMICAL", 86, 96], ["non-encapsulated IgY treatments", "TREATMENT", 22, 53], ["an aureomycin treated group", "TREATMENT", 83, 110], ["encapsulated", "OBSERVATION_MODIFIER", 5, 17], ["non-encapsulated", "OBSERVATION_MODIFIER", 22, 38], ["IgY treatments", "OBSERVATION", 39, 53], ["aureomycin", "OBSERVATION", 86, 96]]], ["Additional study will be needed before microencapsulation can be applied under commercial conditions.Current challengesThe stability of IgY when subjected to feed processingCurrent challengesEgg-yolk antibodies can be administrated to young pigs either as a preventive or prophylactic treatment or as a therapeutic treatment after infection occurs.", [["yolk", "ANATOMY", 195, 199], ["infection", "DISEASE", 331, 340], ["IgY", "GENE_OR_GENE_PRODUCT", 136, 139], ["pigs", "ORGANISM", 241, 245], ["IgY", "PROTEIN", 136, 139], ["Egg-yolk antibodies", "PROTEIN", 191, 210], ["pigs", "SPECIES", 241, 245], ["pigs", "SPECIES", 241, 245], ["Additional study", "TEST", 0, 16], ["microencapsulation", "TREATMENT", 39, 57], ["Current challenges", "TREATMENT", 101, 119], ["Current challengesEgg-yolk antibodies", "TREATMENT", 173, 210], ["prophylactic treatment", "TREATMENT", 272, 294], ["a therapeutic treatment", "TREATMENT", 301, 324], ["infection", "PROBLEM", 331, 340], ["stability", "OBSERVATION_MODIFIER", 123, 132]]], ["It appears that adding antibodies to swine feeds in the form of whole egg powder or whole yolk powder may be the most practical method of inclusion of IgY for preventive or prophylactic treatment.", [["egg powder", "ANATOMY", 70, 80], ["yolk powder", "ANATOMY", 90, 101], ["swine", "ORGANISM", 37, 42], ["egg powder", "ORGANISM_SUBSTANCE", 70, 80], ["yolk powder", "ORGANISM_SUBSTANCE", 90, 101], ["IgY", "GENE_OR_GENE_PRODUCT", 151, 154], ["antibodies", "PROTEIN", 23, 33], ["IgY", "PROTEIN", 151, 154], ["swine", "SPECIES", 37, 42], ["swine", "SPECIES", 37, 42], ["antibodies to swine feeds", "TREATMENT", 23, 48], ["whole egg powder", "TREATMENT", 64, 80], ["whole yolk powder", "TREATMENT", 84, 101], ["IgY", "TREATMENT", 151, 154], ["prophylactic treatment", "TREATMENT", 173, 195]]], ["It is not known if IgY antibodies can tolerate heat-based feed processing techniques such as pelleting.", [["IgY antibodies", "GENE_OR_GENE_PRODUCT", 19, 33], ["IgY antibodies", "PROTEIN", 19, 33], ["IgY antibodies", "PROBLEM", 19, 33], ["based feed processing techniques", "TREATMENT", 52, 84], ["not known", "UNCERTAINTY", 6, 15]]], ["Presumably the stability of IgY antibodies would be similar to that for enzymes and that stability would be greatly influenced by temperature, duration of heat treatment and cooling period as well as the moisture content of the diet.", [["IgY antibodies", "GENE_OR_GENE_PRODUCT", 28, 42], ["IgY antibodies", "PROTEIN", 28, 42], ["enzymes", "PROTEIN", 72, 79], ["IgY antibodies", "TEST", 28, 42], ["enzymes", "TEST", 72, 79], ["heat treatment", "TREATMENT", 155, 169], ["cooling period", "TREATMENT", 174, 188], ["stability", "OBSERVATION_MODIFIER", 15, 24]]], ["It is well known that a change in moisture content from 95 to 90 or 85 % dry matter can dramatically decrease the stability of proteins when heated to high temperatures.", [["a change in moisture content", "PROBLEM", 22, 50], ["change", "OBSERVATION_MODIFIER", 24, 30], ["stability", "OBSERVATION_MODIFIER", 114, 123]]], ["Preliminary studies by Marquardt et al. [84] have demonstrated that low temperature steam pelleting (70\u00b0C) did not reduce antibody titer.", [["Preliminary studies", "TEST", 0, 19], ["low temperature steam pelleting", "PROBLEM", 68, 99], ["antibody titer", "PROBLEM", 122, 136], ["low temperature", "OBSERVATION_MODIFIER", 68, 83]]], ["Further studies need to be carried out on this problemSpecificity of IgYIgY is an attractive and effective alternative approach to antibiotics due to its high specificity.", [["IgYIgY", "CHEMICAL", 69, 75], ["IgYIgY", "SIMPLE_CHEMICAL", 69, 75], ["Further studies", "TEST", 0, 15], ["antibiotics", "TREATMENT", 131, 142]]], ["It should be noted that swine are exposed to many infectious agents in commercial operations and therefore the swine industry will benefit more from IgY antibodies if they are produced against a mixture of common disease causing organisms rather than one specific disease.", [["swine", "ORGANISM", 24, 29], ["IgY antibodies", "PROTEIN", 149, 163], ["swine", "SPECIES", 24, 29], ["swine", "SPECIES", 111, 116], ["swine", "SPECIES", 24, 29], ["swine", "SPECIES", 111, 116], ["commercial operations", "TREATMENT", 71, 92], ["the swine industry", "TREATMENT", 107, 125], ["IgY antibodies", "TREATMENT", 149, 163], ["common disease", "PROBLEM", 206, 220], ["organisms", "PROBLEM", 229, 238], ["one specific disease", "PROBLEM", 251, 271], ["infectious", "OBSERVATION_MODIFIER", 50, 60]]], ["If this approach works well, it may help to justify, to some extent, commercial application of these antibodies.Amount of product added to the diet or administrated by gavageThe efficacy of IgY in the gastrointestinal tract is related to two factors namely the dose of antibodies and the concentration of pathogen.", [["gastrointestinal tract", "ANATOMY", 201, 223], ["gastrointestinal tract", "DISEASE", 201, 223], ["IgY", "GENE_OR_GENE_PRODUCT", 190, 193], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 201, 223], ["antibodies", "PROTEIN", 101, 111], ["IgY", "PROTEIN", 190, 193], ["antibodies", "PROTEIN", 269, 279], ["these antibodies", "TEST", 95, 111], ["IgY in the gastrointestinal tract", "PROBLEM", 190, 223], ["antibodies", "TREATMENT", 269, 279], ["pathogen", "PROBLEM", 305, 313], ["efficacy", "OBSERVATION_MODIFIER", 178, 186], ["gastrointestinal tract", "ANATOMY", 201, 223]]], ["The results of Yokoyama et al. [79] demonstrated that antibodies pass through the digestive system within a relatively short period of time (slightly more than 24 h).", [["digestive system", "ANATOMY", 82, 98], ["digestive", "ORGAN", 82, 91], ["system", "ANATOMICAL_SYSTEM", 92, 98], ["antibodies", "PROTEIN", 54, 64], ["digestive system", "ANATOMY", 82, 98]]], ["In addition, they can reach all sections of the gastrointestinal tract in less than 10 h.", [["sections", "ANATOMY", 32, 40], ["gastrointestinal tract", "ANATOMY", 48, 70], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 48, 70], ["gastrointestinal tract", "ANATOMY", 48, 70]]], ["The supply of antibodies in the intestine must be sufficiently high to prevent binding of pathogen to the intestinal receptors.", [["intestine", "ANATOMY", 32, 41], ["intestinal", "ANATOMY", 106, 116], ["intestine", "ORGAN", 32, 41], ["intestinal", "ORGAN", 106, 116], ["antibodies", "PROTEIN", 14, 24], ["intestinal receptors", "PROTEIN", 106, 126], ["antibodies in the intestine", "PROBLEM", 14, 41], ["pathogen", "PROBLEM", 90, 98], ["antibodies", "OBSERVATION", 14, 24], ["intestine", "ANATOMY", 32, 41], ["pathogen", "OBSERVATION", 90, 98], ["intestinal receptors", "ANATOMY", 106, 126]]], ["The antibody must also be continuously or nearly continuously available in the intestine.", [["intestine", "ANATOMY", 79, 88], ["intestine", "ORGAN", 79, 88], ["The antibody", "TREATMENT", 0, 12], ["intestine", "ANATOMY", 79, 88]]], ["Studies by Marquardt et al. [34] showed that 1.5 g per day per piglet was sufficient to prevent diarrhea induced by infection with 10 10 ETEC and the addition of 0.2 % of egg-yolk antibody in the diet was preventive against diarrhea in commercial farms.", [["yolk", "ANATOMY", 175, 179], ["diarrhea", "DISEASE", 96, 104], ["infection", "DISEASE", 116, 125], ["diarrhea", "DISEASE", 224, 232], ["piglet", "ORGANISM", 63, 69], ["egg", "ORGANISM", 171, 174], ["egg-yolk antibody", "PROTEIN", 171, 188], ["ETEC", "SPECIES", 137, 141], ["Studies", "TEST", 0, 7], ["diarrhea", "PROBLEM", 96, 104], ["infection", "PROBLEM", 116, 125], ["egg-yolk antibody", "TREATMENT", 171, 188], ["diarrhea", "PROBLEM", 224, 232], ["infection", "OBSERVATION", 116, 125]]], ["However, a considerable amount of additional research must be carried out to identify the best antigens to use and the appropriate prevention or treatment protocols for control of intestinal pathogens such as different strains of E. coli.The production cost of high quality IgY antibodiesAt present, the production cost of high quality IgY antibodies is higher than the cost of routine antibiotic inclusion [84] .", [["intestinal", "ANATOMY", 180, 190], ["intestinal", "ORGAN", 180, 190], ["E. coli", "ORGANISM", 230, 237], ["IgY antibodies", "PROTEIN", 274, 288], ["IgY antibodies", "PROTEIN", 336, 350], ["E. coli", "SPECIES", 230, 237], ["E. coli", "SPECIES", 230, 237], ["treatment protocols", "TREATMENT", 145, 164], ["intestinal pathogens", "PROBLEM", 180, 200], ["E. coli", "PROBLEM", 230, 237], ["high quality IgY antibodies", "PROBLEM", 261, 288], ["high quality IgY antibodies", "PROBLEM", 323, 350], ["routine antibiotic inclusion", "TREATMENT", 378, 406], ["considerable", "OBSERVATION_MODIFIER", 11, 23], ["amount", "OBSERVATION_MODIFIER", 24, 30], ["intestinal", "ANATOMY", 180, 190], ["E. coli", "OBSERVATION", 230, 237]]], ["Therefore, the development of methods for large-scale production of IgY which produce a high recovery and purity of IgY are needed.", [["IgY", "GENE_OR_GENE_PRODUCT", 68, 71], ["IgY", "GENE_OR_GENE_PRODUCT", 116, 119], ["IgY", "PROTEIN", 68, 71], ["IgY", "PROTEIN", 116, 119], ["methods", "TREATMENT", 30, 37], ["large-scale production of IgY", "PROBLEM", 42, 71], ["large", "OBSERVATION_MODIFIER", 42, 47], ["high", "OBSERVATION_MODIFIER", 88, 92]]], ["In addition, there is no consensus on the most suitable IgY extraction method for commercial application [20] and this requires further study.ConclusionsOral administration of specific IgY appears to have considerable potential as a means of controlling diarrhea diseases and exerting growth-promoting activity in swine.", [["Oral", "ANATOMY", 153, 157], ["diarrhea", "DISEASE", 254, 262], ["Oral", "ORGANISM_SUBDIVISION", 153, 157], ["IgY", "GENE_OR_GENE_PRODUCT", 185, 188], ["swine", "ORGANISM", 314, 319], ["IgY", "PROTEIN", 185, 188], ["swine", "SPECIES", 314, 319], ["swine", "SPECIES", 314, 319], ["further study", "TEST", 128, 141], ["controlling diarrhea diseases", "PROBLEM", 242, 271], ["exerting growth", "PROBLEM", 276, 291], ["no", "UNCERTAINTY", 22, 24], ["growth", "OBSERVATION_MODIFIER", 285, 291]]], ["IgY technology will probably provide the best alternative to antibiotics.", [["IgY technology", "TREATMENT", 0, 14], ["antibiotics", "TREATMENT", 61, 72]]], ["Some advantages of IgY in the control of swine diseases are:Conclusions1) They are highly effective.Conclusions2) They are highly cost-effective with only a small amount of antibody required per pig.", [["swine diseases", "DISEASE", 41, 55], ["IgY", "GENE_OR_GENE_PRODUCT", 19, 22], ["pig", "ORGANISM", 195, 198], ["IgY", "PROTEIN", 19, 22], ["swine", "SPECIES", 41, 46], ["pig", "SPECIES", 195, 198], ["swine", "SPECIES", 41, 46], ["pig", "SPECIES", 195, 198], ["IgY", "TREATMENT", 19, 22], ["a small amount of antibody", "TREATMENT", 155, 181], ["small", "OBSERVATION_MODIFIER", 157, 162], ["amount", "OBSERVATION_MODIFIER", 163, 169], ["antibody", "OBSERVATION", 173, 181]]], ["3) Collection of eggs is non-invasive.", [["eggs", "ANATOMY", 17, 21], ["eggs", "ORGAN", 17, 21], ["eggs", "OBSERVATION", 17, 21]]], ["4) The treatment is safe and live organisms are not used.", [["The treatment", "TREATMENT", 3, 16]]], ["5) The procedure is environmentally friendly.", [["The procedure", "TREATMENT", 3, 16]]], ["6) No toxic residues are produced and there is no development of resistance.", [["toxic residues", "PROBLEM", 6, 20], ["resistance", "PROBLEM", 65, 75], ["No", "UNCERTAINTY", 3, 5], ["toxic residues", "OBSERVATION", 6, 20], ["no development of", "UNCERTAINTY", 47, 64], ["resistance", "OBSERVATION", 65, 75]]], ["7) The treatment can be used to control many different types of pathogens.", [["The treatment", "TREATMENT", 3, 16], ["pathogens", "PROBLEM", 64, 73], ["pathogens", "OBSERVATION", 64, 73]]]], "PMC3234644": [["Feline infectious peritonitis (FIP) is a common disease in cats and some non-domesticfelids that is caused by feline coronavirus (FCoV).", [["Feline infectious peritonitis", "DISEASE", 0, 29], ["FIP", "DISEASE", 31, 34], ["non-domesticfelids", "DISEASE", 73, 91], ["feline coronavirus", "DISEASE", 110, 128], ["Feline", "ORGANISM", 0, 6], ["cats", "ORGANISM", 59, 63], ["feline coronavirus", "ORGANISM", 110, 128], ["FCoV", "CANCER", 130, 134], ["cats", "SPECIES", 59, 63], ["feline coronavirus", "SPECIES", 110, 128], ["feline coronavirus", "SPECIES", 110, 128], ["FCoV", "SPECIES", 130, 134], ["Feline infectious peritonitis", "PROBLEM", 0, 29], ["FIP", "PROBLEM", 31, 34], ["a common disease in cats", "PROBLEM", 39, 63], ["some non-domesticfelids", "PROBLEM", 68, 91], ["feline coronavirus", "PROBLEM", 110, 128], ["infectious", "OBSERVATION_MODIFIER", 7, 17], ["peritonitis", "OBSERVATION", 18, 29], ["FIP", "OBSERVATION_MODIFIER", 31, 34], ["common", "OBSERVATION_MODIFIER", 41, 47], ["disease", "OBSERVATION", 48, 55]]], ["1This virus is included in the Coronaviridae family, a group of envelopedpositive-stranded RNA viruses.", [["This virus", "PROBLEM", 1, 11], ["stranded RNA viruses", "PROBLEM", 82, 102], ["stranded RNA viruses", "OBSERVATION", 82, 102]]], ["1 Although FIPmanifests itself in effusive or noneffusive forms, the basic lesion is the same, apyogranulomatous inflammation and vasculitis.", [["lesion", "ANATOMY", 75, 81], ["apyogranulomatous", "ANATOMY", 95, 112], ["inflammation", "DISEASE", 113, 125], ["vasculitis", "DISEASE", 130, 140], ["FIPmanifests", "CANCER", 11, 23], ["the basic lesion", "PROBLEM", 65, 81], ["apyogranulomatous inflammation", "PROBLEM", 95, 125], ["vasculitis", "PROBLEM", 130, 140], ["basic", "OBSERVATION_MODIFIER", 69, 74], ["lesion", "OBSERVATION", 75, 81], ["apyogranulomatous", "OBSERVATION_MODIFIER", 95, 112], ["inflammation", "OBSERVATION", 113, 125], ["vasculitis", "OBSERVATION", 130, 140]]], ["1Testing by immunofluorescence assay, ELISA, electron microscopy, RT-PCR and sequenceanalysis may be useful in supporting a diagnosis of FIP.1 , 2", [["FIP", "DISEASE", 137, 140], ["FIP", "PATHOLOGICAL_FORMATION", 137, 140], ["immunofluorescence assay", "TEST", 12, 36], ["ELISA", "TEST", 38, 43], ["electron microscopy", "TEST", 45, 64], ["RT-PCR", "TEST", 66, 72], ["sequenceanalysis", "TEST", 77, 93], ["FIP", "PROBLEM", 137, 140], ["FIP", "OBSERVATION", 137, 140]]]]}